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Abstract 
Transcriptional regulation of CD8+ T cell differentiation during acute and chronic 
viral infections is an intricate web made up of many of transcription factors. While 
several transcription factors have been elucidated in this process, there are still 
many more that remain elusive. In this work, we look into the role of two 
transcription factors, IRF4 and Runx2, and their role in CD8+ T cell terminal 
effector cells and memory precursor cells during acute LCMV-Armstrong 
infection. We found that IRF4 expression was regulated by TCR signal strength 
during infection, and that IRF4 expression levels directly correlated with the 
magnitude of the effector cell response. IRF4 was also shown to regulate T-bet 
and Eomes, two transcription factors critical for CD8+ T cell differentiation into 
effector and memory cells. From these results, we were interested in the 
potential role of IRF4 during chronic LCMV-clone 13 infection, where ratios of T-
bet and Eomes are critical for viral clearance. We found that haplodeficiency of 
IRF4 in the T cell compartment lead to an increase in the ratio of Eomes to T-bet 
in T cells, which in turn affected the proportion of Eomeshi versus T-bethi cells and 
resulted in a loss in ability to clear viral infection. Irf4+/- Eomes+/- compound 
heterozygous mice were generated to test if decreasing Eomes expression would 
rescue the Irf4+/- phenotype. Irf4+/- Eomes+/- mice were phenotypically similar to 
WT mice in terms of Eomes to T-bet ratios, and were able to clear viral infection, 
demonstrating a critical role of IRF4 in regulating T-bet and Eomes during 
chronic viral infection. Next we looked into the role of Runx2 during acute LCMV-
	 ix	
Armstrong infection and found that Runx2-deficient pathogen-specific CD8+ T 
cells had a defect in the total number of memory precursor cells compared to WT 
controls. We further showed that Runx2 was inversely correlated with TCR signal 
strength, and that Runx2 expression was repressed by IRF4. From these work, 
we have introduced two more transcription factors that are critical for CD8+ T 
cells differentiation during acute and chronic viral infection. Given the sheer 
number of transcription factors known to regulate these processes, having a full 
understanding of the transcriptional network will allow us to find the best targets 
for therapeutic intervention for treatments ranging from vaccine development and 
autoimmunity to cancer immunotherapy and treatment of chronic viral infections.  
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The immune system is one of the eleven major organ systems of the human 
body. It’s primary function is to protect the host from foreign pathogens. The 
human body has skin and mucosal surfaces that act as a natural barrier to 
prevent foreign bodies from entering the host. However, if one of these barriers 
becomes compromised, or if a foreign pathogen is able to get through the barrier, 
the immune system is able to eliminate foreign pathogens from the host by 
recognition and destruction of the foreign body.  
 
The first branch of the immune system to respond to the presence of foreign 
antigen is the innate immune system. This branch is called “innate” because 
these immune cells are able to identify foreign pathogens using germline 
products based on components that are often shared between many pathogens. 
An example of this would be an innate immune cell being able to recognize the 
flagellin of an invading Salmonella typhi bacterium, a shared trait that can be 
found on many different types of bacteria. Innate immune cells are able to 
identify these foreign bodies through pathogen recognition receptors (PRRs) that 
identify pathogen-associated molecular patterns (PAMPs). Innate immune cells 
are able to respond rapidly to infection, with their primary goal being to limit the 
spreading of infection via phagocytosis of foreign bodies, activation of 
complement, recruiting immune cells to the infection site through the production 
of cytokines, and activation of the adaptive immune system by antigen 
presentation. 
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The second branch of the immune system is the adaptive immune system. The 
adaptive immune response is activated when an infection is unable to be cleared 
by the innate immune response. This branch is made up of two major cell 
groups: T cells and B cells named after the organ they develop in (T cells in the 
thymus and B cells in the bone marrow). This branch is highly specific to the 
pathogen that has infiltrated the body. This high specificity is possible through 
genetic (VDJ) recombination of the major receptor on these cells (T cell receptor 
or TCR on T cells and the B cell receptor or BCR on B cells). These adaptive 
immune cells allow for individuals to fight and clear a diverse range of infections 
throughout their lifetime. Adaptive immune cells take several days to become 
activated and differentiate into effector cells, but once the pathogen is cleared, a 
small pool of memory cells is left to rapidly respond to reinfection. The work of 
this dissertation focuses on T cell differentiation during acute and chronic viral 
infection, so we will focus on the T cell for the rest of this introduction. 
 
T cells originate from multipotent hematopoietic stem cells in the bone marrow. 
These progenitors migrate from to the thymus via the bloodstream, where they 
undergo maturation. Initial commitment of these multipotent hematopoietic stem 
cells into the T cell lineage occurs with Notch1 signaling within the thymus. After 
this, thymic T cells or thymocytes go through several stages of development. The 
first stage is the CD3-CD4-CD8- or double-negative (DN) stage. These DN cells 
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are able to still develop into γδ T cells and iNKT cells. The DN stage can be 
broken down into 4 parts (DN1-4) based on expression of surface molecules 
CD44, CD25, and Kit. During this stage, the TCRβ receptor undergoes VDJ 
recombination during the DN2/DN3 stages, and successfully recombined TCRβ 
thymocytes with a pre-TCRα go on to proliferate during the DN4 stage. The next 
stage is the CD3+pTαβ+CD4+CD8+ double-positive (DP) stage. During the DP 
stage, TCRα undergoes VJ recombination. DP cells then undergo positive 
selection where thymocytes that are able to recognize self-peptide:self-MHC 
complexes survive and thymocytes that are unable to recognize the peptide:MHC 
complex undergo apoptosis. DP Thymocytes then undergo negative selection 
where cells that become too highly activated in response to self-antigen undergo 
apoptosis. During this time, DP cells stop producing either CD4 or CD8 co-
receptor molecules and become single-positive (SP) thymocytes. CD4+ SP 
thymocytes recognized peptide presented on MHC-II, whereas CD8+ SP 
thymocytes recognize peptide presented on MHC-I. SP thymocytes have 
undergone full thymic maturation and will leave the thymus and move into the 
periphery.  
 
Once the mature T cells enter the periphery, they circulate through the 
bloodstream, the lymphoid organs, and the lymphatics. During this time, T cells 
are naïve in that they have not seen their cognate antigen presented on MHC. In 
order for T cells to become activated, they require three signals: signal 1 from 
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TCR stimulation, signal 2 from costimulation through CD28 and/or other 
costimulatory molecules, and signal 3 from cytokines.   
 
Once a naïve T cells is activated by an antigen presenting cell (APC) presenting 
cognate antigen on it’s MHC, a T cell will undergo activation through the TCR 
signaling pathway. Upon activation of this pathway, several downstream steps 
occur leading to hydrolyzation of phosphatidylinositol 4,5 bisphosphate (PIP2) to 
generate inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 causes release 
of Ca2+ from the endoplasmic reticulum and other intracellular repositories, which 
in turn causes an influx of extracellular calcium through activation of Ca2+-
release-activated Ca2+ channels (CRAC) on the plasma membrane. This influx of 
intracellular calcium leads to activation of Ca2+ sensitive nuclear factor of 
activated T cells (NFAT). DAG activates the mitogen-activated protein kinase 
(MAPK) signaling pathway as well as the nuclear factor of κ light polypeptide 
gene enhancer in B cells (NFκB) signaling pathway. Once these signaling 
pathways have been activated, downstream target genes will become expressed 
leading to T cell proliferation and differentiation. 
 
CD8+ T Cell Differentiation: Effector versus Memory 
Activated CD8+ T cells undergo three major phases during acute infection: clonal 
expansion, contraction, and memory. During clonal expansion, activated CD8+ T 
cells rapidly undergo several rounds of division to expand the population of 
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pathogen-specific CD8+ T cells from ~1x102-1x103 cells within the spleen to 
~1x106 cells. These expanded CD8+ T cells gain effector functions and are able 
to clear infection through release of cytokines such as IFNγ and TNFα, as well as 
killing infected cells via “the kiss of death.” To do this, CD8+ effectors generate 
holes in the membranes of infected target cells with perforins and release 
granzymes into the infected cell to induce programmed cell death. Once infection 
is cleared, CD8+ T cells undergo a contraction phase where around 90% of the 
population undergoes apoptosis, leaving a small pool of memory CD8+ T cells 
that survive and continue on for years post infection. These memory CD8+ T cells 
protect the host from secondary infection with the same pathogen by rapidly 
responding to reinfection. 
 
Experimental differentiation of effector and memory CD8+ T cells is primarily 
through expression of the surface markers CD127 (IL-7rα) and KLRG1 (Schluns 
et al., 2000) (Kaech et al., 2003) (Huster et al., 2004). Terminal effector CD8+ T 
cells (TECs) are KLRG1hi CD127lo, whereas memory percursor CD8+ T cells 
(MPCs) are KLRG1lo CD127hi. Memory cells can be differentiated from effector 
cells as early as day 7 during LCMV-Armstrong infection using these markers. 
Effector CD8+ T cells make up the majority of the T cell response, rapidly 
proliferating in response to activation, whereas memory CD8+ T cells proliferate 
less, but go on to survive after clearance of infection (Figure 1.1). How CD8+ T 
cells are able to differentiate into either effector or memory T cells is still not 
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clear, but there are several potential mechanisms currently under debate in the 
field. 
 
The first mechanism that was proposed was the separate-precursor model, 
where memory and effector CD8+ T cells are pre-programmed in the thymus, and 
an activated CD8+ T cell would differentiate into either an effector T cell or a 
memory T cell depending on how they were programmed previously. This model 
was disproven by adoptive transfer experiments where individual naïve CD8+ T 
cells were barcoded and host mice were infected (Stemberger et al., 2007) 
(Gerlach et al., 2010). These experiments showed that a single T cell was able to 
produce both effector and memory T cells in response to infection. These 
experiments were performed using TCR transgenic cells, so they did not test the 
role for TCR signal strength in effector/memory differentiation. 
 
Another mechanism that has been proposed is the decreasing-potential model, 
where repetitive TCR stimulation with cognate antigen and pro-inflammatory 
cytokines pushes activated CD8+ T cells towards increased proliferation and 
terminal differentiation to effector T cells. This model is able to explain how a 
single naïve T cell is able to produce both effector and memory progeny upon 
activation. Studies that support this model include work by Joshi et al. that show 
inflammatory cytokine IL-12 promotes T-bet expression during T cell priming and  
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Figure 1.1. Kinetics of the CD8+ T cell response and proportions of TECs 
and MPCs in response to acute viral infection 
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Figure 1.1. Kinetics of the CD8+ T cell response and proportions of TECs 
and MPCs in response to acute viral infection 
During acute viral infection, pathogen-specific CD8+ T cells undergo clonal 
expansion and clear viral infection. After viral clearance, CD8+ T cells undergo a 
contraction phase where ~90-95% of the population undergoes apoptosis, and a 
small pool of pathogen-specific memory cells are left to protect the host from 
reinfection by the same pathogen. This pool of CD8+ T cells can be broken down 
into two major groups: terminal effector cells (TECs) and memory precursor cells 
(MPCs). TECs rapidly proliferate and make up the majority of the population at 
the peak of the CD8+ T cell response, whereas MPCs proliferate less, but go on 
to form memory.  
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terminal effector differentiation in CD8+ T cells in response to LCMV (Joshi et al., 
2007). It has also been found that decreasing the length of antigen stimulation a 
T cell receives during infection (Sarkar et al., 2008) or during vaccination 
(Badovinac et al., 2005) leads to an increase in the proportion of MPCs, whereas 
inflammation was shown to reverse the effects seen with decreased antigen 
stimulation (Badovinac et al., 2005). Early clearance of Listeria monocytogenes 
infection through the use of antibiotics has also shown an increase in the 
proportion of MPCs compared to TECs, as well as cause a defect in the clonal 
expansion phase of TECs (Badovinac et al., 2004).  
 
This work also supports the signal-strength model, whereas the intensity of TCR 
signal strength, costimulation, and inflammatory cytokines can lead to terminal 
differentiation of activated CD8+ T cells to the effector lineage. The signal-
strength model differs from the decreasing-potential model in that intensity of 
signal strength is more important than the repetitive stimulation of T cells with 
these signals. The general consensus of the field is that terminal differentiation of 
effector cells lies between these two models, where both intensity and repetition 
are able to drive cells to an effector fate.  
 
One final model that also incorporates elements of differentiation through signal 
strength is the asymmetric cell division model. In this model, differentiation 
between TECs and MPCs is determined by proximity of the daughter cell to the 
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APC. Work done by Chang et al. has shown that the daughter cells that arise 
from the first cell division inherit unequal amounts of proteins that are important 
for CD8+ T cell differentiation (Chang et al., 2007), with the promixal daughter cell 
receiving more proteins and cytokine signaling required for terminal effector 
differentiation (Verbist et al., 2016) and the distal daughter cell receiving more 
proteins required for memory differentiation (Pollizzi et al., 2016). While it is 
implausible that the fate of a daughter cell is strictly determined by whether it was 
proximal or distal to the APC during the first cell division, it is reasonable to 
believe that these division disparities could affect the ultimate fate of a T cell after 
several divisions.  
 
Transcriptional Regulation of CD8+ TECs and MPCs 
During an acute viral infection, CD8+ T cells differentiate into effector and 
memory cells, which are critical for clearance of the pathogen and protective 
immunity from reinfection. These CD8+ T cell fates are regulated through 
transcriptional programs. Several transcription factors are known to play a role in 
CD8+ T cell effector differentiation including BATF (Kurachi et al., 2014) (Grusdat 
et al., 2014) (Godec et al., 2015), T-bet (Intlekofer et al., 2005) (Joshi et al., 
2007) (Rao, Li et al., 2010), Blimp-1 (Rutishauser et al., 2009) (Shin et al., 2013) 
(Xin et al., 2016), and Id2 (Cannarile et al., 2006) (Yang et al., 2011) (Knell et al., 
2013) (Omilusik et al., 2010). Inversely, Eomes (Intlekofer et al., 2005) (Rao et 
al., 2010) (Banerjee et al., 2010), TCF1 (Jeannet et al., 2010) (Zhou et al., 2010), 
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Id3 (Yang et al., 2011) (Ji et al., 2011), and Runx3 (Wang et al., 2018) have been 
shown to play a critical role in CD8+ T memory cells. Two major transcription 
factors, IRF4 and Runx2, are the focus of this dissertation, and our current 
knowledge of their roles in the immune response will be discussed below. 
  
Interferon Regulatory Factor 4 (IRF4) 
IRF4 is a transcription factor that is part of the interferon regulatory factor family. 
This family of proteins was originally discovered as regulating transcription of 
IFN-induced genes upon IFNα/β-treatment (Levy, Kessler et al., 1988) (Fu et al., 
1990) (Kessler et al., 1990).  IRF4 is able to bind to IFN-stimulated response 
elements (ISRE) or IFNγ-activated sequences (GAS) and activate or repress 
target genes (Eisenbeis et al., 1995) (Yamagata et al., 1996) (Matsuyama et al., 
1995). In addition, IRF4 is able to form complexes with other transcription factors 
such as PU.1 (Eisenbeis et al., 1995) and BATF (Kurachi et al., 2014) to bind to 
other DNA-binding sites, allowing for regulation of non-IFN related genes. 
 
IRF4 expression is primarily limited to the immune system, where it has been 
shown to be expressed in T/B cells (Eisenbeis et al., 1995) (Yamagata et al., 
1996), macrophages (Marecki et al., 1999) (Rosenbauer et al., 1999), and 
dendritic cells (DCs) (Williams et al., 2013) (Schlitzer et al., 2013). In DCs, IRF4’s 
primary role is to promote expression of cytokines that help regulate the CD4+ T 
cell response. During an asthmatic response, DCs upregulate IRF4, which 
	 13	
promotes TH2 differentiation in CD4+ T cells through production of IL-10 and IL-
33 (Williams & Bevan, 2007). During a Aspergillus fumigates fungal infection, a 
subset of CD11b+ DCs express IRF4 which regulates production of IL-23 
(Schlitzer et al., 2013). IL-23 in turn, promotes TH17 differentiation in CD4+ T cells 
(Schlitzer et al., 2013) (Gaffen et al., 2014). In macrophages, IRF4 was found to 
repress H2-Ld MHC-I expression, as well as activate transcription of the IL-1β 
promoter (Marecki et al., 1999).  
 
IRF4 has a better-defined role in the lymphoid compartment, where it’s 
expression was first discovered in the immune system (Shukla & Lu, 2014). IRF4 
is unique to other IRF family members in that it is not upregulated in response to 
IFN-stimulation, rather it is upregulated through antigen-receptor mediated 
stimuli, such as IgM and TCR (Matsuyama et al., 1995). In B cells, IRF4 is 
primarily regulated through the NFκB signaling pathway (Saito et al., 2007), 
where it plays several critical roles in B cell development and differentiation. 
IRF4/IRF8 have been shown to play a redundant roll in the pre-B cell stage of 
development (Lu, 2003) (Ma et al., 2006b) by binding to the Ig κ 3’ enhancer 
(Brass et al., 1996) (Brass et al., 1999) and limiting expansion of the pre-B cell 
population through inhibition of cell cycling (Ma et al., 2008) (Johnson et al., 
2008) (Lazorchak et al., 2006). IRF4 alone also plays an important role in 
receptor editing (Pathak et al., 2008), class switching (Klein et al., 2006) 
(Sciammas et al., 2006), and plasma cell development (Sciammas & Davis, 
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2004) (Sciammas et al., 2006) (Klein et al., 2006) (Benson et al., 2007).  
 
IRF4 plays a major role in T cells. Since IRF4 is upregulated in response to TCR 
stimulation (Matsuyama et al., 1995), it is present in most T-cell subsets including 
TH2, TH9, TH17, TFH, and TREG (Huber & Lohoff, 2014). In TH2 cells, IRF4 has 
been shown to promote IL-4 production by directly binding to the Il-4 promoter 
with it’s binding partner NFATc2 (Rengarajan et al., 2002), promote expression of 
the major TH2 transcription factor GATA3 (Lohoff et al., 2002), and regulate the 
expression of Gfi1, a transcription factor that is important for IL-2-mediated TH2 
expansion (Tominaga et al., 2003). In TH9 cells, IL-9 expression is directly 
correlated to IRF4 expression, and loss of IRF4 in the CD4+ T cell compartment 
leads to a loss of TH9 cells during airway inflammation (Staudt et al., 2010). In 
TH17 cells, IRF4 regulates Il-17 and Il-22 expression to promote TH17 function. In 
TH17-mediated autoimmune models such as experimental autoimmune 
encephalomyelitis (EAE) (Brüstle et al., 2007) and irritable bowel syndrome (IBS) 
(Mudter et al., 2008) (Mudter et al., 2011), IRF4 has been shown to play a critical 
role in disease. In EAE, IRF4 has been shown to be required in CD4+ T cells for 
disease to occur (Brüstle et al., 2007). In patients with IBS, IRF4 expression 
directly correlated with IL-17 levels and disease severity (Mudter et al., 2011). In 
TFH cells, loss of IRF4 leads to a defect in TFH differentiation after immunization 
with keynote limpet hemocyanin (KLH) (Kwon et al., 2009) as well as after 
Leishmania major infection (Bollig et al., 2012). These defects are attributed to a 
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defect in Bcl6 expression, a critical gene that IRF4 also regulates in B cells 
(Bollig et al., 2012) (Ochiai et al., 2013). IRF4 has also been shown to regulate 
IL-21, a cytokine required for TFH development (Biswas et al., 2010) (Kwon et al., 
2009) (Huber et al., 2008) and could likely be contributing to the TFH defect seen 
in IRF4 deficient mice. In TREG cells, IRF4 is required for TREG effector function. 
Loss of IRF4 leads to an increase in the total number of TREG cells; however, 
IRF4 deficient TREGs have decreased expression of ICOS, an activation marker 
for TREGs, and IL-10, a cytokine involved in TREG suppressor activity (Zheng et al., 
2009) (Cretney et al., 2013).  
 
IRF4 was first identified in having a potential role in CD8+ T cells through a 
microarray experiment where IRF4 was the most highly downregulated 
transcription factor in IL-2 inductible T cell kinase (Itk)-deficient CD8SP 
thymocytes compared to WT controls (Berg, unpublished data). Initial studies 
found that IRF4 was upregulated, but not required, during thymic development 
(Nayar et al., 2012). Irf4-/- CD8+ T cells showed increased levels of 
innate/memory markers such as CD44, CXCR3, Eomes, and CD122, similar to 
Itk-deficient mice. The authors further showed that dose-dependent inhibition of 
ITK with the small molecule inhibition, 10n, directly correlated with IRF4 
expression levels, providing evidence that IRF4 expression was regulated 
through ITK (Nayar et al., 2012).  
 
	 16	
Following this work, four major articles were published, including one in this 
dissertation, which dissected the role of IRF4 in CD8+ T cell activation, and 
effector differentiation. In work by Raczkowski et al., the authors found that IRF4-
deficient mice were unable to clear Listeria monocytogenes infection. They 
further found this to be a CD8+ T cell intrinsic defect, when adoptively transferred 
WT CD8+ T cells are able to clear L. monocytogenes infection in IRF4-deficient 
mice. They also showed Irf4-/- CD8+ T cells were able to proliferate initially, but 
were unable to at later stages of activation (Raczkowski et al., 2013). Their work 
also identified a defect in effector function (Granzyme B protein expression, Gzk 
and Prf1 mRNA expression, and in vivo cytotoxicity) and cytokine production 
(IFNγ, TNFα, and IL-2 protein expression) in IRF4-deficient CD8+ T cells, as well 
as a decrease in expression of effector transcription factors Blimp-1, Id2, and T-
bet, and an increase in expression of memory transcription factors Bcl6, Eomes, 
and Id3 (Raczkowski et al., 2013).    
 
In Nayar et al., we observed similar results as Raczkowski et al. in LCMV-
Armstrong viral infection as well as Influenza A-PR8 viral infection. Irf4-/- CD4-cre+ 
(Irf4-/-) mice were unable to clear LCMV-Armstrong infection, whereas WT and 
Irf+/- CD4-cre+ (Irf4+/-) were able to clear infection (Nayar et al., 2014). Similar 
results were also observed in effector function and cytokine production during 
LCMV-Armstrong infection (Nayar et al., 2014). This work uniquely showed the 
effects of graded levels of IRF4 expression through the use of Irf4+/- mice, where 
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we showed haplo-deficiency in the Irf4 gene lead to a decrease in IRF4 protein 
expression levels compared to WT cells (Nayar et al., 2014). Graded levels of 
IRF4 expression showed a graded defect in the CD8+ T effector response, with 
IRF4 expression inversely correlating with Eomes expression. Graded IRF4 
expression directly correlating with total number of GP33-tetramer+ CD8+ T cells 
at day 8/14 post infection, IFNγ expression, TNFα expression, and IL-2 
expression (Nayar et al., 2014). This work also showed that Irf4+/- CD8+ T cells 
have no long term defect in MPCs, a defect that is seen in Irf4-/- CD8+ T cells in 
response to LCMV-Armstrong infection (Nayar et al., 2014) as well as L. 
monocytogenes infection (Raczkowski et al., 2013).  
 
In work by Man et al., the authors showed a similar defect seen in the previous 
papers, with a defect in the pathogen-specific CD8+ T cell response in Irf4-/- mice 
during Influenza viral infection with the HKx31 strain, as well as during LCMV-
Armstrong (WE strain) infection. In their work, the authors showed that there 
were no early defects in proliferation, but that there was a significant increase in 
apoptotic markers Annexin V and Caspase3 in Irf4-/- CD8+ T cells compared to 
WT controls (Man et al., 2013). The authors go on to show that there is a defect 
in proliferation at later stages of activation in Influenza (HKx31) in Irf4-/- CD8+ T 
cells compared to WT controls (Man et al., 2013), similar to results seen in 
Raczkowski et al. during L. monocytogenes infection. They further show that 
IRF4 protein expression is TCR signaling dependent, using OVA peptides with 
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single-point amino acid changes which in turn change the affinity of the peptide 
to the OT-I TCR transgenic CD8+ T cell. They show that IRF4 expression level is 
directly correlated to the affinity of the OVA-peptide or OVA-peptide variant to the 
OT-I TCR, and that IRF4 regulates that affinity-driven transcriptional program in 
CD8+ T cells (i.e. genes that are different between high-affinity peptide and low-
affinity peptide) including Eomes, S1pr1, Il7r, and Ccr2 (Man et al., 2013). Their 
work further showed that IRF4 regulated aerobic glycolysis in high-affinity 
effector CD8+ T cells through transcriptional regulation of several metabolic 
genes (Man et al., 2013).  
 
One final paper by Yao et al. was published in this group of publications looking 
at the role of IRF4 in CD8+ T cell activation and differentiation. In their work, they 
showed that mTOR regulated IRF4 expression in activated CD8+ T cells in vitro 
(Yao et al., 2013). This group saw impairment in effector function and 
proliferation, as was previously shown in (Raczkowski et al., 2013) and (Man et 
al., 2013), but uniquely showed that proliferation and survival defects seen later 
during CD8+ T cell differentiation into effector cells was from IRF4 regulating 
CDK inhibitors Cdkn2a, Cdkn1a, and Cdkn1c, as well as regulating Bim 
expression (Yao et al., 2013). From these manuscripts, the groundwork was laid 
for how IRF4 is regulated through TCR signal strength, as well as IRF4’s role in 
CD8+ T cell effector differentiation through regulating of proliferation, survival, 
and effector metabolism.  
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Runt-Related Transcription Factor 2 (Runx2) 
Runx2 is a member of the Runt domain family of transcription factors. Runx2 is 
primarily studied in the osteogenesis where is it required for osteoblast formation. 
Haplodeficiency of Runx2 leads to cleidocranial dysostosis (CCD), a disease 
primarily associated with bone and dental abnormalities (Otto et al., 2002). 
Complete loss of Runx2 leads to neonatal lethality due to a complete loss of 
bone formation (Komori, 2018). Runx2 requires binding partner CBFβ in order to 
bind to DNA. CBFβ does not directly interact with the DNA binding site; however, 
it enhances Runx-proteins ability to bind to DNA by inducing structural changes 
that opens the DNA-binding region of the protein (Tahirov et al., 2001) and 
stabilizes Runx-proteins by protecting them from ubiquitin-mediated degradation 
(Huang et al., 2001).  
 
Runx2 is known to have several transcription factor binding partners including 
AP1 (c-Fos and c-Jun) (D'Alonzo et al., 2001), Smad1 and Smad5 (Hanai et al., 
1999) (Lee et al., 2000) (Nishimura et al., 2002) (Sowa et al., 2004), Ets1 
(Wotton et al., 1994) (Sato et al., 1998), androgen and glucocorticoid receptors 
(Ning & Robins, 1999), Dlx5 (Shirakabe et al., 2001) (Hassan et al., 2004), Hes1 
(McLarren et al., 2000), and Oct-1 (Inman et al., 2005). Runx2 is often times 
found as part of a large transcriptional complex, and many of these heterodimeric 
binding partners are believed to be important in regulating this function. In 
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osteoblasts, Runx2 regulates osteoblast differentiation at multiple stages. Runx2 
promotes osteoblast differentiation in pluripotent mesenchymal stem cells during 
the early stages of osteoblast differentiation by promoting expression of α2(I) 
collagen, osteopontin, and bone sialoprotein (BSP) (Ducy et al., 1999) (Harada et 
al., 1999) (Lee et al., 2000). Later Runx2 blocks osteoblast differentiation at the 
late stages of osteoblast maturation through repression of these same target 
genes (Ducy et al., 1999). This flip in regulation indicates a likely role for 
transcriptional binding partners regulating Runx2 activating/repressive functions 
during osteoblast differentiation.  
 
Runx2 also plays a critical role in proliferation and cell cycle regulation in 
osteoblasts. Runx2 is upregulated in osteoblasts during the G0/G1 phase of cell 
cycle, and downregulated in the S/G2/M phases (Pratap et al., 2003). Further, 
loss of Runx2 leads to an increase in proliferation of osteoblasts, that is inhibited 
by reintroduction of Runx2 (Pratap et al., 2003). Loss of Runx2 expression in 
MEFs also leads to spontaneous immortalization and tumorigenesis (Kilbey et 
al., 2007) (Zaidi et al., 2007), indicating a critical role for Runx2 in the regulation 
of cell cycle and transformation. While Runx2 controls differentiation and 
proliferation as a result of its transcriptional regulation, Runx2 is also modulated 
through post-transcriptional regulation. Runx is primarily post-transcriptionally 
regulated through intracellular localization and phosphorylation.  
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Runx2 transcriptional activity is dependent on its localization to subnuclear foci. 
This localization is dependent on the nuclear matrix targeting sequence (NMTS) 
region of the Runx2 protein (Kanno et al., 1998) (Zeng et al., 1997) (Zeng et al., 
1998), and the NMTS is required for Runx2-dependent transactivation (Zaidi et 
al., 2001). Loss of the NMTS results in loss recruitment of Runx2 to nuclear foci 
(Harrington, 2002), and failure to develop mineralized tissue due to maturational 
arrest of osteoblasts (Choi et al., 2001).  
 
Phosphorylation of Runx2 is another post-translational modification is known to 
regulate Runx2 downstream activity. In vascular endothelial cells, Insulin-like 
growth factor-1 (IGF-1) activates MAPK/ERK pathways through PI3K and 
increases Runx2 phosphorylation and binding to OSE2 (Qiao et al., 2004). 
Mechanical stress has also been shown to activate MAPK/ERK, increase Runx2 
phosphorylation, and increase expression of osteoblast genes (Ziros et al., 2002) 
(Kanno et al., 2007). Fibroblast growth factor-2 (FGF-2), an activator of bone 
growth in vivo, activates osteocalcin mRNA expression by increasing p-ERK1/2 
which in turn phosphorylated Runx2. Use of ERK1/2 phosphorylation inhibitor, 
U0126, blocked FGF-2 mediated Runx2-phosphorylation (Xiao et al., 2002). 
Runx2 transcriptional activity can also be repressed by phosphorylation of serine 
residues S104 and S451, which inhibits heterodimerization with it binding partner 
CBFβ (Wee et al., 2002). 
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Very little work has been done elucidating the role of Runx2 in the immune 
system. Work from Sawai et al showed that Runx2 expression was required in 
plasmacytoid dendritic cells (pDCs) for migration out of the bone marrow, and 
that this defect was CCR5 mediated (Sawai et al., 2013), further work showed 
that this retention was also regulated by Runx2-mediated inhibition of CXCR4 
(Chopin et al., 2016). Within the T cell population, Vaillant et al showed that 
Runx2 was expressed during the DN stage of thymic development, and that 
enforced expression of Runx2 lead to block of thymocyte development at the 
TCRβ-selection stage (Vaillant et al., 2002). These Runx2-enforced DN cells 
went on to become CD4-CD8+TCR- immature single positive thymocytes (ISPs), 
which were more sensitive to TGFβ-induced proliferation (Vaillant et al., 2002).  
 
Two previous studies have hinted at the role of Runx2 in CD8+ T cell memory. 
The first is an immunological genome project resource paper that analyzed the 
transcriptome throughout infection to determine transcriptional factors with 
effector or memory transcriptional profiles. This work found Runx2 was a 
predicted activator/repressor during CD8+ T cell response to infection (Best et al., 
2013). The second study was performed by Hu et al, where they collected 386 
gene expression profiles from naïve, effector, and memory CD8+ T cells from 35 
GEO datasets and generated a genome-wide regulatory network (Hu & Chen, 
2013). In this network, they identified Runx2 as a highly-ranked transcription 
factor important for regulating CD8+ T cell memory. They further showed that 
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Sox4 and Eomes, but not TCF1, bound to the promoter region of Runx2 in 2C T 
cells. Interestingly, they did not find any differences in memory formation in 
retroviral overexpression or shRNA knockdown of Runx2 in 2C T cells activated 
in vitro (Hu & Chen, 2013). With this limited information of Runx2 in the immune 
system, we sought to determine how loss of Runx2 in the T cell compartment led 
to a defect in the total number of pathogen-specific CD8+ T memory cells. 
 
Acute LCMV-Armstrong versus Chronic LCMV-Clone 13 
Lymphocytic Choriomeningitis Virus (LCMV) is a group V ambisense single 
strand RNA (ssRNA) virus from the Arenaviridae family of viruses. LCMV 
contains 2 RNA strands, a long and short strand. The long strand encodes the 
RNA-dependent RNA polymerase as well as a zinc finger binding Z protein, 
whereas the short strand encodes the glycoprotein (GP) precursor that gets 
cleaved into GP1 and GP2 as well as the nucleoprotein (NP). LCMV was first 
isolated in 1933 from monkeys in St. Louis by Charles Armstrong, for whom the 
strain was named (Welsh & Seedhom, 2008). 
 
LCMV has been a model viral infection for studying the immune response for 
decades. This is because LCMV has many features that make it a promising 
candidate for study. The receptor LCMV uses to enter a host cell, α-dystroglycan 
receptor, is a ubiquitous protein that is expressed across many different species, 
making propagation of the virus simple. LCMV is a naturally occurring infection in 
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mice. This allows us to look at the normal in vivo response to infection in an 
animal model that shares many similarities with humans. LCMV is also a non-
cytolytic virus, which means that any response that is occurring, cell death or 
otherwise, is being generated by the immune response, and not through viral-
mediated cell death.  Another reason LCMV is a strong candidate for viral 
infection studies is that there are acute and chronic viral strains of LCMV, with 5 
gene mutations between acute LCMV-Armstrong and chronic LCMV-Clone 13 
leading to two amino acid difference (Matloubian et al.,1993). Because of this, 
LCMV has become a staple viral infection used in studying in vivo viral infection 
responses in mouse models.  
 
LCMV-Armstrong: An Acute Viral Infection 
LCMV-Armstrong is an acute viral infection in mice. LCMV-Armstrong elicits a 
strong CD8+ T cell response where the majority of the response is compromised 
of a two immunodominant epitopes (GP33-41, NP396-404) (Basler et al., 2004) 
(Probst et al., 2003) (Tewari et al., 2004) (van der Most et al., 1998) as well as 
several subdominant epitopes (Kotturi et al., 2007). The peak of the CD8+ T cell 
response occurs around day 8 post-infection, and clearance of virus occurs 
between day 7-9 post-infection. The CD8+ T cell response is required for viral 
clearance in LCMV-Armstrong infection, whereas the CD4+ T cell response is 
dispensable (Matloubian et al., 1994). CD8+ TECs and MPCs can be 
differentiated by flow cytometry starting at day 8 post-infection, when CD127 
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expression can be visualized by fluorescent antibody staining.  LCMV-Armstrong 
generates a typical TEC and MPC response, which was characterized above, 
unlike LCMV-Clone 13, which generates an exhausted CD8+ T cell population. 
 
LCMV-Clone 13: Chronic Viral Infection 
LCMV-Clone 13 varies from LCMV-Armstrong by 5 nucleotides and by 2 amino 
acids, GP1 (F260L) and L-polymerase (K1076Q) (Sullivan et al., 2011). Of these 
two amino acid substitutions, only GP1 (F260L) is believed to be responsible for 
persistent infection in mice. The F260L mutation in the GP1 receptor causes 
increased binding affinity for cellular receptor, α-dystroglycan, which is highly 
expressed on dendritic cells (Cao et al., 1998) (Sevilla et al., 2000) (Smelt et al., 
2001). The point mutation allows LCMV-Clone 13 to displace extracellular matrix 
proteins and facilitate virus-receptor interaction (Kunz et al., 2001). This 
increased binding affinity to α-dystroglycan on dendritic cells also inhibits 
dendritic cell mediated T-cell anti-viral functions (Sevilla et al., 2000) (Smelt et 
al., 2001) which lead to viral persistence in the host and T cell exhaustion. 
 
CD8+ T Cell Exhaustion 
T cell exhaustion is a unique state that T cells differentiate into during chronic 
stimulation. T cell exhaustion occurs often during chronic infection (Zajac et al., 
1998) (Gallimore et al., 1998) or cancer (Lee et al., 1999) and is characterized by 
a decrease in effector function, an increase in inhibitory receptors, and eventual 
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deletion of pathogen-specific cells (Figure 1.2) (Zajac et al., 1998) (Wherry et al., 
2003) (Moskophidis et al., 1993). Exhaustion is directly correlated with TCR 
signal strength, with immunodominant epitopes undergoing clonal deletion and 
sub-immunodominant epitopes becoming the major CD8+ T cell response during 
chronic viral infection (Wherry et al., 2003). Exhausted CD8+ T cells are unable to 
form a memory population (Wherry et al., 2004), and require epitope-specific 
TCR signals in order for long-term maintenance to occur (Shin et al., 2007).  
 
Immunoregulation is a critical part of T cell exhaustion. The two major negative 
regulators during LCMV-clone 13 infection are cell surface inhibitory receptors 
and soluble factors. Inhibitory receptors play a critical role in self-tolerance and 
the prevention of autoimmunity (Freeman et al., 2006). Inhibitory receptors are 
expressed transiently during CD8+ T cell activation, however, prolonged 
expression of inhibitory receptors is a hallmark of T cell exhaustion (Barber et al., 
2005). The major inhibitory receptors known to play a critical role in CD8+ T cell 
exhaustion are PD-1 (CD279), LAG-3, 2B4 (CD244), CD160, TIM-3, and CTLA-
4. PD-1 affects CD8+ T cell survival and proliferation (Petrovas et al., 2006) 
(Petrovas et al., 2007) (Blackburn et al., 2008a) (Blackburn et al., 2010), whereas 
LAG-3 affects CD8+ T cell proliferation alone (Workman et al., 2004). The role of 
2B4 and CD160 is not well defined during CD8+ T cell exhaustion; however the 
number of inhibitory receptors expressed by the same CD8+ T cell directly 
correlates with severity of exhaustion (Blackburn et al., 2008b). 
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Figure 1.2. Graded loss of function in CD8+ T cell exhaustion during 
chronic viral infection 
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Figure 1.2. Graded loss of function in CD8+ T cell exhaustion during 
chronic viral infection 
During infection with a virus, naïve pathogen-specific CD8+ T cells become 
activated, clonally expand, and differentiate into effector CD8+ T cells. Effector T 
cells are able to produce cytokines such as IFNγ and TNFα, and perform 
cytotoxic activities on infected host cells. Clearance of pathogen allows for 
formation of CD8+ T cell memory. These memory cells produce high levels of 
IFNγ, TNFα, and IL-2, and are able to rapidly respond to reinfection by 
proliferating and performing effector functions.  During chronic viral infection 
where antigen is not cleared, CD8+ T cells differentiate into exhausted T cells. 
Exhausted CD8+ T cells slowly lose the ability to produce cytokines, proliferate, 
or perform effector functions as they become more exhausted. They also express 
more inhibitory exhaustion markers (i.e. PD-1, 2B4, LAG-3, CD160) and undergo 
apoptosis as they become more exhausted.  
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Two major immunregulatory cytokines known to play a critical role during LCMV-
clone 13 infection are IL-10 and TGFβ. IL-10 is produced by CD4+ T cells and  
dendritic cells during LCMV-clone 13 infection (Brooks et al., 2006b) (Ejrnaes et 
al., 2006). Blockade of IL-10 has been shown to increase viral control and 
enhance T cell responses during LCMV-clone 13 infection (Brooks et al., 2006b) 
(Ejrnaes et al., 2006). TGFβ has also been shown to suppress CD8+ T cell 
functionality during chronic viral infection, and blocking TGFβ signaling pathways 
in CD8+ T cells leads to increased functionality and prevention of severe 
exhaustion in CD8+ T cells (Tinoco et al., 2009). 
 
Exhausted CD8+ T cells are transcriptionally unique from TECs and MPCs, and 
are believed to be their own differentiation state (Wherry et al., 2007).  Future 
work understanding transcriptional regulation of exhaustion in CD8+ T cells will 
be critical for treatment of chronic infections and cancer systems where 
exhaustion occurs.  
 
Thesis Objectives 
ITK is a major downstream signaling component of the TCR signaling pathway. 
ITK is the first component downstream of TCR signaling that is not required for T 
cell activation; however, loss of ITK leads to sub-optimal T cell activation with a 
decrease in Ca2+ flux and DAG production. As a result ITK-deficient mice 
generate an innate-like population of CD8+ T cells in response to LCMV-
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Armstrong infection. To understand how sub-optimal TCR signaling impacted the 
transcriptional profile of these cells, we performed a microarray comparing ITK-
deficient CD8SP thymocytes to WT controls. The most highly upregulated 
transcription factor in ITK-deficient cells was Runx2, whereas the most highly 
upregulated transcription factor in WT cells was IRF4. These results indicated 
that TCR signal strength positively regulated IRF4 expression levels, and TCR 
signal strength repressed Runx2 expression levels in CD8+ T cells. Both IRF4 
and Runx2 are upregulated upon activation of CD8+ T cells; however, IRF4 is 
upregulated early after TCR signaling, whereas Runx2 is upregulated later during 
the clonal expansion phase and continues to stay upregulated through the 
memory phase of the CD8+ T cell response. IRF4 was also chosen for our study 
because previous work in B cells indicated that IRF4 was upregulated in 
proportion to BCR signal intensity, and regulated differentiation of various B cell 
subsets upon activation. Based on these data, we hypothesized that the 
strength of TCR signaling regulated IRF4 expression in activated CD8+ T 
cells, as well as positively regulating CD8+ T cell differentiation during viral 
infection. Due to the memory-like phenotype of ITK-deficient cells and the 
expression pattern of Runx2, we also hypothesized that Runx2 regulated 
CD8+ T cell memory during viral infection.  These hypotheses have been 
addressed in this thesis in the following three chapters: 
 
Chapter III: Graded Levels of IRF4 Regulate CD8+ T Cell Differentiation and 
	 31	
Expansion during Acute LCMV Armstrong Infection: This chapter tests the 
hypothesis that TCR signal strength through affinity of peptide to TCR and 
peptide dose regulate expression levels of IRF4 in CD8+ T cells, which in turn 
regulates the magnitude of the CD8+ T cell effector response during LCMV-
Armstrong infection.  
 
Chapter IV: IRF4 Regulates the Ratio of Eomesodermin to T-bet in CD8+ T 
Cells Responding to Persistent LCMV Infection: Results from chapter III 
indicated that IRF4 expression was regulated by TCR signal strength, and that 
IRF4 expression levels regulated the magnitude of the CD8+ T cell response. 
One way IRF4 did this is through regulation of the transcription factors T-bet and 
Eomes. An optimal ratio of Eomes to T-bet is required for viral clearance during 
LCMV-Clone 13 infection, however, how this balance is maintained is not well 
understood. This chapter tests the hypothesis that IRF4 regulates the levels of T-
bet to Eomes during LCMV-Clone 13 infection, and that a haplodeficiency in 
IRF4 will lead to a defect in viral clearance through skewed T-bet to Eomes 
ratios. 
 
Chapter V: Runx2 is Required for Long-Term Persistence of Antiviral CD8+ 
T Memory Cells during Acute LCMV-Armstrong Infection: This chapter tests 
the hypothesis that Runx2-deficiency will impact the pathogen-specific CD8+ 
memory response during LCMV-Armstrong infection, and that Runx2 is inversely 
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correlated to TCR signal strength, and is potentially repressed by IRF4.  
 
 
 
 
 
 
 
 
 
	 33	
 
Chapter II:  
Materials and Methods 
 
 
 
 
 
	 34	
Mice 
Mice were bred and housed in specific pathogen-free conditions at the University 
of Massachusetts Medical School (UMMS) in accordance with institutional animal 
care and use committee guidelines.  
 
Chapter III: 
Irf4fl/fl CD4-Cre+ and OT-I Rag1-/- Irf4fl/fl CD4-Cre+ have been described previously 
(Nayar et al., 2012) (Klein et al., 2006). P14 TCRα-/- were purchased from 
Taconic Farms (Germantown, New York). Irf4+/+ CD4-Cre+, Irf4+/fl, and Irf4+/+ 
were used as wild-type (WT) controls.  
 
Chapter IV: 
Irf4fl/fl and Eomesfl/fl mice have been described previously (Klein et al., 2006) (Y. 
Zhu et al., 2010). CD4-Cre+ transgenic mice were a gift from Joonsoo Kang 
(UMMS). Irf4fl/fl mice were crossed to CD4-Cre+ transgenic mice at UMMS to 
generate Irf4fl/fl CD4-Cre+ mice. P14 TCR transgenic TCRα-/- used for in-vitro 
studies were purchased from Taconic Farms (Germantown, New York) and 
crossed to Irf4fl/fl CD4-Cre+ mice at UMMS. P14 TCR transgenic mice used for in 
vivo studies were a gift from Susan Kaech (Yale), and were crossed to Irf4fl/fl 
CD4-cre+ mice to generate P14 Irf4+/fl CD4-cre+ mice. Eomesfl/fl mice were 
purchased from The Jackson Labs (Maine) and crossed to Irf4+/fl CD4-Cre+ at 
UMMS. Irf4+/+ and Irf4+/+ CD4-Cre+ mice were used as WT controls.  
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Chapter V: 
C57BL/6J mice were purchased from Jackson (Bar Harbor, ME) and bred in 
house. OT-I TCR transgenic Rag2-/- mice were purchased from Taconic 
Bioscience (Germantown, NY) and bred in house. Runx2fl/fl mice were a gift from 
Dr. Amjad Javed (University of Alabama at Birmingham) (H. Chen et al., 2011). 
CD4-cre+ transgenic mice were a gift from Dr. Joonsoo Kang (UMMS). P14 TCR 
transgenic mice were a gift from Susan Kaech (Yale), and were crossed to 
Runx2fl/fl CD4-cre+ transgenic mice. Runx2+/+ and Runx2+/+ CD4-cre+ mice were 
used as WT controls. Irf4+/fl CD4-cre+ and Irf4fl/fl CD4-cre+ mice have been 
described previously (Nayar et al., 2012) (Klein et al., 2006). 
 
Virus and Infections 
Chapter III: 
For virus infections, LCMV-Armstrong GP33 and F6L variants were injected i.p. at 
5x104 PFU, unless otherwise specified. For adoptive transfers, splenocytes from 
P14 WT CD45.1+CD45.2+, P14 Irf4+/fl CD45.2+, OT-I WT CD45.1+, or OT-I 
Irf4+/flCD45.2+ mice were stained with Abs to CD8α and Vα2 to determine the 
proportions of P14 or OT I cells, and equal numbers of WT and Irf4+/fl cells were 
mixed. Total P14 cells (2,000, 20,000, or 1,000,0000) were transferred i.v. into 
WT or CD45.1+ hosts 1 day prior to infection.  
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Chapter IV: 
LCMV-clone 13 stocks were propagated in baby hamster kidney 21 cells at 
UMMS (Welsh & Seedhom, 2008) and were generously provided by Dr. 
Raymond M. Welsh and amplified by us. Adult male mice (6–9 weeks old) were 
infected with an exhausting dose, 2x106 PFU of LCMV-clone 13 i.v. For adoptive 
transfers, 1x104 WT or Irf4+/fl P14 cells were i.v. transferred into WT CD4-Cre+ 
host mice one day prior to infection.  
 
Chapter V: 
Adult male mice (7-11 weeks old) were infected with LCMV-Armstrong at 5x104 
PFU i.p.  For rechallenge, mice were infected with LCMV-Clone 13 at 2x106 PFU 
i.v. LCMV-Armstrong and LCMV-Clone 13 were graciously provided by Dr. 
Raymond Welsh (UMMS). For co-adoptive transfers, splenocytes from P14 WT 
CD4-cre+ CD90.1+ CD90.2+ and P14 Runx2fl/fl CD4-cre+ CD90.1+ were stained 
with antibodies to CD8α and Vα2 to determine proportions of P14 cells, and 
equal numbers of WT and Runx2fl/fl cells were mixed. 10,000 P14 cells were 
transferred i.v. into CD90.2+ host mice 1 day prior to infection. 
 
Viral Titers 
Chapter III: 
Spleens were harvested at day 8 postinfection (p.i.), homogenized in media and 
stored at -80°C.  
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Chapter IV:  
Sera, livers and kidneys were harvested from infected mice at the indicated time 
points post-infection (p.i.). Organs were homogenized in one ml of complete 
RPMI media and stored at -80°C. LCMV-clone 13 virus titers were determined by 
plaque assays as previously described (Welsh & Seedhom, 2008).  
  
 
Chapter V: 
Spleens and fat pads were harvested 9 days post LCMV Armstrong infection. For 
rechallenge, kidneys and livers were harvested 4 days post LCMV Clone 13 
infection. Organs were homogenized in 1ml RPMI media and stored at -80°C.  
Plaque assays were performed as described previously (Welsh & Seedhom, 
2008).  
 
Cell Culture 
Chapter III: 
Lymph node cells from P14 WT and P14 Irf4+/fl mice were mixed with equal 
numbers of WT CD45.1 splenocytes and stimulated with GP33–41 epitope (GP33) 
or F6L peptides for 24, 48, and 72 hours. Cells were harvested and analyzed for 
IRF4, Eomes, and TCF1 expression by intracellular staining. For cytokine 
production, splenocytes from infected mice were stimulated with GP33, GP276, 
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and NP396 peptide for 5 hours in the presence of 1 mg/ml GolgiStop and 1 mg/ml 
GolgiPlug, and Abs to CD107a and CD107b.  
 
Chapter IV: 
Lymph node cells from P14 WT, P14 Irf4+/fl or P14 Irf4fl/fl mice were mixed with 
equal numbers of WT CD45.1 splenocytes and stimulated with GP33–41 or F6L 
peptides for 24, 48, and 72 hours. Cells were harvested and analyzed for T-bet 
and Eomes expression by intracellular staining. For cytokine staining, cells were 
stimulated ex vivo with 1µg/ml GP276-286 or GP33-41 peptide for 5 hours at 37°C.  
 
Chapter V: 
Splenocytes from OT-I TCR transgenic mice were stimulated with OVA, T4, or 
G4 peptide with indicated doses for 72 hours. Cells were harvested and analyzed 
for Runx2, Eomes, and CD44 expression by intracellular staining. For cytokine 
experiments, IFNβ and IL-12 were purchased from R&D Systems 
(Minneanapolis, MN). IL-7 and IL-15 were purchased from Peprotech (Rocky Hill, 
NJ). OVA, T4, and G4 peptides were purchased from 21st Century Biochemicals 
(Marlborough, MA). Imiquimod was purchased from invivogen (San Diego, CA). 
LPS was purchased from Sigma (St. Louis, MO). Splenocytes from Irf4+/+ CD4-
cre+, Irf4+/fl CD4-cre+, and Irf4fl/fl CD4-cre+ mice were isolated and plated with 
platebound anti-CD3 /CD28 for 72 hours. Cells were harvested and analyzed for 
Runx2, Eomes, and CD44 expression by intracellular staining. For cytokine 
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production, splenocytes from infected mice were stimulated with GP33-41, GP276-
286, and NP396-404 peptide for 4 hours in the presence of 1µg/ml GolgiStop and 
1µg/ml GolgiPlug, and antibodies to CD107a and CD107b. GP33-41, GP276-286, 
and NP396-404 peptides were generously provided by Dr. Raymond Welsh 
(UMMS) and generated by Keith Daniels.  
 
Antibody and H2-Db Tetramer Staining 
Chapter III: 
Antibodies binding to the following were purchased: 
 CD45.2 (V500) and TNFα (APC-Cy7) were purchased from BD Biosciences 
(San Jose, CA). KLRG1 (FITC), Eomes (PE), CD107a (PE), CD107b (PE), CD27 
(PE), CD127 (PE-Cy5), CD127 (PerCP-Cy5.5), T-bet (PerCP-Cy5.5), IFNγ 
(PerCP-Cy5.5), Eomes (PerCP-efluor710), CD45.1 (PECy7), KLRG1 (PE-Cy7), 
T-bet (PE-Cy7), IRF4 (Alexa Fluor 647), CD44 (Alexa Fluor 700), CD62L (APC-
eFluor780), CD44 (eFluor450), KLRG1 (eFluor450), IFNγ (eFluor450), CD90.2 
(APC-eFluor780), CD45.1 (APC-eFluor780), IL-2 (PerCP-Cy5.5) were purchased 
from eBioscience (San Diego, CA). CD8α (PE-TexasRed), granzyme B (PE), 
granzyme B (APC), Live-Dead-Violet, Live-Dead-Aqua and goat-anti-rabbit IgG 
(Alexa Fluor 647) and (Alexa Fluor 488) were purchased from Life Technologies 
(Grand Island, NY). H2Db-GP33 monomers were prepared at the University of 
Massachusetts Medical School; LCMV-specific (H2Db-NP396 and H2Db-GP276) 
monomers were obtained from the NIH Tetramer Core Facility (Atlanta, GA). 
	 40	
Intracellular TCF1 staining was performed using rabbit-anti-mouse TCF1 (Cell 
Signaling Technology, Danvers, MA), followed by staining with goat-anti-rabbit 
secondary (Life Technologies). Samples were analyzed on an LSRII flow 
cytometer (BD Biosciences), and data were analyzed using FlowJo (Tree Star).  
 
Chapter IV: 
Antibodies to the following were purchased: 
Eomes (PE), CD244.2 (PE), T-bet (PerCP-Cy5.5), Eomes (PerCP-eFluor710), 
CD223 (PerCP-eFlour710), TNFα (PerCP-eFluor710), T-bet (PE-Cy7), IFNγ 
(eFluor450), IL-2 (APC), and CD279 (APC) were purchased from eBioscience 
(San Diego, CA). CD160 (PE-CF594) was purchased from BD (Billerica, MA). 
CD8α (PE-TexasRed), Granzyme B (PE), Live/Dead Fixable Aqua Dead Cell 
Stain Kit were purchased from Life Technologies (Grand Island, NY). H2Db-GP33 
monomers were prepared at UMMS; LCMV-specific H2Db-GP276 and H2Db-GP33 
monomer were obtained from the NIH Tetramer Core Facility (Atlanta, GA). 
Single cell suspensions from spleens were prepared, RBC lysed and Fc receptors 
were blocked using supernatant from 2.4G2 hybridomas. Cells were stained with 
H2Db-GP276 or H2Db-GP33 tetramers prior to staining with cell-surface antibodies. 
For cytokine staining, cells were stimulated ex vivo with 1µg/ml GP276-286 or GP33-
41 peptide for 5 hours at 37°C. LCMV peptides GP276-286 (SGVENPGGYCL), GP33-
41 (KAVYNFATC) and F6L (KAVYN- LATC) were synthesized and HPLC purified 
by 21st century Biochemicals (Marlboro, MA). Peptides were ~90% pure. 
	 41	
Intracellular cytokine staining was performed using BD Cytofix/CytopermTM 
Fixation/Permeabilization Solution kit. Intracellular transcription factor staining 
was performed using eBioscience Foxp3/transcription factor staining kit, as per 
manufacturer’s instructions, unless specified. All samples were analyzed on an 
LSRII flow cytometer (BD Biosciences), and data were analyzed using FlowJo 
(Tree Star).  
 
Chapter V:  
Antibodies to the following were purchased: 
CD127 (FITC), Bcl2 (PE), Bcl6 (PE), IRF4 (PE), CD8α (PE-eFluor 610), TNFα 
(PerCP-eFluor 710), Eomes (PerCP-eFluor 710), CD122 (PerCP-eFluor 710), T-
bet (Pe-Cy7), CD44 (PE-Cy7 and Alexa Fluor 700), KLRG1 (PE-Cy7 and eFluor 
450), IFNγ (eFluor 450), IL-2 (APC), Vα2 (APC), CD27 (APC-eFluor 780), and 
CD90.2 (APC-eFluor 780) antibodies were purchased from eBioscience (San 
Diego, CA). CD107a (FITC), CD107b (FITC), CD62L (FITC), 7-AAD, AnnexinV 
(PE), and CD90.1 (V500) were purchased from BD (Billerica, MA). Antibodies to 
Granzyme B (PE), Live/Dead Violet, Live/Dead Aqua, and Goat α Rabbit (Alexa 
Fluor 647) were purchased from LifeTech (Grand Island, NY). H2-Db GP33-41, H2-
Db GP276-286, H2-Db NP396-404 monomers were obtained from the NIH Tetramer 
Core Facility (Atlanta, GA). Runx2 and TCF1 antibodies were purchased from 
Cell Signaling Technologies (Danvers, MA). Single cell suspensions from 
spleens, bone marrow, lymph nodes, lung, and liver were prepared, RBC lysed, 
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and Fc receptors were blocked using supernatant from 2.4G2 hybridomas. 
Lymphocytes were isolated from lung and liver using Lympholyte-M (CedarLane; 
Burlington, NC), and perfusion was performed on mice to prevent contamination 
of blood lymphocytes in these preparations. Cells were stained with H2-Db GP33-
41, H2-Db GP276-286, and H2-Db NP396-404 tetramers prior to staining with cell 
surface antibodies. For cytokine staining, cells were stimulated ex vivo with 
1ug/ml GP33-41, GP276-286, or NP396-404 for 4 hours at 37°C. Intracellular cytokine 
staining was performed using BD Cytofix/Cytoperm™ Fixation/Permeabilization 
Solution kit. Intracellular transcription factor staining was performed using 
eBioscience FoxP3/transcription factor staining kit. Samples were analyzed on 
the LSRII flow cytometer (BD Bioscience), and data was analyzed on FlowJo 
(Tree Star). 
 
LCMV-Specific Antibody Titers  
To quantify LCMV-specific antibody titers, high-binding 96 well flat bottom ELISA 
plates (Corning) were coated overnight at room temperature with cell lysate from 
LCMV-clone 13 infected BHK21 cells. Plates were washed, blocked and three-
fold serial dilutions of serum samples were plated. Plates were washed again 
and incubated with horseradish peroxidase labeled goat anti-mouse IgG 
detection antibody (Bethyl labs) and developed using 3,3',5,5'-Tetra- 
methylbenzidine substrate. The reaction was quenched 0.18M H2SO4 ELISA stop 
solution (Bethyl Labs) and the optical density (OD) was measured at 450nm 
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using an Emax Endpoint ELISA microplate reader (Molecular Devices). LCMV-
specific antibody titers were determined by end-point titer method and two times 
the mean OD of uninfected control sera was used as the cut-off.  
 
Statistical Analysis 
Chapters III, V: 
All data are represented as mean ± SEM. Statistical significance is indicated by 
nsp > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001, based on 
unpaired student t test. 
 
Chapter IV: 
All data are represented as mean ± SEM. Statistical significance is indicated by 
nsp > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001, based on 
unpaired student t test. For outlined day 112-114 samples, statistical significance 
is indicated by $p ≤ 0.05 and $$p ≤ 0.01. Statistical analysis was performed 
using unpaired t test with Welch’s correction, ordinary one-way ANOVA using 
Tukey’s multiple comparison test or Log-rank (Mantel-Cox) test as indicated in 
the figure legend.  
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Introduction 
In response to acute infections, CD8+ T cells undergo priming, differentiation, and 
expansion to generate robust effector responses that are required for Ag 
clearance (Williams & Bevan, 2007) (Kaech & Wherry, 2007). At the termination 
of the response, the majority of these effector CD8+ T cells die by apoptosis, 
whereas a small population of efficient memory T cells survives. These memory 
CD8+ T cells are primed for rapid proliferation and effector functions upon 
reinfection. 
The magnitude and quality of the CD8+ T cell response to an infection is 
influenced by many factors, including the affinity of TCR-peptide/MHC 
interactions, the Ag load, costimulatory molecule expression, and the 
inflammatory cytokine environment. Differences in TCR affinity do not affect the 
initial activation of Ag-specific CD8+ T cells, but at later time points, T cells with 
the highest affinity for the Ag dominate the response (Zehn et al., 2009). 
Similarly, Ag load does not influence the numbers of CD8+ T cells at the early 
expansion phase but does regulates the size of the overall response at the peak 
of infection (Badovinac et al., 2002) (Mercado et al., 2000) (Prlic et al., 2006). To 
date, the molecular mechanisms linking TCR affinity and Ag density to the 
magnitude of the CD8+ T response have not been characterized. 
CD8+ T cell responses to acute infections are also regulated by variations in 
transcription factor expression. High expression of T-bet and Blimp-1 drive the 
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differentiation of primed CD8+ T cells into terminal effectors, whereas T cell factor 
1 (TCF1) and Eomesodermin (Eomes) are important for the generation and 
maintenance of memory cells (Rutishauser et al., 2009) (Joshi et al., 2007) 
(Kallies et al., 2009) (Zhou et al., 2010) (Banerjee et al., 2010) (Jeannet et al., 
2010). Although the cytokine milieu influences the transcription factor profile of 
activated CD8+ T cells (Joshi et al., 2007) (Cui et al., 2011), how these different 
molecular programs are initially established is not known. 
The transcription factor IRF4 is upregulated by BCR and TCR signaling 
(Matsuyama et al., 1995) (Eisenbeis et al., 1995). In B cells, different levels of 
IRF4 regulate differentiation to Ab-secreting plasma cells versus germinal center 
cells (Sciammas et al., 2006). In T cells, IRF4 is required for the differentiation of 
helper CD4+ T cell subsets, functional regulatory T cells, and effector and innate 
like CD8+ T cells (Mittrücker et al., 1997) (Lohoff et al., 2002) (Rengarajan et al., 
2002) (Staudt et al., 2010) (Brüstle et al., 2007) (Huber et al., 2012) (Chung et 
al., 2009) (Zheng et al., 2009) (Cretney et al., 2011) (Nayar et al., 2012). 
Furthermore, IRF4 was initially found to be required for normal T cell responses 
to acute lymphocytic choriomeningitis virus (LCMV) infection (Mittrücker et al., 
1997). However, the role of IRF4 in CD8+ T cell differentiation to acute infections 
has not been characterized in detail, and importantly, the regulation of this 
process by distinct levels of IRF4 has not been investigated. In this study, we 
show that variations in Ag dose or in the affinity of TCR–peptide/MHC 
interactions lead to different levels of IRF4 expression in CD8+ T cells. In turn, 
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these differences regulate the magnitude of the CD8+ T cell response to acute 
virus infection at the peak of the infection without having any substantial effect on 
CD8+ T cell attrition. Eomes and TCF1 expression are highly sensitive to distinct 
levels of IRF4, whereas the effects of IRF4 on T-bet expression are dependent 
on the nature of the infection. These data indicate that IRF4 is a key factor that 
links signals from the TCR to the transcriptional programming of CD8+ T cells. 
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Results 
The strength of TCR signaling regulates the levels and duration of 
transcription factor expression  
The expression of IRF4 is upregulated in naive T cells by TCR signaling 
(Matsuyama et al., 1995). This response is dependent on the activation of the 
Tec kinase Itk (Nayar et al., 2012). To determine whether the levels of IRF4 were 
affected by the strength of TCR signaling to stimulation by natural ligands, P14 
TCR transgenic TCRα-/- (hereafter referred to as P14 WT) CD8+ T cells (Pircher 
et al., 1989) were stimulated in vitro, and IRF4 levels were examined by 
intracellular staining. The P14 TCR recognizes the GP33 of LCMV bound to H2-
Db. A single amino acid substitution from phenylalanine to leucine at position six 
generates a lower affinity peptide ligand, F6L (Gronski et al., 2004). F6L–H2-Db 
complexes display ∼5-fold reduction in the equilibrium dissociation constant (KD) 
for binding to the P14 TCR, and 100- to 1,000- fold reduction in functional avidity.  
P14 T cells were stimulated with the high-affinity GP33 peptide and the lower 
affinity F6L variant. At 24 hours, both populations of cells expressed similar 
amounts of IRF4. However, high IRF4 expression was sustained at 48 and 72 
hours post-stimulation in cells stimulated with GP33 peptide, whereas cells 
stimulated with F6L peptide showed declining IRF4 as early as 48 hours post-
activation (Figure 3.1A). Histograms showing IRF4 staining on IRF4-deficient 
P14 T cells (Irf4fl/fl) stimulated with the GP33 peptide are included as negative 
	 50	
Figure 3.1. Variations in TCR affinity and Ag dose upregulate IRF4, Eomes, 
and TCF1 to different levels 
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Figure 3.1: Variations in TCR affinity and Ag dose upregulate IRF4, Eomes, 
and TCF1 to different levels 
P14 WT and P14 Irf4fl/fl were stimulated in vitro. At 0, 24, 48, and 72 hours, cells 
were stained and analyzed for IRF4, Eomes, and TCF1 expression. Histograms 
show gated live CD8+CD45.2+ CD44hi T cells. Gray histograms show staining on 
direct ex vivo CD8+CD45.2+ P14 WT cells. P14 Irf4fl/fl cells stimulated with 1mM 
GP33 peptide are included as negative staining controls for IRF4 expression. 
Data are representative of four independent experiments. Graphs are 
compilations of raw MFI of gated live CD8+CD45.2+CD44hi T cells. (A, C, and E) 
P14 WT T cells were stimulated with 1mM GP33 or F6L peptide. *, significant 
differences in MFI of WT cells stimulated with GP33 versus F6L ligands. (B, D, 
and F) P14 WT cells were stimulated with the indicated doses of GP33 peptide. 
(B) 1mM and 100nM stimulation conditions were significantly different for IRF4 
100nM at all time points. (D) 10nM stimulation was significantly different from 
1mM and 100nM at 24 hours. (F) 10nM stimulation was significantly different 
from 1mM and 100nM at 72 hours. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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controls. Alterations in peptide dose also impacted IRF4 expression. As shown, 
higher doses of GP33 peptide (1mM and 100nM) induced strong IRF4 expression 
at 24 and 48 hours post-stimulation relative to the 10nM stimulation condition 
(Figure 3.1B). By 72 hours, differences in IRF4 levels were observed between 
each of the peptide doses, with the highest peptide dose leading to the most 
sustained IRF4 expression (Figure 3.1B). These data indicate that expression of 
IRF4 is transient and is regulated by the strength of TCR stimulation.  
In CD8+ T cells, IRF4 negatively regulates the expression of Eomes: a 
transcription factor that is required for the maintenance of memory cells post-
infection (Banerjee et al., 2010) (Nayar et al., 2012). As shown in Figure 3.1C, 
stimulation with the lower affinity F6L peptide resulted in higher Eomes 
expression, correlating with its reduced IRF4 expression. Similar results were 
seen with diminishing doses of GP33 peptide (Figure 3.1D). Eomes expression in 
CD8+ T expression at 72 hours, 10nM stimulation was significantly different from 
1mM and cells is positively regulated by the transcription factor, TCF1 (Zhou et 
al., 2010). As shown in Figure 3.1E, stimulation with GP33 or F6L peptide resulted 
in similar TCF1 expression 24 hours post-activation; however, at later time 
points, TCF1 remained highest in cells stimulated with the lower affinity F6L 
ligand. A similar pattern was seen with the lowest dose of GP33 peptide (Figure 
3.1F). Taken together, these data demonstrate that varying TCR signal strength, 
either by changes in TCR-MHC/peptide affinity or dose, leads to distinct 
expression patterns of three key transcription factors in CD8+ T cells.  
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Figure 3.2. Irf4 regulates Eomes and TCF1 expression in a dose-dependent 
manner 
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Figure 3.2: Irf4 regulates Eomes and TCF1 expression in a dose-dependent 
manner 
(A–C) P14 WT, P14 Irf4+/fl, and P14 Irf4fl/fl cells were stimulated with 1mM GP33 
peptide for the indicated time points, and cells were stained and analyzed for 
IRF4, Eomes, and TCF1 expression. Histograms show gated live 
CD8+CD45.2+CD44hi T cells. Gray histograms show staining on direct ex vivo 
CD8+CD45.2+ P14 WT cells. Data are representative of four independent 
experiments. Graphs are compilations of raw MFI of gated live 
CD8+CD45.2+CD44hi T cells. (A) IRF4 expression was significantly different 
between all genotypes at 24 and 48 hours and between P14 WT and P14 Irf4+/fl 
cells and P14 WT and P14 Irf4fl/fl cells at 72 hours. (B) P14 WT and P14 Irf4fl/fl 
cells were significantly different at all time points, whereas P14 Irf4+/fl and P14 
Irf4fl/fl cells were significantly different at 48 and 72 hours. (C) TCF1 expression 
was significantly different between P14 WT and P14 Irf4+/fl cells at 72 hours. *p ≤ 
0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. 
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To determine whether IRF4 regulated the expression of Eomes and/or TCF1, we 
used P14 T cells with one or two alleles of Irf4 deleted (Irf4+/fl x CD4-Cre and 
Irf4fl/fl x CD4-Cre, referred to as Irf4+/fl and Irf4fl/fl, respectively). For these studies, 
P14 WT, P14 Irf4+/fl, and P14 Irf4fl/fl T cells were stimulated in vitro with GP33 
peptide. As expected, WT cells expressed the highest levels of IRF4, whereas 
Irf4+/fl cells expressed intermediate levels of IRF4 relative to Irf4fl/fl and WT cells 
24 and 48 hour time points (Figure 3.2A); furthermore, this pattern of expression 
showed a striking similarity to that seen following stimulation of WT P14 T cells 
with the lower affinity F6L ligand or with lower doses of GP33 peptide (compare 
Figure 3.2A with Figure 3.1A-B). Eomes expression inversely correlated with 
IRF4 levels; P14 Irf4fl/fl cells expressed the highest levels of Eomes, with Irf4+/fl T 
cells expressing intermediate levels of Eomes compared with WT cells (Figure 
3.2B). TCF1 expression was elevated in Irf4fl/fl and Irf4+/fl cells at the 72 hour time 
point relative to the WT samples with Irf4+/fl cells expressing the highest levels of 
TCF1 (Figure 3.2C). These data indicate that a complete or heterozygous 
deficiency in Irf4 leads to lower expression of IRF4, and in turn, this alteration 
changes the expression patterns of Eomes and TCF1 in stimulated CD8+ T cells. 
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Figure 3.3. Reduced gene dosage of Irf4 limits CD8+ T cell clonal expansion 
at the peak of the response without affecting attrition (GP33) 
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Figure 3.3. Reduced gene dosage of Irf4 limits CD8+ T cell clonal expansion 
at the peak of the response without affecting attrition (GP33) 
Splenocytes from LCMV-infected WT, Irf4+/fl, and Irf4fl/fl mice were analyzed at 
days 8, 10, 14, and 28 p.i. (A) Dot plots show CD44 versus H2 Db-GP33 tetramer 
staining on gated live CD8+ T cells. Graphs on right show a compilation of 
percentages and numbers from day 8 p.i. (B) LCMV titers in spleen at day 8 p.i. 
Dotted line indicates limit of detection. (C) Dot plots show CD44 versus H2 Db-
GP33 tetramer staining on gated live CD8+ T cells at indicated time points post-
infection. Graphs show the compilation of total numbers of CD44hi GP33-specific 
T cells (left) and proportions of CD44hi GP33–specific T cells at each time point 
normalized to the numbers at day 8 (right). The graph below shows the 
differences in the numbers of CD44hi GP33–specific T cells between days 8 and 
28 p.i. (i.e., average number day 8 - average number day 28) for each genotype; 
the number on the graph indicates the fold difference in the average numbers of 
WT cells lost between days 8 and 28 relative to the loss of Irf4+/fl cells. Data are 
from two or more independent experiments with at least six mice per group per 
time point. (D) Splenocytes from LCMV-infected WT and Irf4+/fl mice at days 14 
and 28 p.i. were stimulated for 5 hours with GP61 peptide and analyzed for IFNγ 
expression. Graphs show a compilation of data indicating the numbers of IFNγ–
producing cells at day 14 (left) and day 28 (right) p.i. (E) Graphs show the 
average numbers at days 14 and 28 p.i. to indicate the rate of attrition (left); bar 
graph indicates the loss of GP61-specific cells at day 14 versus day 28 p.i. 
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(right); the number on the bar graph indicates the fold difference in the average 
numbers of WT cells lost between days 8 and 28 relative to the loss of Irf4+/fl 
cells. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. 
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Figure 3.4. Reduced gene dosage of Irf4 limits CD8+ T cell clonal expansion 
at the peak of the response without affecting attrition (GP276/NP396) 
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Figure 3.4: Reduced gene dosage of Irf4 limits CD8+ T cell clonal expansion 
at the peak of the response without affecting attrition (GP276/NP396) 
Splenocytes from LCMV-GP33-infected WT, Irf4+/fl, and Irf4fl/fl mice were analyzed 
at day 8, 10, 14 and 28 post-infection. Dot plots show CD44 vs H2 Db-NP396 (A) 
or CD44 vs H2 Db-GP276 (B) tetramer staining on gated live CD8+ T cells on day 
8 p.i.. Graphs on right show a compilation of percentages and numbers from day 
8 p.i. Dot plots show CD44 vs H2 Db-NP396 (C) or CD44 vs H2 Db-GP276 (D) 
tetramer staining on gated live CD8+ T cells from the indicated timepoints p.i. 
Graphs show compilations of the total numbers of virus-specific T cells (left), the 
numbers of virus-specific T cells at later timepoints normalized to the numbers 
present at day 8 p.i (right). The graph below shows the differences in the 
numbers of CD44hi GP33-specific T cells between day 8 and day 28 p.i (i.e., 
average # day 8 – average # day 28) for each genotype; the number on the 
graph indicates the fold difference in the average numbers of WT cells lost 
between day 8 and day 28 relative to the loss of Irf4+/fl cells. Data are from 2 or 
more independent experiments with at least 6 mice per group per timepoint. 
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A heterozygous deficiency in Irf4 reduces virus-specific CD8+ T cell clonal  
expansion  
 
To elucidate the role of graded IRF4 expression during polyclonal CD8+ T cell 
differentiation in vivo, WT, Irf4+/fl, and Irf4fl/fl mice were infected with LCMV-
Armstrong. Responses to three LCMV epitopes (i.e., H2-Db/GP33-41, H2-Db/NP396-
404, and H2-Db/GP276-286 [hereafter referred to as GP33, NP396, and GP276]) were 
examined using MHC–peptide tetramers. At the peak of the response (i.e., day 8 
p.i.) the magnitude of the CD8+ T cell response depended on the gene dosage of 
Irf4. WT CD8+ T cells mounted the most robust response, followed by Irf4+/fl, and 
then Irf4fl/fl cells (Figure 3.3A, 3.4A-B). Enumeration of viral titers by plaque assay 
indicated that all WT (5 of 5) and Irf4+/fl (3 of 3) mice had cleared the virus, 
whereas only 30% of Irf4fl/fl (3 of 10) mice had cleared LCMV by day 8 p.i. These 
data indicated that modest reductions in IRF4 expression did not interfere with 
viral clearance but that a minimal level of IRF4 was required for sterilizing 
immunity to LCMV (Figure 3.3B). As our in vitro studies showed reduced IRF4 
expression levels following activation of WT versus Irf4+/fl P14 T cells, these initial 
infection experiments indicated that even modest differences in the magnitude of 
IRF4 expression had a profound effect on the clonal expansion of virus-specific 
CD8+ T cells. 
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Reduced levels of IRF4 do not affect the kinetics of CD8+ T cell expansion 
or attrition  
The reduced numbers of virus specific Irf4+/fl cells at day 8 p.i. could be attributed 
to delayed kinetics of Irf4+/fl CD8+ T cell expansion relative to the WT cells. On 
the basis of previous data indicating a regulatory T cell defect in Irf4fl/fl mice that 
disrupts normal T cell homeostasis (Zheng et al., 2009), studies of Irf4fl/fl mice 
were not included in the subsequent analyses. Instead, we focused on a 
comparison of WT versus Irf4+/fl T cell responses to understand the effect of 
partial loss of IRF4 expression on CD8+ T cell differentiation. Examination of WT 
and Irf4+/fl CD8+ T cell populations at later time points following LCMV-Armstrong 
infection indicated that the peak response for both WT and Irf4+/fl CD8+ T cells 
was at day 8 p.i; by day 10 p.i., both populations had started to contract (Figure 
3.3C, 3.4C-D). Following antigen clearance, the majority of CD8+ T cells undergo 
attrition by apoptosis and form a small but stable pool of memory cells (Kaech & 
Wherry, 2007) (Williams & Bevan, 2007). Examination of virus-specific CD8+ T 
cells at days 14 and 28 p.i. confirmed that this pattern was observed for both WT 
and Irf4+/fl CD8+ T cells. However, by day 28 p.i., the differences in the numbers 
of WT and the Irf4+/fl CD8+ T cells were quite modest, and no longer significant 
for one of the three epitopes examined (Figure 3.3C, 3.4C-D). Normalization of 
virus- specific CD8+ T cell numbers to the peak of the response indicated that 
loss of one allele of Irf4 did not change the kinetics of the CD8+ T response nor 
did it affect the rate of CD8+ T cell contraction. Thus, in comparison with the 
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numbers of virus-specific T cells present at the peak of the response, greater 
numbers of WT CD8+ T cells were lost between days 8 and 28 p.i. relative to 
Irf4+/fl CD8+ T cells (Figure 3.3C, 3.4C-D). Therefore, not only did WT cells 
undergo more robust expansion than the Irf4+/fl CD8+ T cells, the WT cells also 
underwent more extensive contraction.  
We also examined the CD4+ T cell response to LCMV- Armstrong in infected WT 
and Irf4+/fl mice. Similar to our findings for CD8+ T cells, analysis of GP61 epitope–
specific CD4+ T cells at days 14 and 28 p.i. indicated a defect in Irf4+/fl CD4+ T 
cell expansion relative to the WT cells (Figure 3.3D). Furthermore, consistent 
with our analysis of the CD8+ T cell response, we found that greater numbers of 
WT GP61-epitope–specific CD4+ T cells were lost between days 14 and 28 p.i. 
relative to Irf4+/fl CD4+ T cells (Figure 3.3E).  
Taken together, these data suggest that the effects of reduced IRF4 expression 
are a general feature of CD8+ T cell responses to viral infections and furthermore 
are impacting CD4+ T cell responses as well. We conclude that different amounts 
of IRF4 expression during T cell priming regulate the magnitude of the peak 
antiviral T cell response without affecting the kinetics of the response or the rate 
of attrition following Ag clearance.  
 
Reduced gene dosage of Irf4 regulates effector cytokine expression  
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To assess CD8+ T cell effector functions following virus infection, splenocytes 
from LCMV-Armstrong–infected WT, Irf4+/fl, and Irf4fl/fl mice were examined at 
days 8 and 28 p.i. for IFNγ, TNFα, and IL-2 expression. As expected, the gene 
dosage of Irf4 strongly correlated with the numbers of IFNγ–producing CD8+ T 
cells (Figure 3.5, 3.6A-B). No differences in the frequencies of TNFα–producing 
CD8+ T cells as a proportion of IFNγ+ CD8+ T cells were observed at day 8 p.i. 
when comparing WT and Irf4+/fl mice; however, Irf4fl/fl mice showed a substantial 
reduction in the relative proportion of this double cytokine-producing subset. 
Furthermore, at day 28 p.i., the median fluorescence intensity (MFI) of TNFα 
staining and the frequencies of TNFα/IFNγ double-producers and IFNγ/TNFα/IL-
2 triple-producers were significantly decreased in Irf4+/fl mice compared with WT 
controls. Analyses of granzyme B expression and degranulation as assessed by 
CD107a and CD107b staining revealed no differences between any of the 
genotypes at either time point. Overall, these data indicate that reduced 
expression of IRF4 leads to an impaired ability of virus-specific CD8+ T cells to 
produce cytokines other than IFNγ as the cells transition into a long-term memory 
population.  
 
Levels of IRF4 expression selectively impact the short-lived CD8+ effector 
cell population  
In response to acute infections, CD8+ T cells undergo clonal expansion and 
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differentiation to terminal effector cells (TEC; KLRG1hiCD127lo) and memory-
precursor cells (MPC; KLRG1loCD127hi). Examination of these populations 
revealed that reduced IRF4 expression had a more substantial impact on the 
numbers of virus-specific TEC compared with MPC for each population (Figure 
3.7A, 3.8A, 3.9A). Specifically, at day 8 p.i., Irf4+/fl mice had a 2.5- to 4.4-fold 
reduction in numbers of TEC versus a 1.4- to 2.0-fold reduction in MPC numbers 
over the three epitopes examined. Furthermore, despite the increase in MPC 
percentages among virus-specific CD8+ T cells in Irf4+/fl mice at early times post-
infection (days 8, 10, and 14 p.i.), the absolute numbers of MPCs in these mice 
were decreased. Because the numbers of TEC are much greater than the 
numbers of MPC, these data indicate that diminished TEC populations are 
largely responsible for the decrease in the total magnitude of the CD8+ T cell 
effector response in Irf4+/fl mice. Interestingly, by day 28 p.i., WT and Irf4+/fl mice 
had comparable numbers of virus-specific CD8+ T cells, and no significant 
differences in the numbers of MPC were observed for two of the three viral 
epitopes examined. Consistent with these data, examination of virus-specific 
effector (TEM) and central (TCM) memory populations at day 28 p.i. showed only a 
modest reduction in the numbers of TEM in Irf4+/fl compared with WT mice and no 
differences in the numbers of TCM cells between the two genotypes (Figure 3.7B, 
3.8B, 3.9B). These data indicate that reduced IRF4 expression is regulating the 
expansion phase of the T cell response but not impacting the generation of long-
lived virus-specific CD8+ T cells.  
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Figure 3.5. Lower expression of IRF4 impairs production of effector 
cytokines at day 28 post-infection (GP33) 
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Figure 3.5. Lower expression of IRF4 impairs production of effector 
cytokines at day 28 post-infection (GP33) 
Splenocytes from LCMV-GP33–infected WT, Irf4+/fl, and Irf4fl/fl mice from days 8 
and 28 p.i. were stimulated for 5 hours with GP33 peptide and analyzed for IFNγ, 
TNFα, IL-2, granzyme B, and CD107a + CD107b. Dot plots show IFNγ versus 
TNFα staining on gated live CD8+CD44hi T cells, and for day 28 p.i., IFNγ+ cells 
were analyzed for TNFα versus IL-2 staining. Graphs show a compilation of 
numbers of IFNγ+ cells from days 8 and 28 p.i., and percentage of TNFα+IL-2- 
and percentage of TNFα+IL-2+ on gated IFNγ+ cells at day 28 p.i. On the right, 
histograms show granzyme B, CD107a + CD107b, and TNFα staining; gray 
histograms show staining on naive CD8+ T cells from uninfected WT mice; the 
graph shows a compilation of MFIs of TNFα staining at day 28 p.i. normalized to 
WT samples in each experiment. Data are representative of three independent 
experiments with at least five mice per group per time point. *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001, ****p ≤ 0.0001. 
 
 
 
 
 
	 68	
Figure 3.6. Lower expression of IRF4 impairs production of effector 
cytokines at day 28 post-infection (GP276/NP396) 
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Figure 3.6: Lower expression of IRF4 impairs production of effector 
cytokines at day 28 post-infection (GP276/NP396) 
Splenocytes from LCMV-GP33-infected WT, Irf4+/fl and Irf4fl/fl mice were analyzed 
at day 8, 10, 14 and 28 p.i. for NP396 (A) and GP276 (B) epitope-specific 
responses. Data are organized as outlined in the legend for Figure 3.5. 
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Figure 3.7.	Differences in IRF4 expression regulate the nature of CD8+ T cell 
differentiation (GP33) 
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Figure 3.7: Differences in IRF4 expression regulate the nature of CD8+ T cell 
differentiation (GP33) 
Splenocytes from LCMV-GP33–infected WT, Irf4+/fl and Irf4fl/fl mice were analyzed 
at days 8, 10, 14, and 28 p.i. (A) Dot plots show KLRG1 versus CD127 staining 
on CD44hi H2 Db-GP33 tetramer–positive live CD8+ T cells. Graphs show 
compilations of the percentages and numbers of KLRG1hiCD127lo (TEC) and 
KLRG1loCD127hi (MPC) populations. Numbers on time-course graphs indicate 
the relative difference in TEC or MPC numbers between WT and Irf4+/fl mice at 
day 8 p.i. (B) Dot plots show CD44 versus CD62L staining on CD44hi H2 Db-GP33 
tetramer–positive live CD8+ T cells at day 28 p.i. Graphs show compilations of 
the percentages and numbers of CD44hiCD62Llo (TEM) and CD44hiCD62Lhi (TCM) 
populations. (C) Histograms show TCF1, Eomes, and T-bet staining on CD44hi 
H2 Db-GP33 tetramer–positive live CD8+ T cells. Graphs show compilations of 
MFI of transcription factor staining at day 8 p.i., normalized to WT samples in 
each experiment. Data are representative of two or more independent 
experiments with n ≥ 6 mice per time point. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, 
****p ≤ 0.0001. 
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Figure 3.8. Differences in IRF4 expression regulate CD8+ T cell 
differentiation (NP396) 
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Figure 3.8: Differences in IRF4 expression regulate CD8+ T cell 
differentiation (NP396) 
Splenocytes from LCMV-GP33-infected WT, Irf4+/fl, and Irf4fl/fl mice were analyzed 
at day 8, 10, 14 and 28 p.i. for NP396 epitope-specific responses. Data are 
organized as outlined in the legend for Figure 3.7. 
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Figure 3.9.	 Differences in IRF4 expression regulate CD8+ T cell 
differentiation (GP276) 
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Figure 3.9:	 Differences in IRF4 expression regulate CD8+ T cell 
differentiation (GP276) 
Splenocytes from LCMV-GP33-infected WT, Irf4+/fl, and Irf4fl/fl mice were analyzed 
at day 8, 14 and 28 p.i. for GP276 epitope-specific responses. Data are organized 
as outlined in the legend for Figure 3.7. 
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Differential role for IRF4 in regulating TCF1, Eomes, and T-bet expression  
Virus-specific CD8+ T cell differentiation is regulated by the expression of 
transcription factors such as TCF1, Eomes, and T-bet at day 8 p.i (Banerjee et 
al., 2010) (Intlekofer et al., 2005) (Jeannet et al., 2010) (Joshi et al., 2007) (Zhou 
et al., 2010). Consistent with our in vitro stimulation data, LCMV-specific Irf4fl/fl 
cells expressed the highest levels of TCF1 and Eomes, Irf4+/fl cells had 
intermediate levels, and WT cells had the lowest levels of both factors. In 
contrast, the expression of T-bet was reduced in Irf4fl/fl cells compared with WT, 
but no differences were observed in T-bet levels when comparing WT and Irf4+/fl 
cells (Figure 3.7C, 3.8C, 3.9C). These data indicated that TCF1 and Eomes 
expression were more sensitive to modest changes in IRF4 levels than was T-bet 
expression, indicating an IRF4 dose-dependent variation in the regulation of 
these key transcription factors. At later time points post-infection, differences in 
Eomes and TCF1 levels in virus-specific Irf4+/fl versus WT cells were less uniform 
across the three epitope-specific populations, although in general, Irf4+/fl cells 
tended to express higher levels of these factors than WT cells at days 10 and 14 
p.i.; however, by day 28 p.i., no further differences were observed between Irf4+/fl 
and WT cells. Consistent with the transient nature of IRF4 expression and the 
data presented above, these results confirm that variations in IRF4 expression 
levels have the greatest impact at the peak of the virus-specific CD8+ T cell 
response and are not generally altering the long-lived population of virus-specific 
CD8+ T cells found at day 28 p.i.  
	 77	
Cell-intrinsic role for IRF4 in regulating the magnitude of the CD8+ effector 
T cell response  
To assess whether the altered virus-specific CD8+ T cell response seen in Irf4+/fl 
versus WT mice was due to differences intrinsic to the CD8+ T cells, we 
performed adoptive transfer experiments. This approach also allowed us to 
examine whether activation of P14 T cells in vivo with an LCMV variant 
expressing the lower affinity F6L ligand would phenocopy the results of reducing 
IRF4 expression by a heterozygous deficiency in the Irf4 gene. We first 
established that activation of P14 cells with LCMV expressing the GP33 epitope 
results in higher IRF4 expression relative to P14 cells activated in response to 
LCMV-F6L infection. 1*106 congenically marked WT P14 (CD45.1+CD45.2+) cells 
were transferred into naive WT (CD45.2+) hosts. One day later, mice were 
infected with 1*105 PFU LCMV-Armstrong expressing either the WT GP33 epitope 
(LCMV-GP33) or the mutant F6L epitope (LCMV-F6L). Previous studies showed 
that the single amino acid substitution in the LCMV-F6L virus has no impact on 
viral replication or viral clearance when compared with LCMV-GP33 (Gronski et 
al., 2004). As expected, at day 3 p.i., P14 cells activated with LCMV-GP33 
expressed higher levels of IRF4 relative to P14 cells activated in response to the 
F6L epitope (Figure 3.10A). These data were consistent with the results seen 
upon in vitro stimulation of WT P14 cells with the GP33 and F6L ligands (Figure 
3.1A).  
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To assess the cell-intrinsic role of reduced TCR stimulation, either alone or in 
combination with reduced IRF4 expression, in regulating the CD8+ T cell 
response, congenically marked WT P14 (CD45.1+CD45.2+) and Irf4+/fl P14 
(CD45.2+) cells were mixed 1:1 and transferred into naive WT (CD45.1+) hosts 
(Figure 3.10B). When analyzed at day 8 p.i., we observed a substantially greater 
proportion of WT P14 cells relative to the Irf4+/fl P14 population, indicating 
differential expansion of the two populations (Figure 3.10C-D). This trend was 
observed when a total of 2,000 or 20,000 P14 cells were transferred as a 1:1 
mixture of the two genotypes. Strikingly, infection with the LCMV-F6L virus 
reduced the overall expansion of both WT and Irf4+/fl P14 cells but maintained the 
competitive advantage of the WT over the Irf4+/fl cells (Figure 3.10D). These 
findings indicate that the decreased expansion of P14 cells in response to LCMV-
F6L relative to LCMV-GP33 is highly correlated with decreased IRF4 expression. 
Thus, these data suggest that variable upregulation of IRF4 in CD8+ T cells is 
responsible for the effect of TCR signal strength on the magnitude of the peak 
effector response, as reported previously (Zehn et al., 2009). More detailed 
analyses of the P14 populations were performed with mice receiving 20,000 
transferred P14 cells prior to infection, because this provided a greater number of 
cells for analysis. Examination of TEC versus MPC subsets among the P14 
populations indicated that the graded magnitude of the response seen among the 
four experimental groups could be largely attributed to differences in the 
expansion of P14 TEC (Figure 3.11A). This was affected by changes in IRF4 
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expression because of deletion of one Irf4 allele or by infecting mice with an 
LCMV variant expressing only a lower affinity ligand for the P14 TCR, or both. In 
contrast, the MPC populations were largely unaffected by loss of one functional 
Irf4 allele. Regardless of the virus used, Irf4+/fl P14 cells expressed higher total 
levels TCF1 because of the increased proportions of TCF1+ cells among the 
Irf4+/fl P14 populations (Figure 3.11B). However, similar to our observations 
regarding the MPC population, the absolute numbers of TCF1+ cells were not 
affected by a heterozygous deficiency in Irf4 (Figure 3.11B). This is in contrast to 
a recent report showing a ∼2-fold decrease in tcf7 mRNA in in vitro-activated Irf4-
deficient OT-I CD8+ T cells (Man et al., 2013). This discrepancy could arise from 
differential priming of CD8+ T cells in vivo in response to a virus infection versus 
that occurring when T cells are activated in vitro; alternatively, the differences 
seen might arise from differences in the time points examined in our ex vivo 
analysis versus that used for the in vitro stimulation studies. Nonetheless, 
consistent with previous data (Xinyuan Zhou et al., 2010), we found that higher 
TCF1 expression in Irf4+/fl P14 cells correlated with enhanced Eomes expression 
in these cells (Figure 3.11C). In contrast, we observed no differences in the 
expression of T-bet when comparing WT to Irf4+/fl P14 cells (Figure 3.11C).  
The costimulatory molecule CD27 is important for survival of CD8+ effector and 
memory cells (Peperzak et al., 2010); interestingly, we found increased 
expression of CD27 on Irf4+/fl P14 cells than WT P14 cells (Figure 3.11C). This 
finding is consistent with our observation that, following the peak of the antiviral  
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Figure 3.10.	Cell-intrinsic requirement for IRF4 in regulating the magnitude 
of CD8+ T cell responses 
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Figure 3.10:	Cell-intrinsic requirement for IRF4 in regulating the magnitude 
of CD8+ T cell responses 
(A) A total of 1x106 P14 WT (CD45.1+CD45.2+) cells were transferred into 
CD45.2+ hosts 1 day prior to infection with 1x105 PFU LCMV-GP33 or LCMV-F6L 
virus. Histograms show IRF4 staining on gated live CD8+ CD44hi P14 cells; the 
gray histogram represents IRF4 staining on naive CD8+ CD44lo cells. The graphs 
below show compilations of MFI for IRF4 staining normalized to the LCMV-GP33 
infection in each experiment. (B–D) A total of 2,000 or 20,000 P14 cells 
comprising a 1:1 mix of P14 WT (CD45.1+CD45.2+) and P14 Irf4+/fl (CD45.2+) 
were transferred into CD45.1+ congenic hosts 1 day prior to infection with LCMV-
GP33 or LCMV-F6L, and splenocytes were analyzed on day 8 p.i. Dot plots show 
CD45.1 versus CD45.2 staining on input cell mixture (B) or on gated live CD8+ 
CD44hi from mice infected with LCMV-WT (C) or LCMV-F6L (D). Graph shows a 
compilation of percentages of P14 WT and P14 Irf4+/fl populations from mice 
receiving 2000 P14 cells. Data are representative of more than or equal to three 
independent experiments. ***p ≤ 0.001, ****p ≤ 0.0001 
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response, Irf4+/fl cells undergo less cell death than their WT counterparts. To 
address this possibility further, we examined Bcl2 expression. As shown, the loss 
of one allele of Irf4 and/or infection with LCMV-F6L resulted in enhanced 
expression of the pro-survival molecule Bcl2 in P14 cells (Figure 3.11D). This 
increase could be mainly attributed to higher Bcl2 expression in the Irf4+/fl versus 
the WT P14 MPC population (Figure 3.11D). Taken together, these data are 
consistent with the greater survival potential of Irf4+/fl P14 cells relative to WT and 
provide an explanation for the reduced numerical attrition of virus-specific Irf4+/fl 
CD8+ T cells observed (Figure 3.3C, 3.1C-D). Finally, these data also indicate 
that the differences in the clonal expansion and differentiation of virus specific 
effector CD8+ T cells observed upon infection of intact WT and Irf4+/fl mice were 
due to a CD8+ T cell–intrinsic requirement for high levels of IRF4; furthermore, 
these differences mainly arose from the variable expansion of the short-lived 
effector cells. 
 
Differential T cell expansion is driven by variations in the levels of IRF4 
expressed in competing T cell populations  
The data described above establish a CD8+ T cell-intrinsic requirement for IRF4. 
During polyclonal T cell responses, Ag-specific T cells compete for Ag and 
inflammatory cytokines. To test whether variations in IRF4 expression levels 
between competing T cell populations could result in variable T cell expansion, 
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Figure 3.11.	Irf4 haplo-deficiency selectively impairs terminal effector CD8+ 
T cell numbers and alters transcription factor, CD27 and Bcl2 expression 
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Figure 3.11:	Irf4 haplo-deficiency selectively impairs terminal effector CD8+ 
T cell numbers and alters transcription factor, CD27 and Bcl2 expression 
A total of 20,000 P14 cells comprising a 1:1 mix of P14 WT (CD45.1+CD45.2+) 
and P14 Irf4+/fl (CD45.2+) were transferred into CD45.1+ congenic hosts 1 day 
prior to infection with LCMV-GP33 or LCMV-F6L, and splenocytes were analyzed 
on day 8 p.i. (A) Dot plots show KLRG1 versus CD127 staining on gated live 
CD8+CD44hi P14 populations. Graphs show compilations of percentages and 
numbers of TEC and MPC populations for each genotype. (B) The histogram 
shows TCF1 expression on gated live CD8+CD44hiP14+ cells. Open histograms, 
LCMV-WT responding cells; shaded histograms, LCMV-F6L responding cells. 
Colors are as indicated in graphs. The graph below shows the compilation of 
TCF1 MFI normalized to WT cells responding to LCMV-WT virus in each 
experiment. Dot plots show CD8 versus TCF1 staining on gated live CD8+CD44hi 
P14 cells. The graphs at the right show compilations of percentages and 
absolute numbers of CD8+TCF1+ population for each genotype. (C) Histograms 
show Eomes, T-bet, and CD27 staining on CD8+CD44hi P14 cells of each 
genotype, and the graphs below show compilations of MFI for each stain 
normalized to WT cells responding to LCMV-WT virus in each experiment. (D) 
Left histogram shows Bcl2 staining on gated live CD8+ CD44hi P14 populations 
from LCMV-WT responding cells (open histograms) and LCMV-F6L responding 
cells (shaded histograms). Colors are as indicated in the graph. The graph below 
shows the compilation of Bcl2 MFI normalized to WT cells responding to LCMV-
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WT virus in each experiment. Right histogram shows Bcl2 staining on gated live 
CD8+CD44hi P14 TEC (open histograms) and MPC (shaded histograms) 
populations from LCMV-GP33–infected mice. Colors are as indicated in graphs. 
The graph below shows the compilation of Bcl2 MFI normalized to WT TEC 
samples for each experiment. Data are representative of two to three 
independent experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. 
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we transferred WT P14 T cells into either WT or Irf4+/fl host mice and infected 
them with LCMV-GP33 or LCMV-F6L virus. Our findings thus far predicted that, in 
the case where WT P14 cells were responding in a host where all endogenous T 
cells are Irf4+/fl, the WT P14 cells should show an enhanced response relative to 
their response in a WT host environment. In contrast, we reasoned that the WT 
P14 cells should show an impaired response following infection with LCMV-F6L 
in a WT host; however, we predicted that this response should improve if the WT 
P14 cells are transferred into Irf4+/fl hosts, thereby providing the WT P14 cells 
with an advantage based on two functional alleles of Irf4.  
As shown in Figure 3.12A, the data from these experiments supported our 
predictions. A single population of WT P14 T cells was transferred into either WT 
or Irf4+/fl hosts, which were then infected with either LCMV-GP33 or LCMV-F6L. 
We found that WT P14 cells contributed more dominantly to the response to 
LCMV-GP33 when the endogenous T cell population was Irf4+/fl cells, in contrast 
to their contribution when responding in a WT host. Alternatively, the WT P14 
cells contributed little to the response to LCMV-F6L when present in a WT host, 
but this response could be greatly improved by transferring these cells into an 
Irf4+/fl host, where the endogenous T cell response was handicapped in IRF4 
expression. These data indicate that the contribution of an individual virus-
specific CD8+ T cell population to the overall response is not simply regulated by 
the levels of IRF4 expressed in those cells, but also is determined by the levels 
of IRF4 expressed in competing T cell populations present in the same individual.  
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On the basis of these data, we speculated that the CD8+ T cells forming the most 
robust response to an acute infection would express the highest levels of IRF4, 
thus accounting for the predominance of these populations at the peak of the 
response. In acute LCMV infections, CD8+ T cell responses to GP33 and NP396 
epitopes are immunodominant whereas those to GP276 are subdominant (van der 
Most et al., 1998). Because the expression of IRF4 is transient in nature, we 
were unable to detect differences in IRF4 expression in these populations during 
the polyclonal response to LCMV-Armstrong. However, we did observe that the 
magnitude and kinetics of upregulation of TCF1, a target repressed by IRF4, 
were different between the epitope-specific populations. GP276-specific cells 
expressed the highest levels of TCF1, followed by GP33-specific cells, and then 
NP396-specific cells, suggesting lower IRF4 expression in GP276-specific cells and 
the highest expression in NP396-specific cells (Figure 3.12B). Because TCF1 also 
regulates the differentiation of TEM to TCM (Zhou et al., 2010), these data provide 
further mechanistic support for the observation that GP276-specific CD8+ T cells 
are the earliest subset to form TCM in response to LCMV-Armstrong, whereas 
NP396-specific T cell population are the slowest (Sarkar et al., 2007). These 
results show that variations in IRF4 expression can modulate the relative 
proportions of different virus-specific T cell populations recognizing the same 
epitope and suggest that differences observed in the expansion of polyclonal T 
cell responses to different epitopes may be driven by differential upregulation of 
IRF4.  
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Figure 3.12. Ability to express higher levels of IRF4 provides a competitive 
advantage to Ag-specific CD8+ T cells 
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Figure 3.12: Ability to express higher levels of IRF4 provides a competitive 
advantage to Ag-specific CD8+ T cells 
(A) A total of 1000 P14 WT (CD45.1+CD45.2+) T cells were transferred into WT 
or Irf4+/fl hosts (CD45.2+) 1 day prior to infection with LCMV-GP33 or LCMV-F6L, 
and splenocytes were analyzed at day 8 p.i. Dot plots show CD45.1 versus 
CD45.2 staining on gated live CD8+ CD44hi cells. Graphs show a compilation of 
percentages of P14 WT populations. Data are representative of two independent 
experiments with more than or equal to four mice per group. (B) Splenocytes 
from LCMV-GP33-infected WT mice were analyzed at days 8, 14, and 28 p.i. 
Histograms show TCF1 staining of CD44hi H2Db-NP396, -GP33, and -GP276 
tetramer–positive live CD8+ T cells; gray histograms represent isotype control 
staining. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. 
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Discussion 
The adaptive immune system protects us from pathogens by mounting a strong 
primary response, and then retaining protective cells that form immunological 
memory. The recognition of pathogens by CD8+ T cells occurs via interactions of 
the TCR with peptide/MHC complexes. This process not only allows for activation 
of pathogen-specific T cells, but also for the selection of high affinity CD8+ T cell 
clones from the pool of responding	 T cells (Zehn et al., 2009). Although even 
brief Ag exposure is sufficient to induce a programmed proliferative burst of 
effector CD8+ T cell (Kaech & Ahmed, 2001) (van Stipdonk et al., 2001), the 
ultimate magnitude of the response is nonetheless proportional to the overall Ag 
load (Badovinac et al., 2002) (Mercado et al., 2000) (Prlic et al., 2006). These 
findings indicate that TCR signaling contributes to the programming of the CD8+ 
T cell response during the short period of initial Ag exposure. 
The data presented in this study, along with two recent reports (Man et al., 2013) 
(Yao et al., 2013), demonstrate that the transcription factor, IRF4, is a central 
component in translating the strength of TCR signaling into the magnitude of the 
CD8+ T cell response to infection. Man et.al. examined the response of OT-I 
CD8+ T cell to infections with Influenza A virus expressing different affinity 
variants of the OVA peptide. This study showed that decreasing the TCR signal 
strength resulted in lower IRF4 expression in OT-I cells both in vitro and in vivo, 
and dramatic differences in the numbers of OT-I CD8+ T cells at the peak of the 
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response, a phenotype similar to that observed for IRF4-deficient CD8+ T cells 
responding to infection. Yao et.al. also showed that IRF4 expression was 
dependent on the strength of TCR signaling in vitro, and that loss of IRF4 
expression resulted in a diminished polyclonal CD8+ T cell response at the peak 
of the infection. Consistent with these two studies, we found that upregulation of 
IRF4 in P14 TCR transgenic CD8+ T cells was also dependent on the affinity and 
the dose of the stimulating peptide. Further, reduced expression of IRF4 was 
also observed following in vitro stimulation of Irf4 haplodeficient P14 T cells 
compared with WT. Similar to the findings	of Man et al., we also found a dose-
dependent decrease in CD8+ T cell expansion upon loss of one or both alleles of 
Irf4, a phenomenon that could be phenocopied using an LCMV variant 
expressing a lower affinity ligand for the P14 TCR. Taken together, these studies 
provide strong support for the conclusion that levels of IRF4 are tightly regulated 
by the strength of TCR signaling and, in turn, regulate the magnitude of the CD8+ 
T cell response to infection. 
Most importantly, we show that modest variations in the levels of IRF4 
expression, such as those achieved by a heterozygous	 deficiency in Irf4, are 
sufficient to have a dramatic impact on the peak expansion of virus-specific CD8+ 
T cells. In our studies, reduced IRF4 expression decreased the maximum 
numbers of Ag-specific CD8+ T cells by 2- to 3-fold and, furthermore, had a 
greater impact on the numbers of terminal effector cells compared with the 
memory precursor cells. These data provide a mechanistic explanation for 
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previous studies demonstrating that shortening the duration of Ag exposure 
decreases the total CD8+ T cell response and in particular the size of the TEC 
compartment, without affecting the number of MPCs (Badovinac et al., 2002) 
(Prlic et al., 2006) (Joshi et al., 2007). 
Our studies also showed that, following virus clearance and the bulk of the T cell 
attrition, there was virtually no impact on the numbers of Ag-specific T cells 
remaining, regardless of their ability to express high levels of IRF4. This latter 
finding is strikingly similar to the observations of Bevan and colleagues (Zehn et 
al., 2009) in their elegant study examining the response of OT-I T cells to strains 
of Listeria monocytogenes expressing different affinity variants of the OVA 
peptide. In this study, dramatic differences in the peak expansion of OT-I T cells 
were seen following activation by Listeria strains expressing the different OVA 
variants; however, following bacterial clearance, few differences were found in 
the numbers of long-term surviving OT-I memory T cells. A likely explanation for 
these data are that the higher affinity OVA variants induced higher levels of IRF4 
than did the lower affinity variants, thus accounting for the relative response of 
the OT-I T cells to each bacterial strain. Furthermore, because the expression of 
IRF4 is transient in nature, the effects of different levels of IRF4 are limited to 
CD8+ T cell priming and the peak expansion phase but not thereafter. We also 
found increased expression pro-survival factors, CD27 and Bcl2, in P14 Irf4 
haplosufficient cells, consistent with a greater survival potential of these cells 
relative to WT. These data provide a potential mechanism to account for the 
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findings of Bevan and colleagues, that ligands representing a broad range of 
TCR affinities generated relatively similar numbers of memory T cells, despite the 
dramatic differences in T cell expansion at the peak of the response (Zehn et al., 
2009). 
Inflammatory cytokines produced during an infection also increase TCR 
activation by sustaining phosphorylation of ZAP-70 and phospholipase Cγ 
(Richer et al., 2013). Because the activation of phospholipase Cγ, as well as the 
levels of IRF4 expression are Itk dependent (Nayar et al., 2012) (Berg et al., 
2005), it is possible that factors such as cytokines also may help sustain IRF4 
expression, which may lead to an overall enhancement in the TEC response. For 
instance, IL-12 enhances the expression of T-bet (Takemoto et al., 2006), 
another transcription factor that positively regulates the size of the TEC 
compartment (Joshi et al., 2007). Because the expression of T-bet was more 
dependent on IRF4 following infection with influenza A than LCMV, it is possible 
that IRF4 also functions to integrate signals from the TCR and cytokines to 
dictate the magnitude of the CD8+ T cell response. 
Another transcription factor, Blimp1, also plays a central role in terminal effector 
cell differentiation. Blimp1-deficient CD8+ T cells have higher expression of TCF1 
and Eomes transcripts and lower expression of T-bet mRNA (Rutishauser et al., 
2009) (Kallies et al., 2009). Three recent studies found a role for IRF4 in Blimp-1 
expression in CD8+ T cells (Man et al., 2013) (Yao et al., 2013) (Raczkowski et 
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al., 2013). In our study, we find a dose-dependent effect of IRF4 levels on the 
expression of TCF1 and Eomes in CD8+ T cells responding to infection. These 
observations not only confirm our previous data that IRF4 is a negative regulator 
of Eomes expression (Nayar et al., 2012) but also suggest that regulation of 
Eomes is more complex and possibly involves multiple transcription factors 
functioning in a temporal manner. Taken together, these data indicate that IRF4 
is a central component of this transcriptional program and that the magnitude of 
IRF4 upregulation during CD8+ T cell priming is a critical determinant of the 
outcome of the response. 
Our data also provide a potential explanation for observations regarding the 
variable expansion, as well as the varying kinetics, of CD8+ T cell responses to 
different viral epitopes. For instance, polyclonal CD8+ T cells responses to LMCV 
epitopes GP33 and NP396 form the dominant response, whereas those to GP276 
are subdominant (van der Most et al., 1998), suggesting that IRF4 expression is 
higher in the former populations. This possibility would fit with our data showing 
that the response of IRF4-sufficient P14 T cells in an Irf4+/fl host following LCMV 
infection gives the P14 cells a substantial competitive advantage over the 
endogenous response, compared with those same cells responding in a WT 
host. Because of the transient nature of IRF4 expression during T cell priming, 
we were unable to directly test this hypothesis on the polyclonal T cell response 
to LCMV. However, we did observe that the levels of TCF1, a downstream target 
of IRF4, were different between the different epitope-specific populations. TCF1 
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is also important for the conversion of TEM to TCM cells (Zhou et al., 2010). 
Because LCMV GP276–specific cells convert to TCM earlier than NP396-specific 
cells following acute infection (Sarkar et al., 2007), these data are consistent with 
a lower level of IRF4 expression in the GP276- specific subset. In further support 
of this hypothesis, Irf4+/fl CD8+ T cells also convert to TCM more rapidly than WT T 
cells. Thus, differences in the magnitude and/or duration of IRF4 expression may 
be one factor that could account for observed differences in the responses of 
CD8+ T cells to distinct viral epitopes. Overall, our findings, along with those of 
others, demonstrate that variations in the levels of IRF4 expressed during T cell 
priming fine-tune the size and quality of the pathogen-specific adaptive immune 
response. 
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Introduction 
 
Acute virus infections are characterized by the formation of robust CD8+ T cell 
effector responses followed by the generation of immunological memory. Both 
CD8+ effector T cells as well as CD8+ memory cells produce a variety of 
cytokines and cytotoxic molecules, and have high proliferative capacity (Kaech & 
Cui, 2012). In contrast, during chronic viral infections, high viral loads cause 
CD8+ T cell exhaustion that is characterized by hierarchal loss of effector 
functions and eventual deletion of antigen-specific cells (Wherry et al., 2003) 
(Fuller & Zajac, 2003) (Mueller & Ahmed, 2009). The remaining virus-specific 
CD8+ T cells lose the ability to make IFNγ, TNFα, and IL-2, and up-regulate high 
levels of inhibitory receptors such as PD-1 and LAG-3. Eventually the cells 
become completely dysfunctional and are deleted by apoptosis (Wherry et al., 
2003). T cell exhaustion was initially thought to be a viral immune evasion 
mechanism, but recent studies have indicated that it serves to protect the host 
from T cell-mediated immunopathology (Zajac et al., 1998) (Cornberg et al., 
2013). 
 
Many factors regulate T cell exhaustion. The expression of the immuno-
suppressive cytokine IL-10 and inhibitory co-receptors like PD-1 enhance T cell 
exhaustion, whereas help from CD4+ T cells aids in the restoration of CD8+ T cell 
function (Brooks et al., 2006a) (Barber et al., 2005) (Matloubian et al., 1994) 
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(Aubert et al., 2011). Persistent T cell signaling due to high viral loads and 
increased MHC-I presentation is detrimental as well as beneficial during chronic 
infection. Increased antigen presentation results in reduced numbers and 
impaired function of anti-viral CD8+ T cells; however, loss of this interaction also 
leads to poor viral control (Mueller & Ahmed, 2009). Antigen is also required for 
the long-term maintenance of virus-specific cells during chronic infections, as 
these cells do not undergo homeostatic proliferation in response to IL-7 and IL-
15; instead, they require viral antigen (Wherry et al., 2004) (Shin et al., 2007). 
 
In the presence of a persistent infection, exhausted CD8+ T cells were found as 
two distinct subsets, one subset expressing high levels of the transcription factor, 
T-bet, and the other subset expressing high levels of the related transcription 
factor, Eomesodermin (Eomes). Further, Paley, et.al. showed that, in response to 
antigenic stimulation, T-bethi cells give rise to Eomeshi cells. T-bethi cells were 
found to be less exhausted and exhibited higher proliferative rates in response to 
antigen, while the Eomeshi cells were more exhausted, but exhibited greater 
cytotoxic activity than the T-bethi cells. Both subsets were essential for viral 
control, as loss of either transcription factor resulted in viral persistence (Paley et 
al., 2012). These data indicated that optimal expression of T-bet and Eomes and 
the presence of both CD8+ T cell subsets were both essential for efficient viral 
control. However, the pathway that regulates the differentiation of antigen-
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specific T cells into these subsets, and whether a specific ratio of the two subsets 
is critical for viral control, are not known. 
 
IRF4 is a pleiotropic transcription factor that regulates a myriad of functions in a 
wide variety of cell populations (Huber & Lohoff, 2014). Recently, others and we 
have shown that levels of IRF4 in CD8+ T cells are regulated by the strength of 
TCR signaling. Thus, robust expression of IRF4 is important for maximal CD8+ T 
cell expansion in response to acute viral infections (Nayar et al., 2014) (Yao et 
al., 2013) (Man et al., 2013) (Raczkowski et al., 2013) (Grusdat et al., 2014). 
When IRF4 levels are reduced by a haplo-deficiency of the Irf4 gene, the 
magnitude of the CD8+ T cell response is dramatically impaired. The decreased 
numbers of virus-specific T cells are accounted for by a reduction in terminal 
effector cells (TEC; KLRG1hiCD127lo) without a significant effect on the numbers 
of memory precursor cells (MPC, KLRG1loCD127hi) (Nayar et al., 2014). These 
studies also highlighted a role for IRF4 in the expression of key transcription 
factors T-bet and Eomes, important for differentiation and maintenance of TEC 
and MPC populations, respectively, during acute infections (Nayar et al., 2014) 
(Yao et al., 2013) (Man et al., 2013) (Raczkowski et al., 2013) (Grusdat et al., 
2014) (Joshi et al., 2007) (Banerjee et al., 2010). 
 
Here we show that TCR signal strength maintains an optimal balance of T-bet to 
Eomes, and that this process is regulated by the levels of IRF4 expressed. 
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Reduced expression of IRF4 skews this ratio in the favor of Eomes during 
infection with LCMV-clone 13, resulting in reduced differentiation of T-bet+ 
Eomes- precursors and impaired viral control. Reducing Eomes expression in Irf4 
heterozygous mice re-establishes the protective balance of T-bet to Eomes, 
restores differentiation of T-bet+ Eomes- precursors, and ultimately rescues 
defective viral clearance. These data indicate a critical role for IRF4 in regulating 
T cell exhaustion by balancing the relative expression of T-bet and Eomes during 
chronic infection. Overall, these findings demonstrate that reduced differentiation 
of the T-bet+ Eomes- CD8+ T cell population impairs viral clearance, whereas a 
partial reduction in Eomes expression can restore viral control during persistent 
LCMV-clone 13 infections. 
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Results 
 
TCR signal strength via IRF4 regulates the ratio of T-bet and 
Eomesodermin in activated CD8+ T cells 
To understand the role of TCR signal strength in the differentiation of CD8+ T cell 
subsets, we utilized P14 TCR transgenic TCRa-/- cells (hereafter referred to as 
P14 WT), that respond to the lymphocytic choriomeningitis virus (LCMV) GP33-41 
epitope (GP33) bound to H2-Db; additionally, P14 WT cells respond to a lower 
affinity ‘F6L’ peptide variant of GP33-41, containing a single amino acid 
substitution from phenylalanine to leucine at the sixth position of the peptide.  
This alteration leads to a 5-fold decrease in the affinity of the P14 TCR for the 
F6L-H2-Db complex relative to GP33-41- H2-Db, and as a consequence, a 100-
1000-fold reduction in functional avidity(Gronski et al., 2004).  P14 WT T cells 
were stimulated in vitro and then examined for T-bet (Figure 4.1A) and Eomes 
(previously published in (Nayar et al., 2014)) expression by intracellular staining. 
At 24hr post-stimulation, P14 WT T cells stimulated with the high affinity GP33 
epitope, expressed a higher T-bet to Eomes ratio relative to cells stimulated with 
the lower affinity F6L epitope (Figure 4.2A).  A similar trend was also observed 
when P14 cells were stimulated with decreasing doses of the GP33 peptide. 
These data indicate that variations in TCR signal strength, such as those 
achieved by varying the affinity of the peptide-MHC for the TCR or by varying the 
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dose of stimulating peptide, affect the relative expression levels of these key 
transcription factors. 
 
The transcription factor IRF4 is upregulated in CD8+ T cells in a graded manner 
in response to variations in TCR signal strength.  Furthermore, IRF4 is known to 
be a negative regulator of Eomes and a positive regulator of T-bet expression in 
CD8+ T cells (Nayar et al., 2014) (Yao et al., 2013) (Man et al., 2013) 
(Raczkowski et al., 2013) (Nayar et al., 2012) (Huber et al., 2012).  To determine 
if alterations in IRF4 expression affect the relative up-regulation of T-bet and 
Eomes, we compared P14 WT T cells to P14 TCRa-/- cells lacking one or two 
functional alleles of Irf4 (Irf4+/fl X CD4-Cre and Irf4fl/fl X CD4-Cre; referred to as 
P14 Irf4+/fl and P14 Irf4fl/fl, respectively). In response to stimulation with the GP33 
peptide, P14 WT cells expressed the highest T-bet to Eomes ratio, while P14 
Irf4+/fl cells showed a reduced T-bet to Eomes ratio, and P14 Irf4fl/fl cells exhibited 
the lowest T-bet to Eomes ratio (Figure 4.2A). This pattern was observed at all 
time points examined (Figure 4.2B-C). Furthermore, no alterations in the ratio of 
T-bet to Eomes expression was observed when P14 Irf4fl/fl cells were stimulated 
with varying doses of GP33 peptide (Fig 4.2D-F).  These data indicate that the 
strength of TCR signaling via IRF4 regulates the relative expression of T-bet and 
Eomes in CD8+ T cells. 
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Figure 4.1. IRF4 regulates T-bet expression levels in stimulated CD8+ T 
cells at 72 hours post stimulation 
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Figure 4.1: IRF4 regulates T-bet expression levels in stimulated CD8+ T 
cells at 72 hours post stimulation 
P14 WT, P14 Irf4+/fl or P14 Irf4fl/fl cells were stimulated with the indicated 
concentrations of GP33 and F6L peptides in vitro. At 24, 48, and 72 hours, cells 
were stained and analyzed for T-bet expression. The graphs show the raw MFIs 
for T-bet at each time-point. Data were generated from gated live 
CD8+CD45.2+CD44hi T cells analyzed in four independent experiments. 
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Figure 4.2. IRF4 regulates the T-bet to Eomesodermin ratio in stimulated 
CD8+ T cells 
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Figure 4.2: IRF4 regulates the T-bet to Eomesodermin ratio in stimulated 
CD8+ T cells 
P14 WT, P14 Irf4+/fl or P14 Irf4fl/fl cells were stimulated with the indicated 
concentrations of GP33 and F6L peptides in vitro. At (A, D) 24, (B, E) 48, or (C, F) 
72 hours, cells were stained and analyzed for T-bet and Eomes expression. The 
graphs show compilations of the ratios of MFIs for T-bet relative to Eomes, each 
normalized to the value for 1µM GP33-stimulated cells at each time-point. Data 
were generated from gated live CD8+CD45.2+CD44hi T cells analyzed in four 
independent experiments. R, denotes statistically significant difference between 
1µM GP33-stimulated cells and all other sample groups on the graph as 
determined by unpaired t test with Welch’s correction. 
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Levels of IRF4 regulate CD8+ T cell differentiation into T-bet+ Eomes- and T-
bet- Eomes+ subsets in response to LCMV Cl13 infection 
The data described thus far indicated a critical role of IRF4 in maintaining the 
balance of T-bet and Eomes in vitro. To determine whether the levels of IRF4 
regulate the relative expression of T-bet and Eomes in vivo, WT, Irf4+/fl X CD4-
Cre and Irf4fl/fl X CD4-Cre mice (henceforth referred to as Irf4+/fl and Irf4fl/fl, 
respectively) were infected with an exhausting dose of LCMV-clone 13. Due to 
the defects in regulatory T cell populations in Irf4fl/fl mice, CD4+ and CD8+ T cell 
populations are activated in Irf4fl/fl mice even in the absence of infection (Nayar et 
al., 2012) (Zheng et al., 2009). As a result, we focused on understanding how 
modest reductions, rather than a complete loss of IRF4 expression, impacted the 
protective response to persistent virus infection.    
 
Virus specific responses to H2-Db/GP276–286 and H2-Db/GP33–41 were examined 
using MHC-peptide tetramers. At day 8 post-infection, Irf4+/fl and Irf4fl/fl mice had 
reduced proportions and numbers of virus-specific CD8+ T cells compared to WT 
mice, consistent with previous studies of acute virus infections in these mice 
(Figure 4.3A and 4.4A) (Nayar et al., 2014) (Yao et al., 2013) (Man et al., 2013) 
(Raczkowski et al., 2013) (Grusdat et al., 2014).  At day 12 post-infection, WT 
and Irf4+/fl had similar levels of virus in their sera, whereas Irf4fl/fl mice showed 
slightly reduced control of the virus infection (Figure 4.3B).  Analysis of T-bet and 
Eomes expression in the virus-specific CD8+ T cells indicated that WT cells had 
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the highest T-bet to Eomes ratio, followed by Irf4+/fl CD8+ T cells, and then Irf4fl/fl 
cells (Figure 4.3C and 4.4B).  
 
In response to LCMV-clone 13 infection, anti-viral CD8+ T cells differentiate into 
T-bet+ Eomes- precursors that give rise to T-bet- Eomes+ progeny in response to 
antigenic stimulation (Paley et al., 2012). Examination of these subsets at day 8 
p.i. indicated an IRF4 dose-dependent defect in the differentiation of these 
populations. Irf4+/fl mice exhibited a significant decrease in the numbers and 
proportions of the T-bet+ Eomes- precursors with a concomitant increase in the 
differentiation to T-bet+ Eomes+ cells (Figure 4.3D and 4.4C). These double 
positive cells could potentially be an intermediate population that differentiates 
into T-bet- Eomes+ cells later during infection. As the viral titers are not different 
between WT and Irf4+/fl at day 12 p.i. (Figure 4.3B), these data indicate an 
inherent defect in the differentiation of CD8+ T cells expressing lower levels of 
IRF4. The differentiation of the Irf4fl/fl cells into T-bet+ Eomes- and T-bet+ Eomes+ 
populations was severely compromised, likely accounting for the increased viral 
titers in the Irf4fl/fl mice. These data indicate that IRF4 regulates the relative 
expression of T-bet and Eomes and therefore may impact the differentiation of T-
bet+ Eomes- precursors into T-bet- Eomes+ progeny early during persistent LCMV 
infection. Further, high levels of IRF4 are required for robust expansion of virus-
specific T-bet+ Eomes- effector CD8+ T cells and viral control at early times post-
infection. 
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Figure 4.3 Irf4 gene dosage regulates CD8+ T cell clonal expansion in 
response to LCMV-clone 13 infection and the differentiation of T-bethi and 
Eomeshi subsets (GP276) 
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Figure 4.3: Irf4 gene dosage regulates CD8+ T cell clonal expansion in 
response to LCMV-clone 13 infection and the differentiation of T-bethi and 
Eomeshi subsets (GP276) 
(A) Splenocytes from LCMV-clone 13-infected WT, Irf4+/fl and Irf4fl/fl mice were 
harvested at day 8 p.i. and stained with a viability dye, LCMV-specific H2-Db-
GP276 tetramer, and antibodies to CD8, T-bet and Eomes. Dot plots show CD8 
versus H2-Db-GP276 tetramer staining (left). Graphs show compilations of 
proportions and numbers from day 8 p.i. (right). Each data point represents an 
individual mouse and data are a compilation of three independent experiments. 
(B) LCMV-clone 13 titers in serum at day 12 post-infection. Dotted line indicates 
limit of detection. Each data point represents an individual mouse and data are a 
compilation of four independent experiments. (C) Representative dot plots show 
T-bet vs Eomes staining on gated CD8+ live H2-Db-GP276 specific cells at D8 p.i 
(left). Graphs show the MFI of T-bet and Eomes, each normalized to the average 
of WT samples for live CD8+ H2-Db-GP276 specific cells, and the ratio of 
normalized MFIs for T-bet relative to Eomes (right). Each data point represents 
an individual mouse and data are a compilation of three independent 
experiments. (D) Graphs show compilations of proportions and numbers of T-
bet+ Eomes- and T-bet+ Eomes+ cells. Each data point represents an individual 
mouse and data are a compilation of three independent experiments. Significant 
differences determined by Ordinary one-way ANOVA using Tukey’s multiple 
comparison test. 
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Figure 4.4. Irf4 gene dosage regulates CD8+ T cell clonal expansion in 
response to LCMV-clone 13 infection as well as the differentiation of T-bethi 
and Eomeshi subsets (GP33) 
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Figure 4.4: Irf4 gene dosage regulates CD8+ T cell clonal expansion in 
response to LCMV-clone 13 infection as well as the differentiation of T-bethi 
and Eomeshi subsets (GP33) 
(A) Splenocytes from LCMV-clone 13-infected WT, Irf4+/fl and Irf4fl/fl mice were 
harvested at day 8 p.i. and stained with a viability dye, LCMV-specific H2Db-GP33 
tetramer, and antibodies to CD8, T-bet and Eomes. Dot plots show CD8 versus 
H2-Db-GP33 tetramer staining. Graphs show compilations of proportions and 
numbers from day 8 post-infection (right). (B) Representative dot plots show T-
bet vs Eomes staining on gated CD8+ live H2-Db-GP33 specific cells at day 8 p.i. 
Graphs show the MFI of T-bet and Eomes each normalized to the average of WT 
samples in each experiment for live CD8+ H2-Db-GP33 specific cells, and the ratio 
of normalized MFIs for T-bet relative to Eomes. (C) Graphs show compilations of 
proportions and numbers of T-bet+ Eomes- and T-bet+ Eomes+ cells. Each data 
point represents an individual mouse and data are a compilation of three 
independent experiments; significant differences determined by Ordinary one-
way ANOVA using Tukey’s multiple comparison test. 
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WT levels of IRF4 are required to maintain the balance of T-bet to 
Eomesodermin expression during persistent infection 
In activated T cells, the expression of IRF4 is regulated by the strength of TCR 
signaling via the mTOR pathway; furthermore, mTOR signaling is suppressed 
during chronic infection by signaling through the inhibitory receptor PD-1 (Nayar 
et al., 2014) (Yao et al., 2013) (Man et al., 2013) (Nayar et al., 2012) (Staron et 
al., 2014). To test the importance of IRF4 expression levels at later timepoints 
during the persistent infection, we examined CD8+ T cell responses to LCMV-
clone 13 at day 21-24 p.i. At this time point, we observed reduced proportions of 
virus-specific T cells in the spleens of Irf4+/fl mice compared to WT mice; 
however, absolute numbers were not significantly different (Figure 4.5A, D).  As 
expected, Irf4fl/fl mice had significant reductions in both the proportions and 
numbers of both subsets of virus-specific CD8+ T cells.  
 
Examination of T-bet and Eomes expression in virus-specific CD8+ T cells at day 
21-24 p.i. with LCMV-clone 13 indicated that for both of the LCMV epitopes 
examined, virus-specific Irf4+/fl CD8+ T cells exhibited an altered T-bet to Eomes 
ratio relative to WT cells (Figure 4.5C, E). This skewed ratio resulted in reduced 
differentiation of T-bet+ Eomes- and increased differentiation of T-bet- Eomes+ 
populations in Irf4+/fl mice relative to WT mice (Figure 4.5C, E and 4.6A, C).  High 
viral titers have been implicated in the excessive proliferation and eventual 
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Figure 4.5. Persistent reduction in virus-specific T-bet+ Eomes- CD8+ T cells 
in LCMV-clone 13-infected Irf4+/fl mice 
 
 
 
 
 
 
 
7 2.7 0.2
C
D
8
H2-Db GP276-286
WT Irf4+/fl Irf4fl/fl
A
%
G
P
27
6+
WT Irf4+/fl Irf4fl/fl WT Irf4+/fl Irf4fl/fl
3
4
5
6
#G
P
27
6+
10
10
10
10
B
Eomes
T-
be
t
0.0
0.5
1.0
1.5
N
or
m
al
iz
ed
 M
FI
 
T-
be
t:E
om
es
WT Irf4+/fl Irf4fl/fl %
T-
be
t+
E
om
es
-
#T
-b
et
+ E
om
es
-
0
10
20
30
40
WT Irf4+/fl Irf4fl/fl
3
4
5
610
10
10
10
210
WT Irf4+/fl Irf4fl/fl
D21-24 H2-Db GP276-286 response
D21-24 H2-Db GP33-41 response
1.9 1.1 0.2
C
D
8
H2-Db GP33-41
C
WT Irf4+/fl Irf4fl/fl
WT Irf4+/fl Irf4fl/fl
%
G
P
33
+
3
4
5
610
10
10
10#
G
P
33
+
WT Irf4+/fl Irf4fl/fl WT Irf4+/fl Irf4fl/fl
D
Eomes
T-
be
t WT Irf4
+/fl Irf4fl/fl
0
20
40
60
%
T-
be
t+
E
om
es
-
WT Irf4+/fl Irf4fl/fl
0.0
0.5
1.0
1.5
2.0
N
or
m
al
iz
ed
 M
FI
 
T-
be
t:E
om
es
WT Irf4+/fl Irf4fl/fl WT Irf4+/fl Irf4fl/fl#
T-
be
t+
E
om
es
-
3
4
5
610
10
10
10
210
3
4
5
6 **
P
FU
/m
l o
f S
er
um
2 Limit of Detection
D26 p.i.
10
10
10
10
10
WT Irf4+/fl Irf4fl/fl
E
21.5 34.1
3113.4
10.3 35.9
41.512.3
8.62 56.4
22.212.8
33.7 19.7
20.526.1
18.3 29.3
30.122.3
14.1 32.2
1736.7
20
0
10
15
5
0
3
6 ******** * *** *
****
****
******** ***
****
****
***** **
****
****
**
****
**** ****
****
	 116	
Fig 4.5. Persistent reduction in virus-specific T-bet+ Eomes- CD8+ T cells in 
LCMV-clone 13-infected Irf4+/fl mice 
 (A, D) Splenocytes from LCMV-clone 13-infected WT, Irf4+/fl and Irf4fl/fl mice 
were were harvested at day 21-24 p.i. and stained with a viability dye, LCMV-
specific H2-Db-GP276 and H2Db-GP33 tetramers, and antibodies to CD8, T-bet 
and Eomes. Dot plots show CD8 versus H2-Db-GP276 (A) or H2-Db-GP33 (D) 
tetramer staining (left). Graphs show compilations of proportions and numbers 
from day 21-24 p.i. (right). Each data point represents an individual mouse and 
data are a compilation of five independent experiments. (B) LCMV-clone 13 titers 
in serum at day 26 post-infection. Dotted line indicates limit of detection. Each 
data point represents an individual mouse and data are a compilation of two 
independent experiments. (C, E) Dot plots show T-bet vs Eomes staining on live 
CD8+ H2-Db-GP276 (C) or H2-Db-GP33 (E) tetramer positive cells (left). Graph 
shows the ratio of MFIs of T-bet relative to Eomes, each normalized to the 
average value of WT samples (middle). Graphs show a compilation of 
proportions and numbers of T-bet+ Eomes- cells for each population (right). Each 
data point represents an individual mouse and data are a compilation of five 
independent experiments. Significant differences determined by Ordinary one-
way ANOVA using Tukey’s multiple comparison test. 
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Figure 4.6. Irf4 gene dosage regulates the proportions of virus-specific CD8+ T 
cells during persistent LCMV-clone 13 infection 
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Figure 4.6: Irf4 gene dosage regulates the proportions of virus-specific CD8+ T 
cells during persistent LCMV-clone 13 infection 
Splenocytes from LCMV-clone 13 infected WT, Irf4+/fl and Irf4fl/fl mice were 
harvested between day 21-24 p.i. and stained with a viability dye, LCMV-specific 
H2-Db-GP276 and H2Db-GP33 tetramers, and antibodies to CD8, T-bet and 
Eomes. (A, C) Graphs show the numbers and proportions of T-bet+ Eomes+ (left) 
and T-bet- Eomes+ (right) populations. Each data point represents an individual 
mouse and data are compilations of five independent experiments; significant 
differences determined by Ordinary one-way ANOVA using Tukey’s multiple 
comparison test. (B, D) Dot plots of uninfected control and LCMV Armstrong 
infected control used to determine gating of T-bet versus Eomes for each 
tetramer stained subset. 
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conversion of the T-bethi CD8+ T cell population into Eomeshi CD8+ T cell 
population in patients with chronic HCV infection (Paley et al., 2012) (Popescu et 
al., 2014).  However, at day 26 p.i., we observed no difference in serum virus 
titers between Irf4+/fl and WT mice, indicating that the altered CD8+ T cell 
populations were not simply a reflection of differences in viral load (Figure 4.5B).  
These data indicate that a modest reduction in IRF4 expression leads to impaired 
generation of T-bet+ Eomes- virus-specific CD8+ T cells at later timepoints of the 
persistent infection. 
 
Intrinsic role of IRF4 in regulating the balance of T-bet to Eomesodermin 
expression in CD8+ T cells responding to LCMV-clone 13 infection 
To address whether differences in IRF4 expression were regulating the balance 
of T-bet to Eomes by acting in virus-specific CD8+ T cells, we performed adoptive 
transfer experiments. P14 WT or P14 Irf4+/fl CD8+ T cells were transferred into 
congenic hosts, and recipients were infected with LCMV-clone 13.  Beginning at 
day 10 p.i., we observed that a proportion of recipients receiving WT P14 cells 
were succumbing to the infection, a response not seen in recipients that received 
P14 Irf4+/fl cells (Figure 4.7A).  Analysis of viral titers in the sera of the surviving 
mice at D15 p.i. indicated that 75% of recipients receiving WT P14 cells had viral 
titers <7.5x104, whereas for recipients receiving P14 Irf4+/fl cells, this value was 
2.9x105; however, the means of the two datasets were not significantly different. 
Based on previous studies showing that fatality from LCMV-clone 13 infection 
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Figure 4.7. Cell-intrinsic role of IRF4 in regulating the balance of T-bet to 
Eomesodermin expression in CD8+ T cells responding to LCMV-clone 13 
infection  
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Figure 4.7: Cell-intrinsic role of IRF4 in regulating the balance of T-bet to 
Eomesodermin expression in CD8+ T cells responding to LCMV-clone 13 
infection 
1 x 104 CD90.1 WT P14 cells or CD90.1 Irf4+/fl P14 cells were transferred into 
CD90.2 CD4-Cre+ host mice and one day later recipients were infected with 
LCMV-clone 13. (A) Survival curve showing percent survival of recipient mice 
that received either WT or Irf4+/fl P14 cells over 22 days. Data are a compilation 
of three independent experiments. (B) Serum was harvested from recipient mice 
at day 15 post infection and virus titers were determined by plaque assay. Each 
data point represents an individual mouse and data are a compilation of two 
independent experiments. (C) Dot plots show CD90.1 (transferred cells) versus 
CD90.2 (host cells) staining on gated live CD8+ T cells (left).  Graphs show 
compilations of proportions and numbers of transferred P14 cells at day 22 post-
infection (right). Each data point represents an individual mouse and data are a 
compilation of three independent experiments. (D) Dot plots show T-bet versus 
Eomes staining on gated live CD90.1+ CD8+ T cells (left). Graphs show the 
normalized MFI of T-bet and Eomes, each normalized to the average of P14 WT 
transferred samples and the ratio of the normalized MFIs for T-bet relative to 
Eomes, (right). Each data point represents an individual mouse and data are a 
compilation of three independent experiments. Statistical analysis was 
determined by Log-rank (Mantel-Cox) test (A) or unpaired t test with Welch’s 
correction (B-D). 
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results from excessive T cell responses leading to immunopathology (Cornberg 
et al., 2013), these data suggest a more robust effector response of WT 
compared to Irf4+/fl P14 cells to the LCMV-clone 13 infection, consistent with 
previous observations (Grusdat et al., 2014).  
 
To examine the P14 cells directly, surviving mice were analyzed at day 22 p.i..  
At this timepoint, we recovered fewer P14 Irf4+/fl cells from recipient mice 
compared to WT P14 cells (Figure 4.7C).  Examination of these cells for T-bet 
and Eomes expression showed that WT P14 cells had increased levels of T-bet 
and reduced levels of Eomes relative to P14 Irf4+/fl cells, resulting in higher T-bet 
to Eomes ratio in the WT P14 cells (Figure 4.7D).  Overall, these data indicate 
that the magnitude of IRF4 expression in virus-specific CD8+ T cells regulates 
their expansion, as well as the relative expression of T-bet and Eomes in 
response to LCMV-clone 13.  
 
WT levels of IRF4 are essential for optimal control of persistent virus 
infection 
While modest reductions in the levels of IRF4 were inconsequential for early 
control of virus replication through day 26 p.i. long-term studies revealed that 
Irf4+/fl mice had a defect in controlling the persistent virus infection.  Relative to 
WT mice, a lower proportion of Irf4+/fl mice controlled LCMV-clone 13 infection in 
the kidney, liver and serum when examined more than 100 days p.i. (Figure 
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Figure 4.8. High expression of IRF4 is essential for long-term control of 
LCMV-clone 13 
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Figure 4.8: High expression of IRF4 is essential for long-term control of 
LCMV-clone 13 
Kidney (A), livers (B), and sera (C) were harvested from LCMV-clone 13 infected 
WT, Irf4+/fl and Irf4fl/fl mice between day 112-114 post-infection and virus titers 
were determined by plaque assay. Dotted line indicates the limit of detection. 
Each data point represents an individual mouse and data are a compilation of 
three independent experiments. (D) Serum was harvested from infected mice at 
various timepoints post-infection. Graph indicates the proportion of mice with viral 
titers above the limit of detection over time. Data are a compilation of three 
independent experiments; significant differences were determined by Log-rank 
(Mantel-Cox) test. (E) Anti-LCMV IgG antibody titers in sera at day 40 p.i. Each 
data point represents an individual mouse and data are a compilation of three 
independent experiments; significant differences determined by Ordinary one-
way ANOVA using Tukey’s multiple comparison test. (F) Anti-LCMV IgG antibody 
titers in sera at day 112-114 p.i. Data are segregated based on serum viral titers; 
at left are mice with undetectable virus in their sera (cleared) and at right are 
mice with persistent serum virus titers (persistent). Each data point represents an 
individual mouse and data are a compilation of three independent experiments; 
significant differences determined by unpaired t test with Welch’s correction 
(cleared) and Ordinary one-way ANOVA using Tukey’s multiple comparison test 
(persistent). 
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4.8A-C). In addition, enumeration of viral titers in sera over time indicated that the 
kinetics of viral control were slower for Irf4+/fl mice than WT mice (Figure 4.8D). 
As expected, Irf4fl/fl mice exhibited the highest viral titers and a complete 
impairment in viral control (Figure 4.8A-D).  
 
IRF4 is also important for the differentiation of CD4+ TFH cells that regulate 
plasma cell differentiation. As previous studies have shown that during LCMV 
infection reduced antibody responses lead to virus persistence (Bergthaler et al., 
2009) (Thomsen et al., 1996), we considered whether the slower kinetics of virus 
control in Irf4+/fl mice could be accounted for by reduced anti-LCMV antibody 
titers.  Analysis of LCMV-specific IgG antibody titers at day 40 p.i. indicated that 
Irf4fl/fl mice were impaired in antibody production, consistent with the requirement 
for IRF4 in TFH differentiation (Figure 4.8E). However, we observed no difference 
in antibody titers between WT and Irf4+/fl mice, supporting a CD8+ T cell-intrinsic 
defect in viral control in Irf4+/fl mice. We then analyzed virus-specific antibody 
titers at day 112-114 p.i., a timepoint at which the majority of WT mice were 
controlling the infection.  When antibody data were segregated so that WT and 
Irf4+/fl mice were compared based on whether they had detectable virus in their 
sera (Figure 4.8C), we found slightly reduced antibody titers in Irf4+/fl mice that 
were controlling the virus relative to WT mice in this group (Figure 4.8F).  
However, no difference in antibody titers between the two genotypes of mice 
were seen for those that still had persistent virus replication in their sera. These 
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data indicate that high levels of IRF4 expression are essential for optimal long-
term control of the persistent LCMV-clone 13 infection, and that differences in 
viral control are not correlated with differences in anti-viral antibody titers. 
 
Examination of virus-specific CD8+ T cells at day 112-114 p.i. showed no 
significant differences in their numbers of virus-specific CD8+ T cells in Irf4+/fl 
mice compared to WT controls (Figure 4.9A, D). Nonetheless, consistent with our 
observation from day 8 and day 21-24 p.i., virus-specific Irf4+/fl CD8+ T cells at 
day 112-114 p.i. exhibited reduced T-bet to Eomes ratio relative to WT cells 
(Figure 4.10A, C).  This skewed ratio resulted in higher proportions and numbers 
of T-bet+ Eomes- virus-specific CD8+ T cells in WT mice relative to Irf4+/fl mice 
(Figure 4.9B, E).  When the data from the WT mice were segregated according 
to viral titers, we found that WT mice that had not controlled LCMV-clone 13 
infection at this time point, appeared as outliers and had proportions and 
numbers of T-bet+ Eomes- virus-specific CD8+ T cells comparable to Irf4+/fl mice 
(Figure 4.9B, E).  These findings are consistent with the conclusion that 
persistent antigen is essential for conversion of T-bet+ Eomes- cells into T-bet- 
Eomes+ progeny (Paley et al., 2012).  
 
Control of persistent LCMV-clone 13 infection has been associated with high 
numbers of T-bet+ virus-specific CD8+ T cells that lack expression of the     
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Figure 4.9. The proportions of T-bet+ Eomes- cells correlate with viral 
control at late timepoints of LCMV-clone 13 infection 
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Figure 4.9: The proportions of T-bet+ Eomes- cells correlate with viral 
control at late timepoints of LCMV-clone 13 infection 
(A, D) Splenocytes from LCMV-clone 13-infected WT, Irf4+/fl and Irf4fl/fl mice were 
stained with a viability dye, LCMV-specific H2-Db-GP276 and H2Db-GP33 
tetramers, and antibodies to CD8, T-bet and Eomes, and analyzed between day 
112-114 p.i. Dot plots show CD8 versus H2-Db-GP276 (A) or CD8 vs H2Db-GP33 
(D) tetramer staining on live CD8+ T cells. Graphs show compilations of 
proportions and numbers of tetramer-specific cells from day 112-114 post 
infection. (B, E) Graphs show compilations of the numbers and proportions of T-
bet+ Eomes- H2-Db-GP276 (B) or H2-Db-GP33 (E) specific cells. (C, F) Graphs 
show compilations of the numbers and proportions of T-bethi PD-1lo H2-Db-GP276 
(C) or H2-Db-GP33 (F) specific cells.  Symbols outlined in bold represent mice 
with undetectable titers of virus in sera at day 112-114 p.i. Each data point 
represents an individual mouse and data are a compilation of three independent 
experiments; significant differences determined by Ordinary one-way ANOVA 
using Tukey’s multiple comparison test. $ denotes statistically significant 
difference between WT and Irf4+/fl samples when analyzing only mice with 
undetectable serum viral titers (bold outlined symbols). Significant differences 
between outlined samples were determined by unpaired t test with Welch’s 
correction. 
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Figure 4.10. Clearance of LCMV-clone 13 leads to increased T-bet to 
Eomesodermin ratios 
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Figure 4.10: Clearance of LCMV-clone 13 leads to increased T-bet to 
Eomesodermin ratios 
Splenocytes from LCMV-clone 13-infected WT, Irf4+/fl and Irf4fl/fl mice were 
stained with a viability dye, LCMV-specific H2-Db-GP276 and H2Db-GP33 
tetramers, and antibodies to CD8, T-bet and Eomes, and analyzed between day 
112-114 p.i. Graphs show the MFI of T-bet and Eomes each normalized to the 
average of WT samples, and the ratio of normalized MFIs for T-bet relative to 
Eomes, for live CD8+ H2-Db-GP276 (A) and H2-Db-GP33 (C) specific cells. Graphs 
show compilations of the numbers and proportions of Eomeshi PD-1hi H2-Db-
GP276 (B) or H2-Db-GP33 (D) specific cells.  Each data point represents an 
individual mouse and data are a compilation of three independent experiments; 
significant differences determined by Ordinary one-way ANOVA using Tukey’s 
multiple comparison test.  Symbols with bold outlines represent mice whose 
serum viral titers were below the limit of detection at day 112-114 p.i..  $ denotes 
statistically significant difference between WT and Irf4+/fl samples when analyzing 
only mice with undetectable serum viral titers (bold outlined symbols). Significant 
differences between bold outlined samples were determined by unpaired t test 
with Welch’s correction. 
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exhaustion marker, PD-1 (Paley et al., 2012). When analyzed at day 112-114 
p.i., we observed increased proportions and numbers of T-bethi PD-1lo cells in 
WT mice relative to Irf4+/fl and Irf4fl/fl mice infected with LCMV-clone 13 (Figure 
4.9C, F).  However, as with the analysis of T-bet+ Eomes- cells, the T-bethi PD-1lo 
population in WT mice that had not cleared the virus by this timepoint appeared 
more similar to that of the Irf4+/fl cells.  These data suggest that the proportions 
and numbers of T-bethi PD-1lo CD8+ T cells may be more closely associated with 
viral control than with IRF4 expression levels.  Similar findings are evident from 
analysis of Eomes+ PD-1hi CD8+ T cell proportions and numbers at this timepoint 
(Figure 4.10B, D). 
 
Reducing Eomes expression improves viral control in LCMV-clone 13-
infected Irf4+/fl mice 
The data presented above indicated that LCMV-clone 13-infected Irf4+/fl mice 
have a lower T-bet to Eomes ratio than WT mice in their virus-specific CD8+ T 
cells at all time points investigated post-infection. Since optimal expression of 
both of these factors is essential for viral control, we considered whether 
manipulation of this ratio in favor of T-bet would restore protective CD8+ T cell 
responses in Irf4+/fl mice, leading to improved viral control. To address this, Irf4+/fl 
mice were crossed to Eomes+/fl mice to generate Irf4+/fl Eomes+/fl CD4-Cre mice 
(henceforth referred to as Irf4+/fl Eomes+/fl mice).  These compound heterozygotes 
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were infected with LCMV-clone 13, along with WT, Irf4+/fl, and Eomes+/fl mice and 
analyzed at day 77-82 p.i. 
 
We first observed higher proportions of GP276-specific T cells in the spleens of 
WT mice relative to the other three genotypes. Analysis of absolute cell numbers 
indicated that WT mice had more GP276-specific CD8+ T cells than did Eomes+/fl 
or Irf4+/fl Eomes+/fl mice; in addition, Irf4+/fl Eomes+/fl mice had significantly fewer 
cells than did Irf4+/fl mice (Figure 4.11A). In contrast, the proportions of GP33-
specific CD8+ T cells were similar between all four genotypes with only modest 
differences in the absolute numbers of these virus-specific CD8+ T cell 
populations (Figure 4.11C). 
 
Analysis of the levels of T-bet and Eomes in virus-specific CD8+ T cells between 
day 77-82 p.i. indicated that the Irf4+/fl and the compound heterozygotes had 
lower T-bet expression relative to WT, as would be expected due to the role of 
IRF4 in positively regulating T-bet expression (Figure 4.11B, D) (Nayar et al., 
2014) (Yao et al., 2013) (Man et al., 2013) (Kurachi et al., 2014). The expression 
of Eomes was higher in the Irf4+/fl cells relative to Irf4+/fl Eomes+/fl cells, indicating 
that the heterozygous deficiency in Eomes was able to reduce Eomes protein 
expression in Irf4+/fl cells (Figure 4.11B, D).  In addition, Irf4+/fl Eomes+/fl cells 
showed normalized ratios of T-bet to Eomes expression levels that were 
comparable to those seen in WT cells. Furthermore, the re-establishment of the 
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Figure 4.11. Irf4-Eomes compound haplodeficiency restores the T-bet to 
Eomes ratios in virus-specific CD8+ T cells 
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Figure 4.11: Irf4-Eomes compound haplodeficiency restores the T-bet to 
Eomes ratios in virus-specific CD8+ T cells 
Splenocytes from LCMV-clone 13 infected WT, Irf4+/fl, Eomes+/fl and 
Irf4+/flEomes+/fl mice were stained with a viability dye, LCMV-specific H2-Db-GP276 
and H2Db-GP33 tetramers, and antibodies to CD8, T-bet and Eomes and 
analyzed between D77-82 p.i. (A, C) Dot plots show CD8 vs H2-Db-GP276 (A) or 
CD8 vs H2Db-GP33 (C) tetramer staining on live CD8+ T cells. Graphs show 
compilations of proportions and numbers of virus-specific CD8+ T cells. (B, D) 
Dot plots show T-bet vs Eomes staining of H2-Db-GP276 (B) or H2-Db-GP33 (D) 
specific cells. Graphs show the MFI of T-bet and Eomes each normalized to 
average value for WT samples in each experiment, and the ratio of normalized 
MFIs for T-bet relative to Eomes, and the compilation of proportions of T-bet+ 
Eomes- cells for each virus-specific subset. Each data point represents an 
individual mouse and data are a compilation of three independent experiments; 
significant differences determined by Ordinary one-way ANOVA using Tukey’s 
multiple comparison test. 
 
 
 
 
 
	 135	
WT T-bet to Eomes ratio was also accompanied by increased proportions of T-
bet+ Eomes- GP33-specific cells in Irf4+/fl Eomes+/fl mice compared to those found 
in Irf4+/fl mice (Fig 4.11D). 
 
To test the functional consequences of the restored T-bet to Eomes ratio and 
increased differentiation of the T-bet+ Eomes- virus-specific CD8+ T cell 
population in Irf4+/fl Eomes+/fl mice, we examined the viral titers in these mice 
between days 77-82 p.i. This analysis showed a significantly higher titer of virus 
in the kidneys of Irf4+/fl mice compared to the other three genotypes analyzed 
(Figure 4.12A). Additionally, in contrast to the Irf4+/fl mice, virus was efficiently 
cleared from livers and sera of WT, Eomes+/fl, and Irf4+/fl Eomes+/fl mice at this 
timepoint (Figs 4.12B-C). Finally, we observed no difference in the kinetics of 
virus clearance when comparing WT to Irf4+/fl Eomes+/fl mice (Fig 4.12D).  These 
data demonstrate that reducing Eomes expression in Irf4+/fl mice restores a 
protective balance of T-bet to Eomes levels, leading to improved protective T cell 
responses to this persistent virus infection 
 
To determine whether these mice showed differences in T cell exhaustion, we 
examined expression of 2B4, CD160, LAG-3, and PD-1 on virus-specific cells.  
At this timepoint, Irf4fl/fl cells showed a marked reduction in 2B4 expression 
relative to all other genotypes, and Irf4+/fl cells had higher PD-1 expression 
relative to WT cells (Figure 4.13B, 4.14B).  While WT mice exhibited higher 
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Figure 4.12. Irf4-Eomes compound haplodeficiency restores virus control 
during persistent LCMV-clone 13 infection 
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Figure 4.12: Irf4-Eomes compound haplodeficiency restores virus control 
during persistent LCMV-clone 13 infection 
 Kidney (A), livers (B), and sera (C) were harvested from LCMV-clone 13 
infected WT, Irf4+/fl, Eomes+/fl and Irf+/flEomes+/fl mice between day 77-82 post 
infection and virus titers were determined by plaque assay. Dotted lines indicate 
the limit of detection. Each data point represents an individual mouse and data 
are compilations of two independent experiments. (D) Serum was harvested from 
infected mice at various timepoints post infection. Graph indicates the proportion 
of mice with viral titers above the limit of detection in serum over time. Each data 
point represents an individual mouse and data are compilation of two 
independent experiments; significant differences as determined by Ordinary one-
way ANOVA using Tukey’s multiple comparison test (A) and Log-rank (Mantel-
Cox) test (D). (E) Anti-LCMV IgG antibody titers in sera at day 40 and day 78-82 
p.i. were determined.  For day 40 timepoint, data points corresponding to 3 WT 
and 4 Irf4+/fl mice were previously shown in Fig 4.8E. Each data point represents 
an individual mouse and data are a compilation of two independent experiments; 
significant differences determined by Ordinary one-way ANOVA using Tukey’s 
multiple comparison test. 
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Figure 4.13. Compound haplo-deficiency of Irf4 and Eomes does not alter 
exhaustion marker expression, cytokine production, or effector function in H2-Db-
GP276 specific cells 
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Figure 4.13: Compound haplo-deficiency of Irf4 and Eomes does not alter 
exhaustion marker expression, cytokine production, or effector function in H2-Db-
GP276 specific cells 
Splenocytes from LCMV-clone 13-infected WT, Irf4+/fl, Irf4fl/fl, Eomes+/fl and 
Irf4+/flEomes+/fl mice were stained with a viability dye, LCMV-specific H2-Db-GP276 
tetramers, and antibodies to CD8, T-bet, Eomes, 2B4, CD160, LAG-3, PD-1, and 
granzyme B and analyzed at day 22 p.i. (A) Number of H2-Db-GP276 specific cells 
at day 22 p.i. (B) Graphs show the proportions of 2B4-, CD160-, LAG-3-, and 
PD-1-positive H2-Db-GP276 specific cells at day 22 p.i. (C) Dot plots show T-bet 
versus PD-1 staining on H2-Db-GP276 specific CD8+, live cells. Graph shows the 
proportions of T-bethi PD-1lo H2-Db-GP276 CD8+ specific cells. * Indicates 
statistically significant differences relative to WT samples. (D) Dot plots show 
Eomes versus PD-1 staining on H2-Db-GP276 specific, CD8+, live cells. Graph 
shows proportions of Eomeshi PD-1hi H2-Db-GP276 CD8+ specific cells. (E-H) 
Splenocytes from LCMV-clone 13-infected WT, Irf4+/fl, Irf4fl/fl, Eomes+/fl and Irf4+/fl 
Eomes+/fl mice were isolated at day 22 p.i. and stimulated with GP276 peptide, 
stained with a viability dye and antibodies to CD8, IFNγ, TNFα and IL-2. 
(E) Dot plots show representative staining of WT CD8+ live cells (CD8 versus 
IFNγ) and gated IFNγ+ CD8+ live cells (TNFα versus IL-2).  (F) Graph shows the 
proportions of IFNγ+ cells gated on CD8+ live cells for each genotype. (G) Graphs 
show the proportions of TNFα+ IL-2- (left) and TNFα+ IL-2+ (right) cells gated on 
IFNγ+ CD8+ live cells for each genotype. (H) Graph shows the numbers of 
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Granzyme B+ H2-Db-GP276 CD8+ live cells for each genotype. Each data point 
represents an individual mouse and data are compilations of three independent 
experiments; significant differences were determined by Ordinary one-way 
ANOVA using Tukey’s multiple comparison test. 
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Figure 4.14. Compound haplo-deficiency of Irf4 and Eomes does not alter 
exhaustion marker expression, cytokine production, or effector function in H2-Db-
GP33 specific cells 
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Figure 4.14: Compound haplo-deficiency of Irf4 and Eomes does not alter 
exhaustion marker expression, cytokine production, or effector function in H2-Db-
GP33 specific cells 
Splenocytes from LCMV-clone 13-infected WT, Irf4+/fl, Irf4fl/fl, Eomes+/fl and 
Irf4+/flEomes+/fl mice were stained with a viability dye, LCMV-specific H2-Db-GP33 
tetramers, and antibodies to CD8, T-bet, Eomes, 2B4, CD160, LAG-3, PD-1, and 
granzyme B and analyzed at day 22 p.i. (A) Number of H2-Db-GP33 specific cells 
at day 22 p.i. (B) Graphs show the proportions of 2B4-, CD160-, LAG-3-, and 
PD-1-positive H2-Db-GP33 specific cells at day 22 p.i. (C) Dot plots show T-bet 
versus PD-1 staining on H2-Db-GP33 specific, CD8+, live cells. Graph shows the 
proportions of T-bethi PD-1lo H2-Db-GP33 CD8+ specific cells. * Indicates 
statistically significant differences relative to WT samples. (D) Dot plots show 
Eomes versus PD-1 staining on H2-Db-GP33 specific, CD8+, live cells. Graph 
shows proportions of Eomeshi PD-1hi H2-Db-GP33 CD8+ specific cells. (E-H) 
Splenocytes from LCMV-clone 13-infected WT, Irf4+/fl, Irf4fl/fl, Eomes+/fl and Irf4+/fl 
Eomes+/fl mice were isolated at day 22 p.i. and stimulated with GP33 peptide, 
stained with a viability dye and antibodies to CD8, IFNγ, TNFα, and IL-2. (E) Dot 
plots show representative staining of WT CD8+ live cells (CD8 versus IFNγ) and 
gated IFNγ+ CD8+ live cells (TNFα versus IL-2). (F) Graph shows the proportions 
of IFNγ+ cells gated on CD8+ live cells for each genotype. (G) Graphs show the 
proportions of TNFα+ IL-2- (left) and TNFα+ IL-2+ (right) cells gated on IFNγ+ 
CD8+ live cells for each genotype. (H) Graph shows the numbers of Granzyme 
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B+ H2-Db-GP33 specific CD8+ live cells for each genotype. Each data point 
represents an individual mouse and data are compilations of two (A-D,H-I) or 
three (E-G) independent experiments; significant differences were determined by 
Ordinary one-way ANOVA using Tukey’s multiple comparison test. 
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proportions of T-bethi PD-1lo and lower proportions of Eomeshi PD-1hi populations 
relative to Irf4+/fl mice, we did not observe any differences between Irf4+/fl and 
Irf4+/fl Eomes+/fl cells (Figure 4.13C, D and 4.14C, D).  Overall, these data indicate 
that differences in viral control are unlikely to be due to differential expression of 
exhaustion markers.  
 
We next examined cytokine production by virus-specific CD8+ T cells from WT, 
Irf4+/fl, Irf4fl/fl, Eomes+/fl, and Irf4+/fl Eomes+/fl mice at day 22 p.i. Ex-vivo stimulation 
of splenocytes from infected with GP276 or GP33 peptide showed few cells 
capable of producing IFNγ, and little evidence of multi-functional T cells in any of 
the mice (Figure 4.13E, F and 4.14E, F).  We also failed to observe a difference 
in Granzyme B expression between any of the genotypes, with the exception of 
Irf4fl/fl cells (Figure 4.13H and 4.14H), arguing against a difference in cytotoxic 
activity between WT, Irf4+/fl, Eomes+/fl, and Irf4+/fl Eomes+/fl mice at this timepoint. 
 
To determine whether Irf4+/fl Eomes+/fl produced higher levels of anti-viral 
antibodies compared to Irf4+/fl mice, we examined anti-LCMV IgG titers at day 40 
and day 78-82 p.i. with LCMV-clone 13.  No differences in anti-viral antibody 
titers were observed in this analysis (Figure 4.12E), consistent with the 
comparable proportions of IL-21-producing GP61-specific CD4+ T cells in these 
mice (Figure 4.14I).    
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Discussion 
CD8+ T cell exhaustion is commonly observed during persistent infections and 
cancers (Wherry, 2011). Although a number of cell extrinsic factors such as the 
presence of the immune-suppressive cytokine IL-10, absence of help from CD4+ 
T cells, and high viral loads have been implicated in inducing exhaustion, a clear 
understanding of the CD8+ T cell intrinsic molecular mechanisms is still lacking 
(Mueller & Ahmed, 2009) (Doering et al., 2012). The role of several transcription 
factors, such as Blimp-1, T-bet, and Eomes have been examined during chronic 
infection (Paley et al., 2012) (Shin et al., 2009) (Kao et al., 2011). Blimp-1 is 
highly expressed in exhausted CD8+ T cells and its expression correlates with 
greater expression of exhaustion markers. Yet, Blimp-1 knockouts have a defect 
in controlling LCMV-clone 13 infections relative to WT mice, whereas mice haplo-
deficient for Blimp-1 are more proficient at controlling the infection. These data 
indicate that varying levels of Blimp-1 regulate distinct transcriptional modules in 
exhausted CD8+ T cells, and that levels of Blimp-1 that are too high or too low 
are detrimental to the immune response (Shin et al., 2009). Similarly, the 
expression of T-bet and Eomes segregate into T-bethi and Eomeshi populations 
during persistent infections. Even though both proteins are T-box transcription 
factors and function redundantly early in LCMV Armstrong infection, loss of either 
protein results in impaired control of LCMV-clone 13 infections likely due to the 
different gene networks they regulate during LCMV-clone 13 infections (Paley et 
al., 2012) (Doering et al., 2012). Together these data demonstrate that efficient 
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control of LCMV-clone 13 requires an optimal level of each of these transcription 
factors. Interestingly, mice lacking Blimp-1, T-bet, or Eomes have no defect in 
clearing acute LCMV Armstrong infections, yet are impaired in controlling LCMV-
clone 13 (Banerjee et al., 2010) (Rutishauser et al., 2009) (Intlekofer et al., 
2007). Here we find that IRF4 joins this group of transcription factors, as reduced 
expression of IRF4 leads to persistence of LCMV-clone 13 infection, but does not 
affect clearance of LCMV Armstrong (Nayar et al., 2014). 
 
Despite the fact that the function of Tbethi and Eomeshi subsets is well defined, 
the factors regulating the differentiation of anti-viral CD8+ T cells into these 
subsets is not known. We explored the role of TCR signaling via IRF4 in the 
relative expression of T-bet and Eomes and the differentiation of T-bet+ Eomes- 
and T-bet- Eomes+ subsets during chronic LCMV infection. We find that the 
balance of these two transcription factors is dependent on the strength of TCR 
signaling and reduction in the affinity or the dose of the stimulating ligand 
resulted in lowering of this ratio. Molecularly, the relative levels of T-bet and 
Eomes were dependent on the magnitude of IRF4 expression, and reduced IRF4 
expression, such as those achieved by haplo-deficiency of Irf4, resulted in 
skewing of this ratio in the favor of Eomes, both in vitro and in vivo. Previous 
studies have demonstrated that IRF4, together with its binding partner, BATF, 
directly bind to the both the T-bet and Eomes loci in effector CD8+ T cells, 
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indicating a direct role of IRF4/BATF in regulating the expression of these two 
genes (Man et al., 2013) (Kurachi et al., 2014). 
 
The most severe consequence of the altered T-bet to Eomes ratio was the 
reduced differentiation of T-bet+ Eomes- precursors, and long-term viral 
persistence in Irf4+/fl mice. IRF4 regulates multiple pathways such as 
proliferation, metabolism, and expression of effector cytokines in anti-viral CD8+ 
T cells (Yao et al., 2013) (Man et al., 2013). Thus, it is likely that defects in any of 
these pathways could contribute to impaired viral clearance in Irf4+/fl mice rather 
than the lower T-bet to Eomes ratio. To directly test the importance of T-bet to 
Eomes ratio, we reduced Eomes expression in Irf4+/fl mice by generating Irf4+/fl 
Eomes+/fl mice. These compound heterozygotes had lower Eomes expression 
relative to Irf4+/fl mice, exhibited no alteration in the T-bet to Eomes ratio relative 
to WT cells, and showed enhanced differentiation of T-bet+ Eomes- cells relative 
to Irf4+/fl mice. Consequently, Irf4+/fl Eomes+/fl mice were indistinguishable from 
WT mice in terms of viral clearance from multiple organs. These data, to the best 
of our knowledge, are the first to test the importance of relative expression of T-
bet and Eomes in LCMV-clone 13 viral control. 
 
Another consequence of reduced T-bet to Eomes ratio was the altered 
differentiation of T-bethi and Eomeshi populations in Irf4+/fl mice. Using T-bet and 
Eomes knockout mice, Paley et al. showed that both T-bethi and Eomeshi subsets 
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are important for viral control (Paley et al., 2012). However, it is not known if 
reduced differentiation of one population over the other affects viral clearance. 
Our studies suggest that reduced differentiation of T-bet+ Eomes- population in 
Irf4+/fl mice is detrimental to efficient viral control, and that increasing this 
population in Irf4+/fl Eomes+/fl mice restores viral control. Consistent with this 
observation, lower proportions of CD8+ T-bet+ Eomes- cells are observed in lung 
transplant recipients with relapsed CMV infection relative to controllers (Popescu 
et al., 2014). A recent study showed that loss of FoxO1 results in higher levels of 
T-bet and lower levels of Eomes, thus biasing CD8+ T cell differentiation to the T-
bethi subset. Interestingly, the FoxO1 deficient mice were also defective in viral 
control (Staron et al., 2014). Together these data underscore the importance of 
previous observations that both subsets of CD8+ T cells, the T-bethi and the 
Eomeshi populations, play unique and essential functions during anti-viral 
immune responses to LCMV-clone 13 (Paley et al., 2012). Further, these data 
support our conclusion that balanced differentiation of T-bet+ Eomes- and T-bet- 
Eomes+ subsets are important for viral control. 
 
Recently, we and others have shown that the levels of IRF4 regulate the 
magnitude of CD8+ T cell expansion during acute infections (Nayar et al., 2014) 
(Yao et al., 2013) (Man et al., 2013) (Raczkowski et al., 2013) (Grusdat et al., 
2014). Similar to that seen with acute infections, we find here that the levels of 
IRF4 also regulate the magnitude of the CD8+ T cell response to LCMV-clone 13 
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at day 8 post infection. Furthermore, the increased numbers of virus-specific cells 
in WT mice relative to Irf4+/fl mice also resulted in a significant increase in the 
numbers of Tbet+ Eomes- cells at this timepoint. Somewhat surprisingly, total 
virus-specific CD8+ T cell numbers were not different between WT and Irf4+/fl 
mice at day 22 p.i., nor were they different at later timepoints examined. 
Therefore, we speculate that this early difference in the magnitude of the CD8+ T 
cell response may be responsible for the ultimate ability of WT, but not Irf4+/fl 
mice to clear LCMV clone 13. 
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Introduction 
The T cell response to acute viral infections has been well characterized at the 
cellular level. Following infection, a robust pathogen-specific CD8+ T cell 
response is observed, and within 1-2 weeks post-infection, the pathogen is 
cleared from the infected host.  This early effector phase includes the 
proliferation and differentiation of cytotoxic effector T cells, a process that is 
dependent on inflammatory cytokines produced by innate immune cells, and on 
the presentation of viral peptides on host antigen-presenting-cells (APCs) 
(Mempel et al., 2004) (Wherry & Ahmed, 2004) (Kaech & Cui, 2012). After viral 
clearance, the majority of the effector CD8+ T cell population will undergo 
apoptosis, a process that continues for many weeks post-pathogen clearance 
(Zhou et al., 2012).  Ultimately, the host retains a small pool of pathogen-specific 
memory T cells that provide rapid protection upon secondary infection (Cui & 
Kaech, 2010).  
During an acute anti-viral response, the pool of activated CD8+ T cells is not 
homogeneous.  Based on differential expression of surface markers, such as 
KLRG1 and CD127, virus-specific CD8+ T cells can be classified as KLRG1hi 
CD127lo terminal effector cells (TECs) and KLRG1lo CD127hi memory precursor 
cells (MPCs) (Kaech et al., 2003). TECs rapidly proliferate in response to 
infection, make up the majority of the CD8+ effector response, and undergo 
apoptosis after clearance of the infection. MPCs proliferate less than TECs, but 
go on to survive and undergo homeostatic proliferation after the infection is 
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eliminated (Kaech et al., 2003) (Joshi & Kaech, 2008). Several transcription 
factors have been shown to play critical roles in the relative differentiation of 
TECs versus MPCs during acute viral infection. These include IRF4 (Nayar et al., 
2012) (Raczkowski et al., 2013) (Man et al., 2013) (Yao et al., 2013) (Nayar et 
al., 2014), BATF (Kurachi et al., 2014) (Grusdat et al., 2014) (Godec et al., 2015), 
T-bet (Sullivan et al., 2003) (Intlekofer et al., 2005) (Joshi et al., 2007) (Rao et al., 
2010), Blimp-1 (Rutishauser et al., 2009) (Shin et al., 2013) (Xin et al., 2016), 
and Id2 (Cannarile et al., 2006) (Yang et al., 2011) (Knell et al., 2013) (Omilusik 
et al., 2010), which regulate TEC differentiation and effector cell function.  In 
contrast, Eomesodermin (Eomes) (Intlekofer et al., 2005) (Rao et al., 2010) 
(Banerjee et al., 2010) , TCF1 (Jeannet et al., 2010) (Zhou et al., 2010), Id3 
(Yang et al., 2011) (Ji et al., 2011), and Runx3 (Wang et al., 2018) are all 
required for CD8+ T cell memory formation and homeostasis.  
Here we show that a member of the Runt-related transcription factor family 
(RUNX), Runx2, is also important for regulating the long-term persistence of 
CD8+ memory T cells following acute LCMV Armstrong infection. Runx2, like the 
other RUNX factors, contains a runt DNA binding domain, and pairs with CBFβ to 
bind to DNA (Tahirov et al., 2001). Runx2 functions primarily in bone 
development, where it is required for osteoblast generation (Komori, 2018) and 
bone formation (Choi et al., 2001).  
Runx1 and Runx3 have well-characterized roles in T cells, including important 
functions during TREG development (Kitoh et al., 2009), TH1 skewing (Naoe et al., 
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2007), and CD8+ T cell differentiation (D. Wang et al., 2018) (Cruz-Guilloty et al., 
2009). In contrast, no clear function for Runx2 in T cells has been identified, 
although an earlier study showed that ectopic overexpression of Runx2 in 
thymocytes perturbed T cell development at the CD4-CD8- stage (Vaillant et al., 
2002). A genome-wide regulatory network generated by Hu et al. also suggested 
that Runx2 may play a role in CD8+ T cell memory (Hu & Chen, 2013).  Using 
mice carrying floxed alleles of Runx2 crossed to CD4-cre, we find no apparent 
defects in T cell development or T cell homeostasis under steady-state 
conditions.  However, following infection with LCMV-Armstrong, we identify a 
CD8+ T cell-intrinsic defect in the development and persistence of virus-specific 
MPCs.  This correlates with our findings that Runx2 expression levels in 
activated CD8+ T cells are enhanced by TLR and memory cytokine stimulation, 
but inhibited by IRF4 expression.  Together, these data identify Runx2 as an 
important mediator of virus-specific memory T cells following resolution of 
infection by LCMV-Armstrong.  
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Results 
 
Loss of Runx2 in T cells leads to a defect in pathogen-specific CD8+ MPCs 
during LCMV Armstrong Infection 
To circumvent the neonatal lethality of a germline deficiency in Runx2, we 
generated mice that lacked Runx2 only in T cells.  To this end, Runx2fl/fl mice 
(Chen et al., 2011) were crossed to the CD4-cre+ transgenic line (Nayar et al., 
2014) (Nayar et al., 2012) (hereafter referred to as Runx2fl/fl mice). Runx2fl/fl mice 
showed no apparent defect in thymic T cell development or in peripheral T cells 
compared to Runx2+/+ CD4-cre+ controls (hereafter called WT mice) (Figure 
5.1A-C). Additionally, Runx2fl/fl mice exhibited no abnormalities in their numbers 
or proportions of CD8+ CD44hi and CD8+ CD44lo T cells within the spleen (Figure 
5.1D).  
 
To assess the function of Runx2 in anti-viral T cell responses, we infected WT 
and Runx2fl/fl mice with 5x104 PFU LCMV-Armstrong I.P. and harvested spleens 
at day 9 (the peak of the CD8+ T cell response), day 14 (the attrition phase), and 
day 28 (the memory phase) post-infection (Figure 5.2). Compared to WT mice, 
Runx2fl/fl mice had no alterations in the numbers of H2-Db GP33-41 tetramer-
specific cells (GP33) at days 9 and 14 post-infection, but did show reduced 
numbers of virus-specific cells at day 28 post-infection (Figure 5.2A-B). Similar 
results were observed for H2-Db GP276-286 specific cells (GP276) and H2-Db 
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Figure 5.1. No major differences are observed in thymus and spleen of 
Runx2fl/fl mice 
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Figure 5.1: No major differences are observed in thymus and spleen of 
Runx2fl/fl mice 
 
(A) Thymocytes were isolated from WT or Runx2fl/fl and stained with antibodies to 
CD4 and CD8.  Dot-plots show CD4 versus CD8 staining.  (B) Percentages of 
DP thymocytes (left), CD4SP thymocytes (center), and CD8SP thymocytes 
(right) in WT and Runx2fl/fl mice are shown. (C) Splenocytes from WT and 
Runx2fl/fl mice were stained analyzed for CD8 versus live/dead staining (left); 
numbers of live CD8+ cells are shown at right. (D) WT and Runx2fl/fl splenocytes 
were stained for CD8 versus CD44 (left) and absolute numbers of CD8+ CD44lo 
(center) and CD8+ CD44hi (left) cells are shown. Data are representative of 3 
independent experiments with a total of 9-12 mice per group. Mean ± SEM. 
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Figure 5.2. Loss of Runx2 in the T cell compartment leads to a defect in the 
number of CD8+ MPCs during LCMV Armstrong infection without any major 
impact on CD8+ TECs 
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Figure 5.2: Loss of Runx2 in the T cell compartment leads to a defect in the 
number of CD8+ MPCs during LCMV Armstrong infection without any major 
impact on CD8+ TECs 
 
WT and Runx2fl/fl mice were infected with LCMV-Armstrong, and analyzed on day 
9, 14, and 28 post-infection. (A) Gated CD8α+ splenocytes were stained for H2-
Db GP33-41 tetramer and CD44. (B) Compilation of data shows total number of 
H2-Db GP33-41 (left), H2-Db GP276-286 (center), and H2-Db NP396-404 (right) specific 
splenocytes in WT versus Runx2fl/fl mice at day 9, 14, and 28 post infection. (C) 
KLRG1 vs CD127 staining of WT and Runx2fl/fl CD8α+ CD44hi, H2-Db GP33-41 
tetramer+ splenocytes at days 9, 14, and 28 post infection. (D-E) Total number of 
H2-Db GP33-41 (left), H2-Db GP276-286 (center), and H2-Db NP396-404 (right) specific 
TECs (D) and MPCs (E) in WT versus Runx2fl/fl mice at day 9, 14, and 28 post 
infection. (F) Cells were restimulated with H2-Db GP33-41 (left), H2-Db GP276-286 
(center), or H2-Db NP396-404 (right) peptide for 4 hours in vitro. Total number of 
H2-Db GP33-41 (left), H2-Db GP276-286 (center), and H2-Db NP396-404 (right) IFNγ+, 
TNFα+, IL-2+ splenocytes (triple producers) in WT versus Runx2fl/fl CD8α+, CD44hi 
cells at day 9, 14, and 28 post LCMV Armstrong infection. Data are from 9 
independent experiments with a total of 9-12 mice per group per timepoint. Mean 
± SEM. 
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NP396-404 specific cells (NP396), indicating the defect at day 28 post-infection in the 
CD8+ T cells was not an epitope-specific phenotype (Figure 5.2B).  
 
These results suggested a potential defect in the virus-specific MPC population 
in LCMV-Armstrong infected Runx2fl/fl mice. To assess this possibility, we 
examined tetramer-positive CD8+ T cells for KLRG1 and CD127 expression at 
each timepoint post-infection.  This analysis revealed a defect in the total number 
of GP33, GP276, and NP396 MPCs in Runx2fl/fl mice compared to controls at all 3 
timepoints tested; in contrast, no differences were found in the virus-specific TEC 
populations in this comparison (Figures 5.2C-E). Functional memory cells are 
able to produce IFNγ, TNFα, and IL-2, and this poly-functionality is an indicator of 
a robust memory population (Slifka & Whitton, 2000). Comparisons of cytokine 
production by virus-specific WT and Runx2fl/fl CD8+ T cells revealed a significant 
reduction in the total numbers of triple cytokine-producing cells when T cells 
lacked Runx2 expression (Figures 5.2F). These data indicated that the reduced 
numbers of tetramer-positive CD8+ T cells in LCMV-Armstrong infected Runx2fl/fl 
mice was due to a defect in the memory T cell population. 
 
As mentioned above, Runx2fl/fl mice showed no reduction in virus-specific TEC 
numbers compared to WT mice at days 9, 14, or 28 post-LCMV infection. We 
also observed only modest defects in Granzyme B expression and no defects in 
CD107a+b expression at day 9 post-infection in Runx2fl/fl mice (Figure 5.3A-B). 
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Figure 5.3. Loss of Runx2 in the T cell compartment has no major effect on 
CD8+ T cell antiviral effector function 
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Figure 5.3: Loss of Runx2 in the T cell compartment has no major effect on 
CD8+ T cell antiviral effector function 
 (A) MFI of Granzyme B in WT versus Runx2fl/fl cells day 9 post infection. Cells 
were restimulated in vitro for 4h with GP33-41 peptide, GP276-286 peptide, or NP396-
404 peptide and stained for intracellular Granzyme B. (B) MFI of CD107a+b in WT 
versus Runx2fl/fl cells day 9 post infection. Cells were restimulated in vitro for 4h 
with GP33-41 peptide, GP276-286 peptide, or NP396-404 peptide and stained for 
CD107a+b. (C) PFU/ml LCMV virus in spleen or fat pad of WT versus Runx2fl/fl at 
day 9 post infection.  Positive control shows LCMV-Armstrong stock solution. 
Mean ± SEM. 
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These results suggested there were no defects in anti-viral effector cell functions 
when T cells lacked Runx2.  Analysis of viral clearance in LCMV-Armstrong-
infected WT versus Runx2fl/fl mice confirmed this supposition (Figure 5.3C).  
 
Based on these data, we considered whether virus-specific CD8+ T cell subsets 
might express different levels of Runx2.  To test this, we infected WT C57/BL6 
mice with LCMV-Armstrong and harvested spleens at day 9 post-infection. 
Runx2 protein levels were examined in CD8+ MPCs and TECs specific for three 
viral epitopes. While Runx2 was upregulated in both subsets of virus-specific 
cells relative to the levels present in naïve CD8+ T cells, we observed increased 
levels of Runx2 in the MPCs compared to the TECs for each of the epitopes 
tested (Figure 5.4A). These results indicated that Runx2 is upregulated within all 
activated CD8+ T cells, but is higher within the MPC population than in the TEC 
subset.  
 
To further assess potential molecular differences between WT and Runx2fl/fl anti-
viral CD8+ T cells, we examined the expression levels of several transcription 
factors that are important for TEC and MPC differentiation and function.  This 
analysis revealed that at days 14 and 28 post-infection, Runx2fl/fl CD8+ T cells 
expressed lower levels of Eomesodermin and TCF1 compared to WT T cells, 
consistent with the reduced numbers of MPC in these mice.  In contrast, 
expression of T-bet, a factor associated with CD8+ effector function, was not 
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Figure 5.4. Runx2 is upregulated in MPCs compared to TECs, and loss of 
Runx2 leads to a defect in MPC differentiation TFs Eomes and TCF1 
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Figure 5.4: Runx2 is upregulated in MPCs compared to TECs, and loss of 
Runx2 leads to a defect in MPC differentiation TFs Eomes and TCF1  
(A) WT C57/BL6 mice were infected with LCMV-Armstrong and analyzed on day 
9 post-infection for Runx2 expression levels in CD8α+, CD44hi  H2-Db GP33-41, 
GP276-286, and NP396-404 specific MPCs versus TECs. (B-D) Normalized MFI of 
Eomes, TCF1, and T-bet in (B) H2-Db GP33-41, (C) H2-Db GP276-286, and (D) H2-
Db NP396-404 tetramer-specific WT versus Runx2fl/fl splenocytes were analyzed at 
day 9,14, and 28 post LCMV Armstrong infection by staining for Eomes, TCF1 or 
T-bet. Data show normalized MFI for transcription factor staining in gated CD8α+, 
CD44hi (B) H2-Db GP33-41, (C) H2-Db GP276-286, or (D) H2-Db NP396-404 cells. 
Samples were normalized to average MFI value for each protein in the WT 
samples in each experiment. Data from (A) are from 2 independent experiments 
with a total of 12 mice. Data from (B-D) are from 3 independent experiments with 
a total of 9-12 mice per group. Mean ± SEM. 
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Figure 5.5. Loss of Runx2 does not increase apoptosis of virus-specific 
TEC or MPCs following LCMV Armstrong infection 
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Figure 5.5: Loss of Runx2 does not increase apoptosis of virus-specific 
TEC or MPCs following LCMV Armstrong infection  
WT and Runx2fl/fl mice were infected with LCMV-Armstrong and splenocytes 
were isolated 10 days post-infection. (A) Cells were analyzed for Annexin-V and 
7-AAD staining as shown. (B) Percentage of AnnexinV+ 7-AAD- TECs and MPCs 
among each virus-specific population, including H2-Db GP33-41, H2-Db GP276-286, 
and H2-Db NP396-404 tetramer specific cells in WT and Runx2fl/fl mice. Samples 
are gated on CD8α+, CD44hi, tetramer+ cells. Data are from 2 independent 
experiments with a total of 8 mice per group. Mean ± SEM. 
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altered between WT and Runx2fl/fl cells (Figure 5.4B-D), consistent with previous 
results indicating no defect in CD8+ effector function (Figure 5.3).  
 
We next considered whether the loss of MPCs in LCMV-Armstrong infected 
Runx2fl/fl mice were due to Runx2 promoting apoptosis in MPCs. However, 
examination of splenocytes from LCMV-Armstrong infected WT or Runx2fl/fl mice 
at day 10 post-infection failed to show a significant increase in apoptosis of virus-
specific CD8+ T cells in the absence of Runx2 (Fig 5.5A-B). Taken together, 
these results indicated that Runx2 is regulating an alternative aspect of memory 
CD8+ T cell persistence, such as homeostatic proliferation, rather than survival. 
 
Loss of pathogen-specific CD8+ memory T cells is due to a CD8+ T cell-
intrinsic deficiency in Runx2 
To determine whether the loss of LCMV-specific Runx2-deficient CD8+ memory T 
cells was caused by an intrinsic loss of Runx2 in the CD8+ T cells, we performed 
adoptive transfer experiments.  WT and Runx2fl/fl mice were crossed to the P14 
TCR transgenic line that expresses a TCR specific for the GP33 epitope of LCMV.  
WT (CD90.1+ CD90.2+) and Runx2fl/fl (CD90.1+) P14 cells were co-transferred 
into CD90.2+ host mice at a 1:1 mixture (Figure 5.6A), and recipients were 
infected with LCMV-Armstrong the following day. Four weeks later, donor cells 
were examined in the spleens of infected mice.  As shown in Figure 5.6, Runx2fl/fl 
P14 cells were significantly reduced in numbers relative to WT P14 cells (Figure 
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5.6B). Assessment of TEC and MPC subsets showed that both populations of 
Runx2fl/fl P14 cells were reduced in numbers compared to their WT counterparts, 
but a more dramatic reduction was observed in the Runx2fl/fl MPC subset, where 
WT P14 cells outnumbered Runx2fl/fl P14 cells by a 23-fold margin (Figure 5.6C).  
Examination of several proteins associated with MPC differentiation and survival, 
including Eomesodermin, TCF1, CD27, CD122, Bcl-2, showed reduced 
expression by Runx2fl/fl P14 cells relative to WT P14 cells at this timepoint.  
Surprisingly, this was not the case for Bcl-6, which was upregulated in Runx2fl/fl 
cells compared to WT controls (Figure 5.6D).  We also assessed cytokine 
production by WT and Runx2fl/fl P14 cells at day 28 post-infection, and observed 
markedly fewer triple-cytokine producing cells amongst the Runx2fl/fl P14 cells 
relative to WT P14 cells (Figure 5.6E). Overall, these data demonstrate that the 
defect in memory CD8+ T cell persistence in Runx2fl/fl mice following LCMV-
Armstrong infection is a CD8+ T cell-intrinsic phenotype. Mean ± SEM. 
 
Runx2-dependent CD8+ memory T cell loss does not impair the recall 
response to LCMV 
To determine whether the defect in numbers of Runx2fl/fl CD8+ memory T cells 
would impact the recall response, we rechallenged LCMV-Armstrong-infected 
WT and Runx2fl/fl mice with LCMV-clone 13. Initially, WT and Runx2fl/fl mice were  
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Figure 5.6. Loss of pathogen-specific T cell memory is due to the absence 
of Runx2 in CD8+ T cells 
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Figure 5.6: Loss of pathogen-specific T cell memory is due to the absence 
of Runx2 in CD8+ T cells 
 WT P14 (CD90.1+/CD90.2+) and Runx2fl/fl P14 cells (CD90.1+) were mixed 1:1 
and transferred into WT (CD90.2+) recipients. (A) Mixture of donor T cells prior to 
transfer.  (B) One day after transfer, recipient mice were infected with LCMV-
Armstrong, and splenocytes were analyzed on day 28 post-infection. WT P14 
(CD90.1+/CD90.2+) and Runx2fl/fl P14 cells (CD90.1+) cells are shown (left) and 
the total numbers of WT P14 and Runx2fl/fl P14 splenocytes day 28 post-infection 
were compiled (right). (C) Cells were stained for KLRG1 and CD127 and donor 
populations were gated on (left); total numbers of WT P14 and Runx2fl/fl P14 
TECs (middle) and MPCs (left) in host mice at day 28 post infection are shown. 
(D) Normalized expression of Eomes, TCF1, CD27, CD122, Bcl2, and Bcl6 at 
day 28 post-infection. MFI are normalized to the average of WT P14 cells 
analyzed in each sample. (E) Cells were restimulated with GP33-41 peptide for 4 
hours in vitro, and stained for intracellular IFNγ, TNFα, and IL-2 as shown (left). 
Total numbers of H2-Db GP33-41 specific IFNγ+, TNFα+, IL-2+ splenocytes (triple 
producers) in WT versus Runx2fl/fl P14 cells at day 28 post LCMV Armstrong 
infection are shown (right). Data are from 2 independent experiments with a total 
of 9 mice. Mean ± SEM. 
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infected with LCMV-Armstrong, and 90 days after infection, mice were 
rechallenged with a high dose of LCMV-Clone 13.  Prior to rechallenge, we 
examined the surviving populations of virus-specific CD8+ T cells and found 
reduced numbers of tetramer-positive cells in Runx2fl/fl mice compared to 
controls; furthermore, Runx2fl/fl mice had a more substantial deficit in the CD62Lhi 
than the CD62Llo subset of each epitope-specific memory T cell population 
(Figure 5.7A-D).  Four days after rechallenge, we observed substantial 
expansion of the both WT and Runx2fl/fl virus-specific memory cells.  This robust 
recall response was observed for all three viral epitopes tested (Figure 5.8A-B). 
A careful examination of TECs and MPCs showed no significant differences in 
either population when comparing WT to Runx2fl/fl mice (Figure 5.8C). We also 
found no differences in viral clearance between WT and Runx2fl/fl at day 4 post-
rechallenge (Figure 5.8D). Phenotypic and functional analysis of the cells after 
rechallenge showed few significant differences between virus-specific WT and 
Runx2fl/fl cells (Figure 5.9A-C).   These results indicate that the loss of memory T 
cells seen in Runx2fl/fl mice does not impair their protective response to 
secondary challenge.  
 
Based on these data, we considered whether the reduced numbers of virus-
specific memory CD8+ T cells seen in the spleens of Runx2fl/fl mice might be due 
to altered migration of these cells to other tissues, rather than to an absolute 
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Figure 5.7 Runx2 deficiency leads to a significant loss of CD62Lhi memory 
CD8 T cells at a late memory timepoint 
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Figure 5.7 Runx2 deficiency leads to a significant loss of CD62Lhi memory 
CD8 T cells at a late memory timepoint  
WT and Runxfl/fl mice were infected with LCMV-Armstrong, and then 90 days later 
spleens were harvested for staining. (A) Dot-plot shows CD62Lhi and CD62Llo 
cells from an uninfected control to indicate gating strategy. (B) Splenocytes were 
analyzed on day 90, prior to secondary challenge, for CD44hi CD62Lhi staining 
(gated H2-Db GP33-41 tetramer+ CD8+ cells) (left), as well as total numbers of 
CD62Lhi cells (center) and CD62Llo cells (right). (C) Total numbers of CD62Lhi 
(left) and CD62Llo (right) H2-Db GP276-286 specific cells at day 90 post-primary 
infection. (D) Total numbers of CD62Lhi (left) and CD62Llo (right) H2-Db NP396-286 
specific cells day 90 post-primary infection. Data are from 3 independent 
experiments with a total of 12 mice per group. Mean ± SEM. 
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Figure 5.8. Runx2 deficiency in T cells does not impair proliferation of 
pathogen-specific CD8 T cells or viral clearance during recall response to 
LCMV-Clone 13 
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Figure 5.8. Runx2 deficiency in T cells does not impair proliferation of 
pathogen-specific CD8 T cells or viral clearance during recall response to 
LCMV-Clone 13 
WT and Runx2fl/fl mice were infected with LCMV-Armstrong, and on day 90 post-
infection were rechallenged with a high dose of LCMV-clone 13. (A) H2-Db GP33-
41 tetramer+ CD8+ CD44hi staining is shown on day 4 post-rechallenge (left). 
Timecourse of virus-specific cells including day 4 post LCMV-clone 13 
rechallenge is shown (right). (B) Total numbers of GP276-286 (left) and NP396-404 
(right) specific cells 4 days after LCMV Clone 13 rechallenge. (C) H2-Db GP33-41 
specific CD8+ cells were stained for KLRG1 and CD127 at day 4 post LCMV-
clone 13 rechallenge (left), and total cell numbers of H2-Db GP33-41 specific TECs 
(center) and MPCs (right) were quantified. (D) Plaque assay of LCMV titers in 
kidney and liver on day 4 post LCMV-clone 13 rechallenge. Data are from 2 
independent experiments with a total of 5 mice per group. Mean ± SEM. 
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Figure 5.9. Runx2 deficiency in T cells does not impair transcriptional 
profile of pathogen-specific CD8 T cells during recall response to LCMV-
Clone 13 
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Figure 5.9: Runx2 deficiency in T cells does not impair transcriptional 
profile of pathogen-specific CD8 T cells during recall response to LCMV-
Clone 13 
WT and Runx2fl/fl mice were infected with LCMV-Armstrong, and on day 90 post-
infection were rechallenged with a high dose of LCMV-clone 13. (A-C) MFI of 
Eomes, T-bet, IRF4, Granzyme B, CD107a+b, and total number of triple 
producers on day 4 after LCMV Clone 13 rechallenge for (A) H2-Db GP33-41, (B) 
H2-Db GP276-286, and (C) H2-Db NP396-404 tetramer specific cells . Intracellular 
cytokine staining was performed after a 4 hour GP33-41 peptide stimulation in 
vitro. Data from LCMV-clone 13 rechallenge are from 2 independent experiments 
with a total of 5 mice per group. Mean ± SEM. 
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reduction in the total memory cell population.  This hypothesis was suggested by 
a previous study that showed loss of Runx2 in the plasmacytoid dendritic cell 
compartment led to a retention of the cells in the bone marrow (Chopin et al., 
2016). To test this, we examined several organs for pathogen-specific CD8+ T 
cells 14 days post-primary infection with LCMV-Armstrong. As shown, we found 
significantly fewer LCMV-specific memory CD8+ T cells in nearly all organs 
examined, and for each of the viral epitopes assessed (Figure 5.10A-C).  These 
data indicate that the reduced numbers of splenic Runx2fl/fl LCMV-specific 
memory CD8+ T cells is not due to enhanced homing or retention of these cells to 
or in other organs.    
 
Runx2 expression is regulated by TLR4/TLR7 signals and cytokine 
signaling pathways in vitro 
Previous work has shown a role for TLR signaling in CD8+ T cell memory 
formation (Quigley et al., 2009) (Mercier et al., 2009). We next wanted to 
determine if Runx2 expression in activated CD8+ T cells was regulated by TLR 
signaling in vitro. To determine the optimal day post stimulation to look at Runx2 
expression, we isolated splenocytes from P14 TCR transgenic mice and looked 
for Runx2 expression up to 5 days post stimulation with GP33 peptide. We found 
that Runx2 was upregulated by day 3 post-stimulation, and remained elevated 
through day 5 (Figure 5.11A); however, cell death increased dramatically starting 
day 4 post infection (Figure 5.11B). We therefore chose seventy-two hours post 
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Figure 5.10 Loss of Runx2 leads to a defect in MPCs in multiple organ 
compartments after LCMV-Armstrong infection 
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Figure 5.10 Loss of Runx2 leads to a defect in MPCs in multiple organ 
compartments after LCMV-Armstrong infection 
(A-C) Spleen, lymph node, lung, liver, and bone marrow lymphocytes were 
isolated on day 14 post primary infection with LCMV-Armstrong. Frequencies of 
(A) H2-Db GP33-41, (B) H2-Db GP276-286, and (C) H2-Db NP396-404 specific MPCs in 
tissues from infected WT versus Runx2fl/fl mice are shown. Data are from 3 
independent experiments with a total of 9-10 mice per group. Mean ± SEM. 
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Figure 5.11. TLR and cytokine signaling enhance Runx2 expression in vitro 
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Figure 5.11: TLR and cytokine signaling enhance Runx2 expression in vitro 
(A) Runx2 expression and (B) cell death in P14 splenocytes stimulated with 
GP33-41 peptide (1uM) and IL-2 supernatants. Each day, cells were analyzed for 
Runx2 and cell death by flow cytometry.  Graphs show MFI of Runx2 staining (A) 
and percentages of dead cells (B). (C-H) OT-I TCR transgenic splenocytes were 
isolated and cultured in vitro with high (100nM) or low (C-D 0.4nM) (E-H 0.8nM) 
doses of T4 peptide, in the presence or absence of (C) LPS, (D) Imiquimod, (E) 
IFNβ, (F) IL-12, (G) IL-7, (H) IL-15. Cultures also contained 20ng recombinant IL-
2 (C-D), or supernatants from IL-2 producer cells (E-H). Samples were stained 
for Runx2 72 hours post stimulation.  Graphs show MFI of Runx2 staining 
normalized to signal in OT-I cells stimulated with high dose T4 peptide in the 
absence of cytokine or TLR agonist. Data are representative of 3-5 experiments. 
Mean ± SEM. 
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stimulation as the optimal timepoint for assessing Runx2 expression 
accompanied by minimal cell death in vitro. To test the role of TLR agonists on 
Runx2 expression we isolated splenocytes from OT-I TCR transgenic Rag2-/- 
mice, stimulated OT-I T cells with high or low concentrations of the lower affinity 
OVA peptide variant SIITFEKL (T4), and incubated with or without TLR agonists 
LPS (Figure 5.11C) or Imiquimod (Figure 5.11D). We found that Runx2 was 
upregulated in cells treated with either TLR agonist at both high and low T4 
peptide doses, but this upregulation was more dramatic when cells were 
stimulated with the low peptide dose.  
Previous work from M. Mescher and colleagues has shown that type-I IFN and 
IL-12 regulate memory CD8+ T cell development in several viral and intracellular 
bacterial infection systems (Agarwal et al., 2009) (Xiao et al., 2009). These 
findings prompted us to assess whether type-I IFN or IL-12 was contributing to 
the high expression of Runx2 in CD8+ T cells stimulated in the presence of TLR 
agonists. We stimulated OT-I T cells with either high or low concentration of T4 
peptide, and incubated cells with or without IFNβ (Figure 5.11E) or IL-12 (Figure 
5.11F). We found treatment with IFNβ had no significant effect on Runx2 
expression, while treatment with IL-12 led to increased Runx2 expression at the 
lower peptide dose. These results suggest a direct effect of IL-12 on T cells.  
Furthermore, the fact that IFNβ had no direct effect on T cells suggests that the 
enhanced Runx2 upregulation observed when stimulation cultures were treated 
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with TLR agonists might be acting via upregulation of costimulatory molecules on 
splenic antigen-presenting cells (APCs).  
We also tested additional cytokines known to be important in homeostatic 
proliferation and survival of memory cells for their effects on Runx2 expression. 
Splenocytes from OT-I TCR transgenic mice were isolated and stimulated with 
high or low doses of the T4 peptide. Cultures were supplemented with or without 
IL-7 (Figure 5.11G) or IL-15 (Figure 5.11H), and analyzed at day 3 post-
stimulation.  These studies demonstrated that both IL-7 and IL-15 promoted 
increased expression of Runx2 when T cells were activated with weak TCR 
stimulation.  
Together, these data show that TLR signaling, most likely in APCs, and 
stimulation of T cells with cytokines known to be important in CD8+ T cell memory 
development and homeostasis, enhance Runx2 upregulation; interestingly, these 
cytokine and TLR agonist signals have the greatest impact in T cells activated 
with weaker strength of TCR signaling. 
 
Runx2 expression is regulated by TCR signaling pathways in activated 
CD8+ T cells in vitro 
From our TLR and cytokine data, we found that OT-I cells stimulated with low 
concentrations of T4 peptide expressed higher levels of Runx2 than cells 
stimulated with a higher concentration of peptide (Figure 5.11). These data 
suggested an important role for TCR signal strength in controlling Runx2 
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expression levels.  Previous studies have shown an important inverse correlation 
between TCR signal strength and the development of CD8+ MPCs after infection 
(Kaech & Cui, 2012) (Restifo & Gattinoni, 2013). To assess more 
comprehensively a role for TCR signal strength in regulating Runx2 expression, 
we performed experiments using extensive dose ranges of three peptides 
recognized by the OT-I TCR.  For these studies OT-I cells were stimulated with 
APCs plus varying concentrations of the highly potent SIINFEKL (N4) peptide, 
the medium potency (T4), or the low potency SIIGFEKL (G4) peptide.  These 
experiments clearly revealed an inverse correlation between peptide dose and 
Runx2 expression (Figure 5.12A). Similar results were also observed for Eomes 
expression (Figure 5.12B). As expected, CD44 upregulation showed a positive 
correlation with peptide dose (Figure 5.12C).  
These findings suggested that the transcription factor IRF4 might regulate Runx2 
expression.  This possibility was suggested by our previous studies showing that 
IRF4 is upregulated to different levels based on TCR signal strength, and further, 
that IRF4 is a negative regulator of Eomes expression (Nayar et al., 2012) (Nayar 
et al., 2014). To test this possibility, we stimulated WT, Irf4+/fl CD4-cre+, and Irf4fl/fl 
CD4-cre+ (hereby referred to as Irf4+/fl and Irf4fl/fl respectively) naïve CD8+ T cells 
with !CD3/CD28 for 72 hours and examined Runx2 expression. As shown, we 
observed a significant increase in Runx2 expression in stimulated Irf4fl/fl CD8+ T 
cells compared to WT or Irf4+/fl cells (Figure 5.12D). Consistent with            
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Figure 5.12. Runx2 expression inversely correlates with TCR signal 
strength and Irf4 expression levels 
 
 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80 ****
****
0
10
20
30
40 WT
Irf4+/fl
Irf4fl/fl
***
***
Unstimulated Stimulated Unstimulated Stimulated
Runx2
100 101 102 103 104 105 106 107 108
0
1
2
3
OVA peptide (pM)
N
or
m
al
iz
ed
 M
FI
0
0.5
1.0
1.5
N
or
m
al
iz
ed
 M
FI
OVA peptide (pM) OVA peptide (pM)
N
or
m
al
iz
ed
 M
FI
A B C
D E
Eomes
Runx2
N4
G4
T4
Naive
0
1
2
3
4
5 Eomes CD44
0 102 103 104 105
0
20
40
60
80
100
%
 o
f M
ax
0 102 103 104 105
0
20
40
60
80
100
%
 o
f M
ax
N
or
m
al
iz
ed
 M
FI
N
or
m
al
iz
ed
 M
FI
Runx2 Eomes
100 101 102 103 104 105 106 107 108 100 101 102 103 104 105 106 107 108
	 188	
Figure 5.12. Runx2 expression inversely correlates with TCR signal 
strength and Irf4 expression levels 
(A-C) OT-I TCR transgenic splenocytes were isolated and cultured in vitro with 
various doses of N4, T4, or G4 peptide in the presence of supernatants from IL-
2-secreting cells. After 72h, OT-I cells were stained for (A) Runx2, (B) Eomes, 
and (C) CD44. Graphs show MFI of Runx2, Eomes, or CD44 staining normalized 
to signal in OT-I cells stimulated with 10nM N4 peptide.  (D-E) CD8+ T cells were 
isolated from splenocytes of WT, Irf4+/fl, or Irf4fl/fl mice, and plated with αCD3/28 
plus IL-2 supernatants. Cells were harvested 72h after stimulation and stained for 
Runx2 (D) or Eomes (E).  Filled histograms shows staining in naïve WT OT-I 
cells.  Graphs at right show compilations of data normalized to WT unstimulated 
control. Data are representative of 3-5 experiments. Mean ± SEM. 
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previously published data, similar results were observed for Eomes (Figure 
5.12E). Together these results indicate that Runx2 is more highly expressed 
when CD8+ T cells are stimulated with low levels of antigen, and that IRF4 is a 
negative regulator of Runx2 and Eomes expression following CD8+ T cell 
activation. 
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Discussion 
A key aspect of the adaptive immune response is the generation of long-term 
memory cells that provide rapid and robust protection upon secondary exposure 
to an infecting pathogen.  Improving memory CD8+ T cell responses is currently a 
focus of many vaccine efforts, whereas inhibition of memory T cell responses is 
an ongoing challenge in the development of therapies to treat autoimmune 
diseases.  Thus, there is a need to understand in more detail the molecular 
mechanisms regulating memory T cell development and persistence. 
 
Our studies identified Runx2 as an important factor in the maintenance of long-
term memory CD8+ T cells.  However, we found that Runx2 was not necessary 
for anti-viral effector function, or for robust recall responses to secondary 
challenge.  These features of the CD8+ T cell response to infection in Runx2fl/fl 
mice show striking resemblance to previous studies examining the 
consequences of a deficiency in IL-15 or IL-15Rα (Lodolce et al., 1998) (Ma et 
al., 2006a). In these earlier studies, IL-15 signaling was found to be essential for 
long-term memory CD8+ T cell homeostasis and self-renewal.  We observed that 
IL-15 stimulation of CD8+ T cells in vitro promoted enhanced Runx2 upregulation 
only under conditions of weak TCR stimulation.  These findings suggest the 
possibility that in vivo tonic TCR signals plus IL-15 are functioning to maintain 
memory cells in part through the upregulation of Runx2.  Consistent with this 
possibility, IL-15 is thought to promote memory T cell homeostatic proliferation, 
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rather than memory cell survival (Becker et al., 2002) (Schluns et al., 2002) 
(Goldrath et al., 2002) (Burkett et al., 2003) (Rubinstein et al., 2008), a function 
that aligns well with data demonstrating that Runx2 overexpression in 
thymocytes promotes uncontrolled cellular proliferation leading to 
lymphomagenesis (Vaillant et al., 1999). 
 
We also found that Runx2 expression levels are enhanced by weak, rather than 
strong, TCR signal intensity, likely due to negative regulation by the transcription 
factor IRF4.  This pattern mirrors that of Eomes, another transcription factor 
associated with long-term memory CD8+ T cell maintenance (Banerjee et al., 
2010).  Along with weak TCR signaling, cytokines that promote memory T cell 
formation and signals that activate APCs, also promote enhanced Runx2 
upregulation.  These data further strengthen an association of Runx2 expression 
with optimal formation of long-lived memory CD8+ T cells (Cui & Kaech, 2010) 
(Restifo & Gattinoni, 2013).  
 
Determining the precise mechanism underlying the loss of memory CD8+ T cells 
in the absence of Runx2 has remained. Early on, studies using microarrays were 
performed to identify differentially expressed genes between WT and Runx2fl/fl 
CD8+ T cells. Cells isolated from LCMV-Armstrong infected mice and analyzed 
directly ex vivo failed to yield informative gene targets of Runx2 regulation; 
similar uninformative results were obtained when comparing WT and Runx2fl/fl 
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CD8+ T cells stimulated in vitro (data not shown). This prompted us to consider 
alternative mechanisms for Runx2 function, such as a change in rRNA 
transcription and processing, based on the known role for Runx2 in regulating 
this pathway in osteoblasts (Ali et al., 2012); these studies also failed to identify a 
function for Runx2 in CD8+ T cells (data not shown). One additional possibility is 
that Runx2 is affecting memory formation through regulation of chromatin 
accessibility, a known function of Runx3 in CD8+ T cells (D. Wang et al., 2018).  
Runx family members have been shown to have redundant roles CD4+ TREG 
cells; thus the most robust alterations are observed in the absence of Cbfβ, the 
binding partner for all three Runx proteins (Rudra et al., 2009). Future studies 
examining CD8+ T cell memory using Cbfβ-deficient T cells may be informative in 
this regard.  Alternatively, Runx2 may function intermittently in memory CD8+ T 
cells, during short time windows when memory cells associate with stromal cells 
in lymphoid organs and receive homeostatic TCR and IL-15/IL-7 signals.  
Capturing the cells during these brief interactions may be required to identify the 
specific genes and/or pathways regulated by Runx2 in memory CD8+ T cells. 
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Chapter VI: Discussion 
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IRF4 and CD8+ Effector T Cell Differentiation during Acute LCMV-
Armstrong Infection 
The adaptive immune system protects us from pathogens by generating a strong 
Ag-specific response, which forms a small population of memory cells capable of 
rapidly responding to reinfection. CD8+ T cells are able to recognize pathogens 
through their TCR via Ag presented on MHC-I on APCs. This process allows for 
T cells to be selected based on affinity to Ag, as well as allowing for high-affinity 
T cell clones to be activated in response to Ag stimulation (Badovinac et al., 
2002).  
 
Work from chapter three of this dissertation as well as from (Raczkowski et al., 
2013), (Man et al., 2013), and (Yao et al., 2013) have shown a major role for the 
transcription factor IRF4 in regulating the level of activation of CD8+ T cells in 
response to TCR signal strength during pathogen infection. (Man et al., 2013) 
determined the role of IRF4 during Influenza A viral infection using viruses that 
expressed OVA peptides of various affinities to the OT-I TCR. This study found 
that IRF4 expression levels directly correlated with TCR signal strength (i.e. 
antigen affinity to the OT-I TCR), and the difference in TCR signal strength 
corresponded with an effect on the total number of CD8+ OT-I cells at the peak of 
the CD8+ T cell response. (Yao et al., 2013) found similar results, where TCR 
signal strength directly correlated with IRF4 expression and the total number of 
effector CD8+ T cells in response to Infuenza A infection. Consistent with these 
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two studies, we found that IRF4 expression levels directly correlated with peptide 
affinity to Ag in P14 TCR transgenic CD8+ cells. We also found that IRF4 
expression levels were decreased in IRF4 haplodeficient P14+ T cells stimulated 
in vitro compared to WT controls. Using this system, we looked at the effects of 
decreasing levels of IRF4 expression in WT, Irf4+/fl, and Irf4fl/fl CD8+ T cells during 
LCMV Armstrong infection, and found that lower levels of IRF4 corresponded to 
lower levels of pathogen-specific CD8+ T effector cells at the peak of response. 
Similar results were observed in adoptively transferred WT P14 cells in hosts 
infected with WT and F6L variant LCMV-Armstrong. From our work and others, 
there is strong evidence that levels of IRF4 are regulated by TCR signal strength, 
and in turn, IRF4 regulates the magnitude of the CD8+ T cell effector response.  
 
We also show that modest variation in IRF4 levels, through use of Irf4+/fl mice can 
lead to significant decrease in the total number of CD8+ T cells at the peak of the 
CD8+ T cell response. We further show that this decrease in IRF4 expression 
primarily impacts the TEC population, while only have minor effects on the MPC 
population, indicating that levels of IRF4 primarily impacts the effector population, 
while having no major impact on the memory population. These results parallel 
work from Zehn et al, where use of a Listeria-OVA model with several OVA 
peptide variant strains found that peptide affinity directly correlated with the total 
number of cells at the peak of the CD8+ T cell response, but found no defects on 
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the surviving memory populations for any of the peptide variants (Zehn et al., 
2009).   
 
From our work and others, it is clear that IRF4 is regulated by TCR signal 
strength, but it is unknown whether other signals, such as pro-inflammatory 
cytokines, may potentially affect IRF4 expression. We found that IRF4 protein 
expression was quickly upregulated after TCR signaling and peaked at 24 hours 
post stimulation in vitro.  After 24 hours, expression quickly went down in WT 
GP33-41 peptide stimulated WT P14 TCR transgenic CD8+ T cells. Future studies 
looking into the potential role of pro-inflammatory cytokines in regulating either 
intensity of the IRF4 peak, or duration of IRF4 expression, would be a potential 
avenue of interest. Work from Richer et al has show that inflammatory cytokines 
are able to enhance TCR signaling by sustaining phosphorylation of ZAP-70 and 
phospholipase Cγ (Richer et al., 2013). Phospholipase Cγ activation and IRF4 
expression are both ITK dependent, so it is possible that cytokines could help 
sustain IRF4 expression (Berg et al., 2005) (Nayar et al., 2012). Previous studies 
have shown an important role for pro-inflammatory cytokine IL-12 in regulation of 
T-bet expression (Takemoto et al., 2006) (Joshi et al., 2007). T-bet is another 
transcription factor that promotes CD8+ effector T cell differentiation, indicating 
that pro-inflammatory cytokines are able to regulate transcription factors required 
for CD8+ T effector cell fate. Besides known roles of pro-inflammatory cytokines 
in regulation of other TEC transcription factors, IRF4 has also been shown to be 
	 197	
regulated by cytokine stimulation in CD4+ T cells (Gomez-Rodriguez et al., 2016), 
where ITK-deficient CD4+ T cells are able to increase expression of IRF4 through 
IL-2 stimulation or constitutively active STAT5. This study further showed that 
STAT5 bound directly to the Irf4 promoter region, demonstrating a mechanism 
for increasing IRF4 levels in weakly activated CD4+ T cells (Gomez-Rodriguez et 
al., 2016). Further work studying the potential role of inflammatory cytokines on 
IRF4 expression intensity and duration in CD8+ T cells may help advance our 
understanding of how signaling outside of TCR signal strength can regulate the 
effector fate in CD8+ T cells.  
 
While IRF4’s role in downstream regulation of effector cell fate has been 
intensely studied (Raczkowski et al., 2013) (Yao et al., 2013) (Man et al., 2013) 
(Nayar et al., 2014), future work looking into which downstream components of 
the TCR signaling pathway regulate IRF4 expression, and how they regulate the 
graded levels of IRF4 expression requires further study. The three major 
downstream pathways of the TCR signaling complex are MAPK, NFκB, and 
calcium signaling/NFAT. Previous studies have indicated that MAPK and NFκB 
show a more digital response to TCR stimulation. MAPK signaling is activated 
through binding of RasGRP to diacylglycerol (DAG) followed by phosphorylation 
via protein kinase c (PKC) at the plasma membrane. Activated RasGRP can then 
bind with SOS (Das et al., 2009), increasing GTPase activity of RasGTP and 
causing a positive feedback loop of the MAPK signaling pathway (Das et al., 
	 198	
2009). This turns graded signaling into a digital signaling response, allowing for 
and “ON” or “OFF” switch for target genes of the MAPK pathway (Das et al., 
2009) (Altan-Bonnet & Germain, 2005). NFκB signaling has also been shown to 
be digital in nature in Jurkat cells, where IκBα degredation showed a digital 
response, even with graded levels of TCR signaling  (i.e. varying doses of α-CD3 
antibody) (Kingeter et al., 2010). Calcium signaling on the other hand is highly 
graded and dependent on TCR signal strength (Chen et al., 2010) (Christo et al., 
2015). IRF4 expression has been previously shown to be regulated by NFκB 
(Grumont & Gerondakis, 2000), but more work needs to be done to understand 
the roles of MAPK pathway and calcium signaling on IRF4 expression (Figure 
6.2). Future work studying these pathways and how they regulate graded 
expression of IRF4 is important for fully understanding how the TCR signaling 
pathway regulates CD8+ T cell activation and differentiation.  
 
One final potential point of interest would be determining the role of IRF4 in 
immunodominance of T cell epitopes. During LCMV-Armstrong infection, two 
major epitopes (GP33-41 and NP396-404) dominate the CD8+ T cell response, while 
several subdominant epitopes (GP276-286, GP34-41, etc.) also form a small pool of 
the CD8+ T cell response (van der Most et al., 1998). Future work studying the 
potential role of IRF4 signal strength in regulating which populations become 
immunodominant or subdominant during infection would be interesting to look 
into. It would unfortunately be very challenging since IRF4 is upregulated early  
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Figure 6.1. Graded IRF4 expression is potentially regulated through 
multiple TCR signaling pathways 
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Figure 6.1. Graded IRF4 expression is potentially regulated through 
multiple TCR signaling pathways 
Activation of the TCR leads to downstream signaling of three major pathways: 
MAPK, NFκB, and calcium signaling/NFAT. Previous work shows that the MAPK 
and NFκB signaling pathways likely act in a digital manner, with genes either 
being switched “ON” or “OFF”, whereas calcium signaling has been shown to be 
important for graded signaling in response to varying levels of TCR signal 
strength. We hypothesize that graded IRF4 expression is likely occurring through 
the calcium signaling/NFAT pathway.  
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after activation, prior to clonal expansion, when the average number of epitope-
specific cells is ~100-1000 in the entire spleen. Issues from low cell numbers 
would also be compounded by the fact that CD8+ T cells are not activated at the 
exact same time during viral infection in a host, so variability in APC-T cell 
interactions would also lead to further issues. Testing this theory would likely 
require in vitro work using TCR transgenic cells of pathogen-specific TCRs to 
synchronize activation of pathogen-specific T cells, as well as have enough 
pathogen-specific cells for experimental analysis. 
 
Through this work and others, IRF4 has been shown to be a critical component 
of CD8+ T cell differentiation into the TECs during acute viral and bacterial 
infection. IRF4 has been shown to be important for regulating proliferation, 
survival, and expression of transcription factors critical for memory and effector 
differentiation. Future studies elucidating how TCR signaling regulates graded 
levels of IRF4, as well as how IRF4 can regulate which populations of pathogen-
specific cells become the dominant response in the CD8+ T cell population are 
interesting directions to further tease apart IRF4 in the CD8+ T cell.   
 
IRF4 and CD8+ T Cell Exhaustion during Chronic LCMV-Clone 13 Infection 
CD8+ T cell exhaustion is a commonly observed phenotype during persistent viral 
infections and cancers (Wherry, 2011). T cell exhaustion is believed to be a 
mechanism to prevent complications from severe immunopathology (Shin et al., 
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2017). There are several extrinsic factors that have been identified in regulating 
CD8+ T cell exhaustion including increased levels of the immunosuppressive 
cytokine IL-10, loss of help from CD4+ T cells, and high viral loads (Mueller & 
Ahmed, 2009) (Doering et al., 2012). The role of Blimp-1, T-bet, and Eomes have 
been examined during chronic infection (Paley et al., 2012) (Shin et al., 2009) 
(Kao et al., 2011). These transcription factors have known roles in CD8+ T cell 
differentiation and effector function during acute viral infection. Blimp-1 is 
upregulated in exhausted CD8+ T cells during LCMV-clone 13 infection, and 
increases in Blimp-1 expression correlated with an increased is exhaustion 
markers PD-1, LAG3, 2B4, and CD160 (Haina Shin et al., 2009). Blimp-1-
deficient mice were unable to control LCMV-clone 13 infection compared to WT 
controls; however, Blimp-1 haplodeficient mice were able to more rapidly control 
LCMV-clone 13 infection compared to WT control (Shin et al., 2009). These 
results indicated a sort of Goldilocks effect with Blimp-1 expression levels where 
Blimp-1 expression that was too high or too low had a detrimental effect on the 
CD8+ T cell response. Similar results have been observed for T-bet and Eomes 
during LCMV clone-13 infection. During LCMV-clone 13 infection, the CD8+ T cell 
response is divided into T-bethi and Eomeshi populations. Even though T-bet and 
Eomes are both T-box transcription factors and function redundantly early during 
acute LCMV-Armstrong infection, loss of either protein results in an impaired 
ability to control LCMV-clone 13 infection (Paley et al., 2012). This is likely due to 
the different gene networks they regulate during LCMV-clone 13 infection 	
	 203	
(Doering et al., 2012). Together these data demonstrate that control of LCMV-
clone 13 infection requires optimal regulation of these major transcription factors. 
Our work in Chapter IV implicates IRF4 as another transcription factor that 
requires optimal control in order for chronic viral clearance to occur. Blimp-1, T-
bet, Eomes, and IRF4 all require optimal expression in order for viral clearance to 
occur during LCMV-clone 13 infection. This phenotype is unique to the chronic 
infection model. Loss of these transcription factors during LCMV-Armstrong 
infection does not affect clearance of virus from the host.  
 
The function of T-bethi and Eomeshi CD8+ T cell subsets during chronic viral 
infection has been well studied (Paley et al., 2012); however, how differentiation 
of these subsets is transcriptionally regulated is not understood. In our work in 
chapter IV, we explored the role of TCR signal strength via graded levels of IRF4 
in the relative expression of T-bet and Eomes as well as the differentiation of T-
bethi and Eomeshi subsets during chronic LCMV-clone 13 infection. We found 
that levels of IRF4 expression directly regulated the ratio of T-bethi and Eomeshi 
populations, with decreasing levels of IRF4 leading towards an increase in the 
proportion of Eomeshi cells both in vitro and in vivo. Previous work has 
demonstrated that IRF4, along with it’s binding partner BATF, directly bind to the 
Tbet and Eomes loci in effector CD8+ T cells, showing a direct role of IRF4/BATF 
in regulating T-bet and Eomes expression (Man et al., 2013) (Kurachi et al., 
2014).  
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The largest defects in the altered ratios of T-bet and Eomes in Irf4+/fl mice was 
the reduced differentiation of T-bethi precursors, and the reduced ability to clear 
viral infection. T-bethi cells have a lower ability to proliferate and have decreased 
cytotoxicity compared to Eomeshi cells; however, they seed the Eomeshi pool and 
are critical for viral clearance (Paley et al., 2012). IRF4 regulates multiple 
pathways, such as proliferation, metabolism, and expression of effector cytokines 
in antiviral CD8+ T cells during acute viral infection (Man et al., 2013) (Yao et al., 
2013) so it is also possible that any defects in these pathways could contribute to 
impaired viral clearance in Irf4+/fl mice. To directly test the importance of the T-bet 
to Eomes ratio, we reduced the expression of Eomes in the Irf4+/fl mice by 
generating Irf4+/fl Eomes+/fl mice. These compound heterozygotes had lower 
Eomes expression compared to Irf4+/fl mice, exhibited similar Eomes to T-bet 
ratios as WT controls, and showed similar levels of T-bethi precursor cells 
compared to WT controls. Irf4+/fl Eomes+/fl mice were able to clear viral infection 
from multiple organs at a similar rate to WT controls. These results showed that 
Eomes overexpression, defects in viral clearance, and defects in T-bethi ratios in 
Irf4+/fl mice could be rescued by compound Irf4+/fl Eomes+/fl mice.  
 
Another consequence of the reduced T-bet to Eomes ratio in Irf4+/fl mice was the 
altered differentiation of T-bethi and Eomeshi populations. Using T-bet and Eomes 
knockout mice, Paley et al showed that loss of either the T-bethi or Eomeshi 
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population is detrimental to viral control (Paley et al., 2012); however, it is not 
known whether reduced levels of one population over the other affects viral 
control. Our work suggests that reduced differentiation of T-bethi populations in 
Irf4+/fl mice is detrimental to efficient viral control. Consistent with this 
observation, lower proportions of T-bethi CD8+ T cells are observed in lung 
transplant recipients with relapsed CMV infection relative to CMV controllers 
(Popescu et al., 2014). Loss of FoxO1 results in higher levels of T-bet and lower 
levels of Eomes, thus biasing CD8+ T cell differentiation towards T-bethi subsets 
during chronic LCMV-clone13 infection (Staron et al., 2014). Interestingly, 
FoxO1-deficient mice are also unable to clear chronic viral infection (Staron et 
al., 2014). These data support our conclusion that balanced differentiation of T-
bethi and Eomeshi subsets are important for viral control. 
 
Levels of IRF4 are known to regulate the magnitude of the effector CD8+ T cell 
response during acute infection (Raczkowski et al., 2013) (Man et al., 2013) (Yao 
et al., 2013) (Grusdat et al., 2014) (Nayar et al., 2014). We observed that IRF4 
regulated the magnitude of the CD8+ T cells response to LCMV-clone 13 
infection at day 8 post infection. Furthermore, the increased numbers of viral-
specific CD8+ T cell numbers were not different between WT and Irf4+/fl mice at 
day 22 post infection or at later timepoints examined. Therefore, it is also 
possible that this early difference in the magnitude of the CD8+ T cell response 
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may be responsible for the ultimate ability of WT mice, but not Irf4+/fl mice, to be 
able to clear LCMV-clone 13 infection. 
 
 
Runx2 and CD8+ T Cell Memory during Acute LCMV-Armstrong Infection 
CD8+ T cell memory is a critical component of the immune response. It allows the 
host to be protected from reinfection of the same pathogen. CD8+ T cell memory 
formation is a critical component of vaccine development, allowing protection 
against deadly pathogens a host has not previously encountered by eliciting an 
immune response against pathogen-specific antigens. CD8+ T cell memory also 
has a dark side. Self-reactive CD8+ T cells can recognize a host cell component 
as a foreign antigen and generate a strong CD8+ T cell response against that 
population forming a memory pool, which can be reactivated leading to 
autoimmunity.  
 
Understanding how CD8+ T cells differentiate into memory cells is critical for 
biomedical research advancement. With this knowledge we could manipulate 
CD8+ T cells towards a memory phenotype, such as in the case of vaccination, 
where an increased CD8+ T memory cell pool is highly desired to help protect 
against infection. We could also manipulate activated CD8+ T cells away from 
differentiating into a memory cell, such as the case with autoimmunity and CAR-
T cell therapy, where the memory pool could cause damage to the host.  
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The work discussed in Chapter V of this dissertation shows an important role for 
the transcription factor Runx2 in CD8+ T cell memory. Runx2 is an interesting 
candidate for CD8+ T memory cell targeted therapies because loss of Runx2 in 
the CD8+ T cell population has no major effect on the CD8+ TEC response during 
LCMV infection. Runx2fl/fl mice are still able to clear infection at day 9 post 
infection as WT mice, and there are no major defects seen in the total number of 
pathogen-specific TECs, as well as effector molecules GranzymeB and 
CD107a+b for the three epitopes tested. Viral kinetics were not tested, so the 
rate of viral clearance may vary between WT and Runx2fl/fl mice. This makes 
Runx2 a strong candidate for translational therapies, such as CAR-T cells, where 
effector function is critical for clearance of cancer cells from the host, while 
memory function can be destructive and lead to autoimmunity.  
 
Runx2fl/fl show a striking resemblance to IL-15 and IL15rα-deficient mice. IL-15-
deficient mice are able to mount a strong CD8+ T effector response against 
LCMV-Armstrong infection with no defect in proportions of pathogen-specific 
cells early after infection clearance; however, IL-15-deficient mice have a 
decrease in the proportion of pathogen-specific cells at memory time points 
compared to WT controls (Becker et al., 2002). Similar results are observed in IL-
15-deficient mice during VSV infection (Schluns et al., 2002). These results are 
similar to what we see with Runx2fl/fl mice during LCMV-Armstrong infection. IL-
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15-deficient mice are also able to elicit a strong recall response during reinfection 
(Becker et al., 2002), similar to what we have seen with Runx2fl/fl mice. CD8+ T 
memory cell loss in IL-15-deficient and Runx2-/- mice is similar in that there is not 
a complete loss of the MPC population, rather, a significant decrease in the total 
number of MPCs. This is likely due to the fact that MPCs in an IL-15-deficient 
mouse are able to survive, however, they do not homeostatically proliferate 
(Becker et al., 2002). Another potential mechanism for this phenotype is that IL-7 
and IL-15 have been shown to perform similar functions in CD8+ T cell memory 
survival and homeostatic proliferation (Goldrath et al., 2002) allowing a 
decreased amount of CD8+ MPCs to survive and continue during the memory 
phase of infection off of IL-7 stimulation alone. Further work examining the 
effects of IL-15 on homeostatic proliferation of Runx2-/- MPCs would further help 
to shed light on the potential role of IL-15 in Runx2-mediated MPC defects seen 
during LCMV-Armstrong infection.  
 
One potential mechanism for IL-15 regulating Runx2 transcriptional control is 
through phosphorylation of Runx2. Work from Li et al. has shown that 
phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2) is critical for 
phosphorylation of Runx2 in osteoblasts (Y. Li et al., 2012). They further show 
that Runx2 phosphorylation is required for transcription of Runx2 downstream 
target genes (Y. Li et al., 2012) (Ge et al., 2012).  Stimulation of the IL-15 
receptor leads to downstream activation of three major signaling pathways: the 
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STAT3/STAT5 signaling pathway, Atk/PKB anti-apoptotic pathway, and the 
MAPK/ERK signaling pathway. From this information, one hypothesis is that IL-
15 regulates Runx2 dependent MPC genes through phosphorylation of Runx2 
via the MAPK/ERK pathway (Figure 6.2). This hypothesis would also explain the 
results observed from two microarray experiments performed ex vivo and in vitro. 
For the ex vivo experiments, congenically marked WT and Runx2fl/fl P14 TCR 
transgenic cells were co-adoptively transferred into a host mouse. Mice were 
then infected with LCMV-Armstrong and six days later, cells were sorted and 
RNA was isolated from WT and Runx2fl/fl populations. There was no difference 
observed in transcription between WT and Runx2fl/fl cells. Similar results were 
observed for WT and Runx2fl/fl P14 cells stimulated in vitro with GP33 peptide. If 
Runx2 downstream transcription was regulated by Runx2 phosphorylation via the 
MARK/ERK pathway, no differences in transcription would be observed between 
WT and Runx2fl/fl CD8+ T cells ex vivo because only a small minority of MPCs 
actively receive IL-15 signaling at any given time, and no difference would be 
observed in vitro because the cells were not treated with IL-15.  
 
This hypothesis requires further studies looking into p-Runx2 levels in response 
to IL-15 signaling in CD8+ MPCs. If there is confirmed regulation of Runx2 
phosphorylation via IL-15 signaling, it would be ideal to look for transcriptional 
differences between WT and Runx2fl/fl P14 MPCs stimulated with IL-15. To help 
tease apart which IL-15 downstream target genes are regulated by Runx2, IL-15- 
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Figure 6.2. IL-15 regulates expression of Runx2 target genes through p-
ERK1/2 mediated Runx2 phosphorylation 
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Figure 6.2. IL-15 regulates expression of Runx2 target genes through p-
ERK1/2 mediated Runx2 phosphorylation 
Hypothetical model for transcriptional regulation of Runx2 target genes via 
phosphorylation of Runx2. Runx2 requires phosphorylation in order for 
transcription of downstream target genes. Runx2 phosphorylation could 
potentially be regulated through the IL-15 signaling pathway via p-ERK1/2. This 
model would explain defect seen in MPC population in Runx2fl/fl CD8+ T cells 
during LCMV-Armstrong infection as well as the fact that no transcriptional 
differences are observed between WT and Runx2fl/fl CD8+ P14 cells.  
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deficient or IL-15Rα-deficient P14 MPCs could also be included in transcriptional 
studies. MAPK/ERK inhibitors such as U0126 could be used to help dissect the 
role of IL-15 mediated p-ERK expression in Runx2 phosphorylation. It would also 
be valuable to look into the potential role of IL-7 signaling and p-Runx2, since 
stimulation of the IL-7 receptor also leads to downstream MAPK/ERK signaling.  
 
Our work also demonstrated that Runx2 expression inversely correlated with 
TCR signal strength, with TCR signaling on the cusp of activating T cells leading 
to the strongest expression of Runx2. Similar results were observed for another 
major memory transcription factor, Eomes. We further showed that loss of IRF4 
in CD8+ T cells lead to a significant increased in Runx2 expression. This work 
agrees with previous models showing that TCR signal strength intensity helps to 
regulate effector and memory differentiation in activated CD8+ T cells during 
infection, with lower TCR signal strength leading towards a memory fate and 
higher TCR signal strength leading towards an effector fate. Future work studying 
the effects of TCR signal strength in vivo on Runx2 expression and memory 
formation would be interesting. The LCMV-Armstrong F6L mutant strain could be 
used to identify differences in Runx2 expression in P14 TCR transgenic cells 
between WT and F6L mutant infection, where the F6L mutant has a lower affinity 
for the P14 TCR.  
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Future work looking into the role of inflammatory cytokines known to regulate 
effector and memory fate in CD8+ T cells in regulating levels of Runx2 would also 
be interesting. We performed in vitro stimulations of WT P14 cells treated with 
various cytokines and looked for differences in Runx2 expression. While we 
found that pro-inflammatory cytokine IL-12 suppressed Runx2 expression, further 
work looking at the in vivo role of inflammatory cytokines in Runx2 expression 
during LCMV-Armstrong infection would be interesting to determine whether 
Runx2 is regulated via TCR signal strength alone, or also by pro-inflammatory 
cytokines.  
 
Determining the precise mechanism of Runx2 downstream signaling that 
regulated the MPC defect during LCMV-Armstrong infection has eluded us. We 
initially performed microarrays to determine transcriptional differences between 
WT and Runx2fl/fl P14 cells ex vivo from LCMV-Armstrong infection as well as 
during in vitro stimulation; however, no transcriptional differences were observed 
in either experimental setting. This led us to consider alternative mechanisms of 
Runx2 function in MPCs.   
 
Runx2 has been shown to bind to histone deacylase 1 (HDAC1) and 
downregulate rRNA transcription through acetylation of the protein upstream 
binding factor (UBF) in osteoblasts (Ali et al., 2012). In this way, Runx2 can 
globally repress translation of mRNA into protein, while having no impact on 
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transcription. It is known that effector cells are more transcriptionally active 
compared to memory cells (Best et al., 2013) (Chang et al., 2014), and this post-
transcriptional regulation of mRNA translation could be another step to help keep 
MPCs more quiescent and push them towards the memory fate. However, we 
found no difference in pre-rRNA transcription between WT and Runx2fl/fl P14 
cells. This led us to believe that Runx2 was likely not regulating MPCs through 
globally repressing translation of mRNA to protein.  
 
One additional possibility is that Runx2 is affecting memory formation through the 
regulation of chromatin accessibility, a known role of Runx3 in T cells (Wang et 
al., 2018). In this work, authors found a significant increase in Runx2 and Runx3 
binding motifs in open regions of the chromosome in MPCs compared to naïve 
cells (Wang et al., 2018). The authors saw no major defect in MPCs with Runx2 
shRNA knockdown, but the shRNA knockdown had a very partial defect on 
Runx2 protein expression, only really showing that partial loss of Runx2 had no 
major defect on MPC formation during LCMV infection (Wang et al., 2018).  The 
authors further show that the most dramatic loss of MPCs during LCMV infection 
occurred with shRNA knockdown of CBFβ, the binding partner of all Runx 
proteins (Wang et al., 2018). Runx family proteins have been shown to have 
redundant roles in CD4+ TREG cells (Rudra et al., 2009), and thus could explain 
why knockdown of the CBFβ binding partner led to the most dramatic phenotype. 
Runx2 and Runx3 could be playing redundant roles in regulating Memory cell 
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chromatin accessibility. To further test this hypothesis, ATAC-seq would need to 
be performed on WT versus Runx2fl/fl P14 MPCs from LCMV-Armstrong 
infection. This would help us determine if Runx2 was enabling accessibility of 
chromatin required for memory cells. Future studies looking at the role of CBFβ 
in MPC formation would also be important for determining whether Runx2 and 
Runx3 are playing redundant roles in regulating chromosome accessibility for 
MPCs. Runx1 and Runx3 have known roles in CD8+ T cell effector function and 
differentiation, so Cbfβfl/fl mice with an inducible cre (ex. tamoxifen-cre), may be 
required to help tease apart this mechanism.  
 
From this work it is clear that Runx2 is playing a role in MPCs during LCMV-
Armstrong infection, and loss of Runx2 leads to a defect in the total number of 
MPCs. Although we have been unable to determine the downstream 
mechanisms of Runx2 within the CD8+ MPC population, we have several 
potential hypotheses as to how this may be occurring, and directions for future 
studies. From our work it is clear that, while Runx2 is regulated inversely from 
TCR signal strength (in a similar fashion as other memory transcription factors), it 
is not playing the conventional role of a transcription factor in MPCs. This work is 
a critical addition to the field. While Runx2 may seem like another transcription 
factor to add to the list of many that regulate memory differentiation and function 
in CD8+ T cells, Runx2 has shown a potential uniqueness, in that it does not 
regulate transcription in MPC steady state. We hypothesize that it likely requires 
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IL-15 signaling to phosphorylate Runx2, thus allowed downstream transcription 
of target genes to occur. Our other major hypothesis is that it is required for 
chromatin accessibility of MPC related genes. Both of these functions are 
relatively unique and uncommon among known memory transcription factors, 
and would make it an interesting candidate for targeted therapies once these 
mechanisms have been fully elucidated.  
 
IRF4 and Runx2: Major Regulators of CD8+ T Cell Effector and Memory 
From our work we have determined inverse roles for the transcription factors 
IRF4 and Runx2 in CD8+ T cell effector and memory differentiation. IRF4 is 
transiently expressed early after T cell activation, and plays a critical role in the 
CD8+ T cell effector response. Runx2 expression is upregulated later after T cell 
activation; around 3 days post stimulation in vitro and remains upregulated for 
the life of the CD8+ T cell. In chapter V, we determined that IRF4 was able to 
repress Runx2 expression in activated CD8+ T cells. This could be potentially 
caused by direct repression of Runx2 by IRF4. IRF4 has also been shown to bind 
directly to the Runx2 promoter in activated CD8+ T cells (Kurachi et al., 2014). 
From these results, we generated a model of CD8+ T cell differentiation during 
CD8+ T cell activation (Figure 6.3) where repression of Runx2 by IRF4 potentially 
regulates memory cell differentiation. In our model, IRF4 expression, which has 
been shown to be positively regulated by TCR signal strength (Nayar et al., 
2014) as well as by proinflammatory cytokines, represses Runx2 expression, 
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Figure 6.3 Model of IRF4 and Runx2-mediated terminal effector versus 
memory cell fate during acute viral infection 
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Figure 6.3 Model of IRF4 and Runx2-mediated terminal effector versus 
memory cell fate during acute viral infection 
Work from Chapter V has shown that IRF4 is able to repress Runx2 expression. 
We hypothesize that inceased TCR signaling and pro-inflammatory cytokine 
signaling in activated CD8+ T cells promotes increased expression levels and 
duration of IRF4. High levels of IRF4 lead to promotion of the terminal effector 
cell fate. Low TCR signaling and lower levels of pro-inflammatory cytokines lead 
to decreased levels of IRF4 and increased levels of Runx2. Increased levels of 
Runx2 promote Memory CD8+ T Cell fate.  
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promoting terminal effector cell fate. Lower levels of TCR signaling, as well as a 
decrease in proinflammatory cytokines could promote memory cell fate through 
decreased levels of IRF4 and therefore increased levels of Runx2. Future work 
looking into the role of TCR signaling and pro-inflammatory cytokines in 
regulation of Runx2 in vivo will be required to really tease apart how these 
effector-promoting signals regulate Runx2, as well as molecular work teasing 
apart how IRF4 represses Runx2 expression in activated CD8+ T cells. 
 
Runx2 expression is not present in naïve CD8+ T cells. We have two major 
hypotheses as to how this may be occurring. One hypothesis is Runx2 
expression is not present in naïve CD8+ T cells due to fact that the majority of the 
chromosomal DNA is inaccessible in naïve T cells (Kurachi et al., 2014). During 
CD8+ T cell activation, the chromosomal DNA is opened up by several 
transcription factors including BATF and IRF4 (Kurachi et al., 2014). During this 
time, access to the Runx2 gene may become accessible; however, IRF4 
repression of Runx2 could inhibit Runx2 expression until IRF4 expression goes 
down. Another hypothesis is that the transcriptional regulators of Runx2 are not 
present in naïve T cells, and are expressed after T cell activation. These two 
hypotheses are not mutually exclusive, since Runx2 likely requires a 
transcriptional regulator to promote RNA polymerase binding to the Runx2 gene. 
Further work determining which transcription factors are regulating Runx2 
expression, and chromosomal accessibility of the Runx2 gene in naïve versus 
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activated CD8+ T cells will be required to determine how Runx2 is regulated in 
activated CD8+ T cells on the molecular level. 
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Appendix I 
Loss of Sox4 in the T cell compartment has no impact on CD8+ T cell 
memory during LCMV-Armstrong infection 
In Hu et al, Sox4 was identified as binding to the Runx2 promoter region, and 
was identified as a regulator of Runx2 expression (Hu et al. 2013). To test if Sox4 
was regulating Runx2-mediated memory functions during LCMV-Armstrong 
infection, we infected Sox4fl/fl CD4-cre+ mice (hereby referred to as Sox4fl/fl mice) 
with LCMV-Armstrong and looked for defects in MPCs during and after clearance 
of infection (Figure A.1). While we saw significant defects in proportions of 
KLRG1- pathogen-specific cells at day 7 post infection, no defect in the total cell 
number was seen (Figure A.1 A). A significant decrease in CD27, a surface 
marker associated with MPCs, was also observed in Sox4fl/fl mice compared to 
WT controls (Figure A.1 B). At day 28 post infection, no difference in MPCs was 
observed between WT and Sox4fl/fl mice (Figure A.1 C), indicating that any 
defects seen in MPCs early on in Sox4fl/fl mice had no long term effect on the 
total number of the memory pool. While Sox4 may bind to the Runx2 promoter 
region in activated CD8+ T cells, it seems loss of Sox4 does not mimic memory 
defects seen in Runx2 deficient mice. While this work was far from exhaustive, 
we chose to end this portion of the study to focus on elucidation of Runx2 in 
CD8+ T cell memory. 
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Figure A.1. Loss of Sox4 in the T cell compartment has no impact on CD8+ 
T cell memory during LCMV-Armstrong infection 
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Figure A.1. Loss of Sox4 in the T cell compartment has no impact on CD8+ 
T cell memory during LCMV-Armstrong infection 
WT and Sox4fl/fl CD4-cre+ mice were infected with 5*104 PFU LCMV-Armstrong 
i.p. Spleens were harvested at day 7 and 28 post infection, and stained for 
pathogen-specifc CD8+ T cells.  (A) Percentage (top) and total number (bottom) 
of GP33-41 (left), GP276-286 (middle), and NP396-404 (right) specific KLRG1+ and 
KLRG1- CD8+ T cells. (B) MFI of CD27 in WT and Sox4fl/fl GP33-41 (left), GP276-286 
(middle), and NP396-404 (right) specific cells at day 7 post infection. (C) Total 
number of GP33-41 (left), GP276-286 (middle), and NP396-404 (right) MPCs (KLRG1lo 
CD127hi) at day 28 post infection. Data are representative of 2-3 experiments 
with 7-12 mice per group. Error bars indicate mean ± SEM.  
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Appendix II 
Loss of IL-4 has no defect on CD8+ T cell memory during LCMV-Armstrong 
infection 
We performed a large in vitro cytokine panel to determine if any cytokines had an 
effect on Runx2 expression in activated CD8+ T cells. IL-4 significantly and 
reproducibly downregulated Runx2 expression compared to no cytokine control 
(Figure A.2 A). From this we were interested to see if loss of IL-4 would have any 
effect on the memory population during LCMV-Armstrong infection (Figure A.2 B-
D). To test this we infected WT and IL-4 KO mice with LCMV-Armstrong, and 
harvested spleens 90 days post infection. We looked for tetramer-specific cells, 
and found no defect in GP33, GP276, and NP396 specific responses in IL-4 KO 
mice compared to WT controls (Figure A.2 B-D). From these results, we 
determined that loss of IL-4 had no major impact on the total number of memory 
cells during LCMV-Armstrong infection. While this work was far from exhaustive, 
we chose to end this portion of the study to focus on elucidation of Runx2 in 
CD8+ T cell memory. 
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Figure A.2. Loss of IL-4 has no defect on CD8+ T cell memory during LCMV-
Armstrong infection 
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Figure A.2. Loss of IL-4 has no defect on CD8+ T cell memory during LCMV-
Armstrong infection 
(A) P14 splenocytes were isolated from mice and incubated with GP33-41 peptide, 
IL-2, and with or without IL-4 for 4 days and stained for Runx2. (B-D) WT and IL-
4 KO mice were infected with 5*104 PFU LCMV-Armstrong i.p. Spleens were 
harvested at day 90 post infection, and stained for pathogen-specifc CD8+ T 
cells. (B) The H2-Db GP33-41 specific response. (left) Gating strategy for GP33-41 
specific T cells. (center) Percentage of GP33-41 specific cells. (left) Total number 
of GP33-41 specific cells. (C) The H2-Db GP276-286 specific response. (left) Gating 
strategy for GP276-286 specific T cells. (center) Percentage of GP276-286 specific 
cells. (left) Total number of GP276-286 specific cells. (D) The H2-Db NP396-404 
specific response. (left) Gating strategy for NP396-404 specific T cells. (center) 
Percentage of NP396-404 specific cells. (left) Total number of NP396-404 specific 
cells. Data are representative of two experiments with 10 mice per group. Error 
bars indicate mean ± SEM. 
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